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ABSTRACT 
Mast cells are crucial effector cells in host defense and immunoregulation. They 
are equipped with an impressive array of receptor systems which allows them to rapidly 
respond to pathogen-associated signals. G protein-coupled receptors (GPCRs) mediate 
mast cell activation and mediator release in response to various stimuli. The effects are 
differential; while some GPCR can induce chemotaxis, adhesion, degranulation and 
mediator release, others can stimulate chemotaxis and adhesion but not degranulation. 
Signaling through GPCRs can also modulate antigen-mediated activation of mast cells. 
The effect mediated via a GPCR depends on the G protein it couples with. Signal 
WUDQVGXFWLRQYLD*Įi initiates FHOODFWLYDWLRQZKHUHDV*Įs downregulates cell activation. 
My thesis investigated the roles of novel stimulatory and inhibitory GPCRs in human 
mast cells. I hypothesized that human mast cells express both stimulatory and inhibitory 
chemoattractant GPCRs which differentially activate mast cells but chemotaxis pathway 
itself remains conserved. For the first sub-hypothesis, expression and function of FPRL1 
receptor in human mast cells was investigated. I showed that Laboratory of Allergic 
Diseases 2 (LAD2) human mast cells expressed cell surface FPRL1. Stimulation of 
LAD2 cells with a novel Į-cationic antimicrobial peptide, pleurocidin, induced mast cell 
chemotaxis, adhesion, degranulation and production of lipid mediators, cytokines, and 
chemokines. The effect was sensitive to pertussis toxin, indicating that FPRL1 mediates 
stimulatory signaOLQJLQKXPDQPDVWFHOOVYLD*Įi protein.  
In the next sub-hypothesis, expression and function of C5a receptors, C5aR and 
C5L2, in human mast cells was LQYHVWLJDWHG:KLOH&D5LVDNQRZQ*Įi-coupled GPCR 
in human mast cells, the signaling mechanism for C5L2 is unknown. My data showed 
that LAD2 human mast cells express cell surface C5L2 but not C5aR. C5a activated 
LAD2 cells to migrate, adhere and produce cytokines and chemokines. The effects were 
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abolished in mast cells in which C5L2 expression was knocked-down using lentiviral 
C5L2 shRNA. Moreover, the effect of C5a on cell adhesion was pertussis toxin-
dependent, indicating that C5L2 mediates stimulatory signaling in human mast cells via 
GĮi proteins.  
In the final sub-hypothesis, function of C3a receptor, C3aR, in human mast cells 
was investigated in conjugation with adenosine receptor signaling. Stimulatory signal 
WUDQVGXFWLRQWKURXJK*Įi-coupled C3aR in human mast cells is well-established. To test 
the expression and function of inhibitory GPCRs, adenosine receptors were utilized. I 
showed that while adenosine did not activate human mast cells by itself, it inhibited C3a-
mediated activation of human mast cell adhesion, chemotaxis, degranulation, and 
chemokine production. An A2A receptor specific agonist, CGS 21680, blocked the 
inhibitory effect of adenosine, indicating that *Įs-coupled adenosine receptor exert 
LQKLELWRU\HIIHFWVRQ*Įi-coupled GPCR activation in human mast cells. 
Overall, my thesis research provides crucial information on the effects of novel 
chemoattractant GPCRs in human mast cells. While these receptors differentially 
PRGXODWHGYDULRXVKXPDQPDVWFHOOIXQFWLRQVHLWKHUSRVLWLYHO\YLD*Įi-coupled GPCRs or 
QHJDWLYHO\YLD*Įs-coupled GPCRs, chemotaxis remained conserved and occurred via a 
*Įi-dependent signal transduction mechanism.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
A version of this chapter has been published as: 
P Pundir, M Kulka, 2010. The role of G protein-coupled receptors in mast cell activation 
by antimicrobial peptide: is there a connection? Immunology Cell Biology. 88(6), 632-
640. 
P Pundir, M Kulka, 2013. Complement receptors in inflammation. Inflammation, Chronic 
Diseases and Cancer-Cell and Molecular Biology, Immunology and Clinical Bases. doi: 
10.5772/25599. 
 
1.1 OVERVIEW 
Mast cells are long-lived, tissue-resident leukocytes that are found throughout the 
body at locations in close contact with the external environment such as the skin, 
airways, and the gastrointestinal tract. Activation of mast cells through their cell surface 
receptors leads to selective and timely release of granule-stored and de novo-generated 
proinflammatory mediators. The multitude of mediators that can be released plays a 
pivotal role in determining the nature of mast cell responses, ranging from protection 
against pathogens to hypersensitivity and atopic diseases. This response can occur as a 
consequence of antigen binding to IgE molecules which occupy high affinity receptors 
for immunoglobulin (Ig)()Fİ5,RQWKHPDVWFHOOVXUIDFH0DVWFHOOUHVSRQVHVKRZHYHU
can also be regulated by other receptors expressed on their surface. One such class of 
these receptors are the G protein-coupled receptors (GPCRs). The responses elicited by 
GPCRs are quite divergent, ranging from induction of chemotaxis and adhesion to 
potentiation of mast cell activation. GPCRs can not only activate mast cell function alone 
but also can interact with other GPCRs to augment or diminish activation. This thesis will 
describe chemoattractant GPCRs that are stimulatory or inhibitory in function and 
differentially activate mast cells depending on the particular G protein utilized for signal 
transduction.  
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1.2 MAST CELLS 
Mast cells were first reported by Friedrich von Recklinghausen when he 
described in 1863 the presence of granulated cells in unstained connective tissues from 
various species, including the tail of tadpoles. They were later identified and named in 
E\3DXO(KUOLFKLQKLVGRFWRUDOWKHVLV³&RQWULEXWLRQVWRWKH7KHRU\and Practice of 
+LVWRORJLFDO6WDLQLQJ´SUHVHQWHGDW/HLS]LJ8QLYHUVLW\*HUPDQ\ (1). He identified them 
as aniline-positive granular cells in connective tissue, which KH QDPHG ³0DVW]HOOHQ´
*HUPDQ ZRUG 0DVW µIDWWHQLQJ¶ +H GHVFULEHG WKHVH FHOOV DV EHLQJ ORFDOL]HG DURXQG
developed pre-formed structures in the connective tissue, such as blood vessels, 
nerves, secretory ducts, sites of inflammation, and tumors. He also noted that the 
granules contained an undetermined chemical substance that reacted metachromatically 
ZLWK DQLOLQH G\HV 6XEVHTXHQW VWXGLHV IROORZLQJ (KUOLFK¶V SLRQHHULQJ REVHUYDWLRQV
revealed the biological role of mast cells in hypersensitivity reactions. Today, mast cells 
are no longer viewed just as mediators of allergic reactions, but also as protective cells 
throughout the body, functioning as critical sentinel and effector cells (2).  
1.2.1 Morphology 
Morphologically, mast cells have a variable shape depending on their location in 
the body. In loose connective tissues they are round, in close proximity to blood vessels 
they are elongated or ovoid, and in dermal fibers they are spindle shaped (3). Their 
diameter ranges between 8- ȝP (4) and the non-segmented nucleus is relatively 
large, measuring 4- ȝP LQ GLDPHWHU ZLWK YDU\LQJ DPRXQWV RI FKURPDWLQ (5). The 
cytoplasm of mature cells contains numerous secretory granules, which can occupy up 
to 50-55% of the cytoplasmic space, and stain metachromatically with thiazine dyes, 
such as toluidine blue, showing variable patterns of scrolls, swirls, circles and lattices. 
When viewed by electron microscopy mast cells present numerous short and long 
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microvilli, numerous bulges corresponding to granules lying beneath the plasma 
PHPEUDQH DQG ³RSHQLQJV´ RU FDYHRODH ZKHQ JUDQXODU GLVFKDUJH KDV WDNHQ SODFH ,Q
addition to granules, the mast cell cytoplasm contains mitochondria, Golgi apparatus, 
rough endoplasmic reticulum and electron-dense lipid bodies with numerous free 
ribosomes (6) (Figure 1.1). 
1.2.2 Development 
Mast cells originate from pluripotent CD34+ stem cells derived from 
hematopoietic bone marrow and extramedullary tissues. They are released from bone 
marrow as CD34+, Kit+ )FȖ5,,-, CD14-, and CD17- immature progenitors into the 
circulating blood (7, 8) and then are subsequently recruited into various tissues, 
completing their maturation under the control of locally-produced cytokines and growth 
factors. Interleukin (IL)-3 controls the development of progenitor mast cells and is also 
an important growth factor for the differentiation of rodent mast cells (9). The most 
important factor for maturation of human mast cells is stem cell factor (SCF), which is 
the ligand for receptor tyrosine kinase Kit, and is secreted by fibroblasts, stromal cells 
and endothelial cells (10). SCF can regulate the migration of mast cell precursors in vivo 
and the adhesion and migration of immature mast cells in vitro, promote the proliferation 
of both immature and mature mast cells, promote mast cell maturation, and modulate 
the expression of mast cell secretory functions (11). Pleotropic cytokines, such as IL-4, 
IL-6 and IL-10 also play a role in the regulation and proliferation of mast cells and 
together with other microenvironmental factors, they determine the final mast cell 
phenotype (12).  
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Figure 1.1 Electron micrograph of human mast cells. Laboratory of Allergic Diseases 2 (LAD2) 
mast cells show electron-dense secretory granules, a nucleus and numerous narrow surface 
folds. X 100. (Original image). 
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1.2.3 Heterogeneity 
Mast cells exist in vivo and in vitro as a heterogeneous population of immune 
effector cells, subpopulations of which may be distinguished on the basis of their 
anatomic location, granule contents, and functional activity in response to a variety of 
secretagogues. In rodents, two major mast cell subpopulations have been described: 
mucosal-type mast cells (MMC) and connective tissue-type mast cells (CTMC) which 
can be differentiated using Alcian blue/safranin histochemical staining. MMC stain blue 
with Alcian blue, while CTMC stain red with safranin (13). MMC are mainly found in 
mucosa of gastrointestinal tract and in lamina propria of respiratory tract. CTMC localize 
mostly in the submucosa of the gastrointestinal tract, in skin, and the peritoneum. These 
also differ in their T cell-dependence (MMC are dependent on T cell-derived cytokines 
for proliferation), mediator content (proteoglycans, proteases, histamine, lipid mediators), 
surface antigens, and functional heterogeneity (secretagogue compound 48/80 [c48/80] 
induces histamine release from CTMC but not from MMC (14) (Table 1.1). 
In humans, the distinct classification of MMC and CTMC cannot be made based 
on staining with dyes. Instead, immunohistochemical staining of mast cell-specific 
proteases tryptase and chymase is the main criterion (15, 16) of differentiation into two 
subpopulations: mast cells containing only tryptase (MCT) and mast cells containing both 
tryptase and chymase (MCTC) (17). MCT are found in higher proportions in the lungs and 
mucosa of small and large intestines, while MCTC are predominant in the skin and 
submucosa of the small and large intestines. Morphologic diversity exists between MCT 
and MCTC. MCT from the intestinal mucosa and lungs have granules containing discrete 
scrolls  (scroll-rich morphology), while MCTC from the skin and intestinal submucosa 
have granules rimmed by incomplete scrolls (scroll-poor morphology) (18). Functionally, 
MCTC from the skin degranulate in response to c48/80, polymyxin B, and substance P 
(SP), whereas MCT from the lung and intestinal mucosa do not (19) (Table 1.2).  
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Table 1.1 Murine mucosal and connective tissue mast cells 
Feature Mucosal mast cells Connective tissue mast cells 
 
Tissue localization 
 
Small intestine mucosa 
 
Small intestine submucosa, skin, 
skeletal  muscle, serosal 
surfaces 
Dye binding after fixation 
 
  
&DUQR\¶V0RWD¶V
lead acetate, 
isotonic 
formaldehyde 
acetic acid 
 
+ + 
Neutral buffered 
formalin 
 
- + 
Staining 
 
  
Alcian 
blue/safranin O 
 
Blue Red 
Berberine 
sulphate 
 
- + 
Mediators 
 
  
Histamine <1 pg per cell 1 - 30 pg per cell 
Proteoglycan Chondroitin sulphate di-B, A, E Heparin, Chondroitin sulphate E 
Protease MCP-1 and -2 MCP-3, -4, -5, -6, -7, and 
carboxypeptidase 
LTC4 >25 ng per 106 cells n.d. 
LTB4 3 -12 ng per 106 cells n.d. 
PGD2 
 
1 - 5 ng per 106 cells n.d. 
Response to 
secertagouges 
 
  
IgE-antigen + + 
A23187 + + 
Substance P + + 
Compound 48/80 - + 
Neuropeptides 
 
- + 
 
LT, leukotriene; PG, prostaglandin; MCP, mast cell protease; IgE, immunoglobulin E; n.d., not determined 
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Table 1.2 Human T and TC mast cells 
Feature MCT  MCTC 
 
Tissue localization 
 
Bronchial epithelium and 
subepithelium, lung alveoli, 
dispersed lung mast cells, small 
intestine mucosa, nasal 
mucosa epithelium, conjunctival 
epithelium 
 
Skin, very few in bronchial 
subepithelium, small intestine 
submucosa, nasal mucosa 
subepithelium, 
Mediators   
Histamine <1 pg per cell >10 pg per cell 
Tryptase 10 pg per cell 35 pg per cell 
Chymase 5 pg per cell <0.05 pg per cell 
Caroxypeptidase - 10 ± 20 pg per cell 
LTC4 10 - 80 ng per 106 cells 3.5 ng per 106 cells. 
PGD2 39 ng per 106 cells 43 ng per 106 cells 
Response to 
secertagouges 
 
  
IgE-antigen + + 
A23187 + + 
Substance P - + 
Compound 48/80 - + 
Neuropeptides 
 
- + 
 
LT, leukotriene; MCT, Tryptase+ mast cells; MCTC, Trypytase+Chymase+ mast cells; PG, prostaglandin; IgE, 
immunoglobulin E 
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1.2.4 Distribution 
The distribution and density of mast cells in the body are related largely to the 
content of connective tissue. They are more abundant in the dermal and subcutaneous 
tissue of skin, but comparatively less prevalent in liver, spleen and adrenal glands. While 
mast cells reside in all vascularized tissues (20), the highest numbers are observed at 
the interfaces of the host and environment, i.e. in skin and mucosal surfaces in the 
respiratory and gastrointestinal tracts (21).   
1.2.5 Activation 
The strategic location of mast cells within the body allows them to participate in 
the regulation of both innate and adaptive immune responses, as well as drive 
pathological hypersensitivity reactions. This versatility is reflected in numerous pathways 
of activation and modulation of these responses.  
1.2.5.1 )Fİ5,-dependent activation 
6WLPXODWLRQ YLD WKH )Fİ5, UHFHSWRU LV WKH EHVW VWXGLHG PHFKDQLVP RI PDVW FHOO
DFWLYDWLRQ)Fİ5,LVDWHWUDPHULFUHFHSWRUFRQVLVWLQJRIRQHĮFKDLQRQHȕFKDLQDQGWZR
disulphide-OLQNHGȖFKDLQV7KHĮFKDLQELQGVWR,J(ZKHUHDV WKHȕDQGȖFKDLQVLQLWLDWH
signal transduction via their immunoreceptor tyrosine-based activation motifs (ITAM). 
:KHQ )Fİ5, LV DJJUHJDWHG XSRQ FURVV-linking of bound IgE by antigen, Lyn 
SKRVSKRU\ODWHVWKH,7$0LQWKHF\WRSODVPLFGRPDLQVRIWKHȕDQGȖFKains and recruits 
6\N W\URVLQH NLQDVH WR WKH Ȗ FKDLQ 6\N SKRVSKRU\ODWHV RWKHU W\URVLQH NLQDVHV WKXV
activating the signaling cascade. Some of these proteins include phospholipase C (PLC) 
which catalyzes the conversion of membrane bound phosphatidylinositol-4,5-
bisphosphate (PIP2) into inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
interacts with its receptors on the endoplasmic reticulum and triggers intracellular 
calcium (Ca2+) release. DAG activates protein kinase C (PKC) leading to cytoskeletal 
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FKDQJHV DQG GHJUDQXODWLRQ 3/&Ȗ-dependent increase of intracellular Ca2+ levels and 
activation of PKC together orchestrate the degranulation of mast cells. Phosphorylation 
of the linker molecule LAT initiates the Ras-Raf-Mitogen activated protein kinase/ERK 
kinase (MEK)-extracellular signal regulated kinase (ERK) cascade which leads to the 
generation of lipid mediator. The activation of PKC phosphorylates transcription factors 
and leads to the production of cytokines. (Figure 1.2) 
1.2.5.2 )Fİ5,-independent activation  
0DVW FHOOV DOVR FRQVWUXFWLYHO\ H[SUHVV )FȖ5,, D ORZ DIILQLW\ UHFHSWRU IRU ,J*
ZKLOH WKH H[SUHVVLRQ RI )FȖ5, WKH KLJK DIILQLW\ UHFHSWRU IRU ,J* DQG )FȖ5,,, D ORZ
affinity receptor for IgG) are induced following exposure to interferon (I)1Ȗ)FȖ5VFDQ
contribute to mast cell activation in two ways: in an antigen-dependent manner through 
the binding of pathogen-specific antibodies; or independently of pathogen-specific 
antibodies through the action of pathogen-derived Ig-binding proteins (also known as B 
cell superantigens). Such activation leads to degranulation, production of lipid mediators, 
cytokines and chemokines (22). The tyrosine-protein kinase receptor Kit is expressed on 
the surface of mast cells. When this receptor binds to SCF it forms a dimer that activates 
its intrinsic tyrosine kinase activity, which in turn recruits and activates various signaling 
molecules. Subsequent propagation of signals leads to mast cell growth, differentiation, 
survival, chemotaxis, and cytokine production. In addition, mast cells can be activated by 
polybasic compounds via the activation of G proteins. Mast cells express various 
GPCRs; hence their function can be modulated by GPCR ligands (23, 24). They can 
also be activated by directly interacting with pathogens through pattern recognition 
receptors (PRRs), including: Toll-like receptors (TLRs), Nod-like receptors (NLRs), and 
the glycosylphosphatidylinositol (GPI)-anchored protein CD48 (21) (Figure 1.3).  
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Figure 1.2 +LJKDIILQLW\,J(UHFHSWRU)Fİ5,,J(ELQGVWRWKH,J-OLNHGRPDLQVRIWKHĮFKDLQ7KHȕ
DQG Ȗ FKDLQV PHGLDWH VLJQDO WUDQVGXFWLRQ YLD WKHLU ,7$0V ZKLFK UHFUXLW Lyn and Syk. (Image 
adapted from Kuby Immunology. Sixth Edition). 
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Figure 1.3 Mechanisms of mast cell activation. Mast cells express a variety of cell surface 
receptors that may play a role in host defense as well as hypersensitivity reactions. These include 
KLJKDIILQLW\,J(UHFHSWRU)Fİ5,,J*UHFHSWRUV)FȖ5,)FȖ5,,DQG)FȖ5,,,*3&5V7/5V1/5V
and GPI-anchored receptors that sense pathogen-associated molecular patterns. (Original 
image). 
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1.2.6 Mast cell mediators 
Activation of mast cells results in the release of an impressive array of 
biologically active mediators, that can be divided into three major categories: (i) 
preformed mediators, (ii) de novo synthesized lipid mediators, and (iii) cytokines, 
chemokines and growth factors (25) (Table 1.3). Preformed mediators are stored in 
cytoplasmic granules and can be quickly released at sites of inflammation through the 
process of degranulation. Degranulation occurs within seconds of stimulation giving 
mast cell-derived mediators a temporal advantage over those produced by other 
immune cells. They also produce lipid-derived inflammatory mediators in the initial 5-30 
minutes of activation, as gene transcription is not required for these mediators to be 
converted to an active form. With time, usually minutes to hours, mast cells release 
cytokines and chemokines that are transcribed and translated in response to stimulus. 
The profile of mediators produced by mast cells can significantly differ depending on the 
nature of stimulus and microenvironmental factors (21, 26). 
1.2.6.1 Preformed mediators 
Mast cell secretory granules contain biogenic amines, lysosomal enzymes, 
proteoglycans, proteases, and preformed cytokines. Histamine is the most well-known of 
these mediators and is tightly associated with proteoglycans inside the granules and 
released with degranulation (27). Of all the lysozomal enzymes known to be present in 
PDVWFHOOJUDQXOHVȕ-hexosaminidase is associated with granules of all subpopulations 
and species, hence its release is frequently used as a means of quantifying the extent of 
degranulation in the laboratory setting (28).  
Serglycin proteoglycans are also major constituents of mast cell granules (29). In 
rodent CTMC, heparin is the main constituent of serglycin, whereas in MMC chondroitin- 
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Table 1.3 Mast cell-derived proinflammatory mediators 
Class of Product Examples Biological effects 
 
Preformed 
mediators 
 
 
Histamine, heparin 
 
Increase vascular permeability, cause 
smooth muscle contraction 
Enzymes Tryptase, chymase, 
cathepsin G, 
carboxypeptidase 
 
Remodel tissue matrix 
Lipid mediators Prostaglandin D2, E2,  
Leukotriene B4, C4 
Cause smooth muscle contraction, increase 
vascular permeability, recruit leukocytes, 
stimulate mucus secretion 
 
 Platelet-activating factor Attracts leukocytes, amplifies production of 
lipid mediators, activates neutrophils, 
eosinophils and platelets, enhances 
angiogenesis and induces physiological 
inflammation 
 
Cytokines IL-3, IL-4, IL-5, IL-13 
 
Stimulate and amplify Th2 cell response 
 IL-3, IL-5, GM-CSF Promote eosinophil production and 
activation 
 
 IL-12, IFN-Ȗ 
 
Stimulate and amplify Th1 cell response 
 TNF Promotes inflammation, stimulates cytokine 
production by immune cells 
 
Chemokines CCL2, CCL3, CCL4, 
CXCL1, CXCL2, CXCL3, 
CXCL10 
 
Attracts monocytes, macrophages and 
neutrophils 
Others Nitric oxide and 
superoxide radicals 
 
Antimicrobial 
 Antimicrobial peptides Antimicrobial 
 
 Osteopontin Tissue remodeling 
   
 
CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; GM-CSF, granulocyte 
macrophage-colony stimulating factor; IFN, interferon; IL, interleukin, TNF, tumor necrosis factor 
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sulphate is the predominant component. In contrast, serglycin in human mast cells 
contains both heparin and chondroitin-sulfate, in a 2:1 ratio, respectively (30). Staining of 
mast cells by various cationic dyes can be explained by their strong binding to serglycin 
present in the granules; therefore, the binding properties of these dyes can be employed 
to distinguish subpopulations. Granules are also a major site for stored proteases, 
accounting for >25% of the total mast cell protein content, with chymase, tryptase and 
carboxypeptidase A being the major proteases expressed (31). In addition, mast cells 
can also store preformed cytokines/growth factors within secretory granules, such as 
tumor necrosis factor (TNF), IL-4, transformation growth factor (TGF)-ȕ (32), vascular 
endothelial growth factor (VEGF) (33), nerve growth factor (NGF) (34) and SCF (35).  
1.2.6.2 Lipid mediators 
Activated mast cells from all species have the capacity to synthesize and release 
lipid mediators and specifically leukotrienes and prostaglandins, which are synthesized 
quickly from their polyunsaturated fatty acid precursor arachidonic acid. Arachidoinic 
acid is mobilized from its storage sites in membrane lipids by the enzyme phospholipase 
A2 (PLA2). It is then metabolized by cyclooxygenase and lipoxygenase enzymes to 
generate prostaglandins, thromboxanes and leukotrienes, respectively, which affect 
vascular permeability, chemotaxis of immune cells, mucus production and activation of 
nerve cells (36). Mast cells exhibit heterogeneity in the release of lipid mediators. Rat 
peritoneal mast cells produce PGD2 but little leukotriene, whereas MMC produce LTB4 
and LTC4 along with PGD2 (37, 38). Human lung mast cells (MCT) synthesize nine times 
more leukotrienes when compared to human skin mast cells (MCTC) (39).  
1.2.6.3 Cytokines, chemokines and other factors 
The list of cytokines and chemokines that mast cells produce following 
stimulation is extensive. At the present, more than thirty different cytokines have been 
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shown to be produced by human mast cells (40). Cytokines and chemokines act both to 
activate local immune cells and to promote cell recruitment to sites of infection. In 
addition, mast cells have also been shown to synthesize products such as antimicrobial 
peptides (41) and free radicals (42) that influence the immune response at epithelial 
surfaces.  
1.2.7 Mast cell chemotaxis and adhesion 
As previously mentioned, mast cells are derived from progenitors that are 
released from bone marrow into the circulation, and subsequently migrate into peripheral 
tissues, where they undergo differentiation and maturation. This recruitment depends on 
the presence of chemoattractants, which are produced locally at the sites of 
inflammation by immune cells (neutrophils, monocytes, NK cells, dendritic cells, 
basophils, eosinophils, B cells, and T cells) and non-immune cells (epithelial cells, 
fibroblasts, and keratinocytes).  There are two type of mast cell migration: chemokinesis 
and chemotaxis. Whereas chemokinesis is a random, non-vectorial moiety, chemotaxis 
is a directional movement towards high concentrations of chemoattractant (43). 
Numerous chemoattractants have been described as inducing chemotaxis by mast cells, 
and will be discussed in detail in sections 1.4 and 1.5. Chemoattractants recruit mast 
cells by binding surface receptors that activate integrins (e.g., the receptor for 
fibronectin) causing adhesion to respective ligands on the vascular endothelium. Arrest 
of mast cell movement (similar to leukocytes) and its subsequent diapedesis through the 
endothelium is regulated by coordinated adhesive interactions and cytoskeletal changes 
in the mast cell (44). The ability of mast cells to adhere to fibronectin, collagen, and 
laminin plays a role in their migration into tissues (45). SCF, a main mast cell growth 
factor, is also a potent mediator of mast cell adhesion to fibronectin and functions 
through its interaction with the  integrin ȕ-1 (46).  
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1.2.8 Methods in mast cell research 
Investigation of the biochemistry and function of mast cells has been made 
possible by various human and animal models available for research. These models 
have allowed researchers to study mast cells in vitro, in vivo as well as ex vivo. In vitro 
studies have used rodent and human mast cells. In vivo studies performed in animals 
such as mice and rats deficient in mast cells are discussed in following subsections.  
1.2.8.1 Rodent mast cells 
1.2.8.1.1 Mouse bone marrow-derived mast cells (BMMC) 
BMMCs are the most widely used primary mast cell model. Bone marrow cells 
cultured in the presence of recombinant murine (rm)IL-3 for 3 weeks give rise to >98% 
SXUH )Fİ5,+ Kit+ mast cells that can be maintained in culture for 8-12 weeks. 
Phenotypically, these cells resemble MMC (Figure 1.4). The addition of rmSCF to 
culture skews the phenotype towards CTMC. BMMC have many advantages as they are 
easy to grow in large quantities and to maintain cost effectively in culture. They also 
prove useful in adoptive transfer technology for replenishing mast cells in mast cell-
deficient animals (47).  
1.2.8.1.2 Mouse peritoneal cell-derived mast cells (mPCMC) 
One limitation to BMMC is their MMC phenotype; they do not respond to 
secretagouges and are not truly representative of a human MCTC phenotype (Table 1.1 
and 1.2). To overcome this limitation, mPCMC can be cultured in the presence of 
rmSCF and closely resemble CTMC. After two weeks, cultures consist of >98% pure 
)Fİ5,+ Kitlow mast cells that can be kept growing for about one month. Following that the  
cells stop growing but can be kept alive in rmSCF-containing medium for another 2-3 
months (48). Although mPCMC respond to IgE-antigen, the relevance of this cell type is 
questionable since humans normally have few mast cells in the peritoneal cavity.  
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Figure 1.4 Murine mast cells cultured from bone marrow in IL-3 for 7 weeks stained with toluidine 
blue. Relatively few purple granules are seen, suggesting that BMMC present only small amounts 
of histamine and heparin. X 100. (Original image).  
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
1.2.8.1.3 Rat basophilic leukemia-2H3 cells (RBL-2H3)  
RBL-2H3 cells have been extensively used for studying IgE-)Fİ5, LQWHUDFWLRQV
signaling pathways for degranulation and testing novel mast cell stabilizers. As these 
cells are adherent, they have also been used in microscopy experiments and drug 
screening. However, discrepancies have been observed between the results of various 
experiments. RBL-2H3 cells were isolated and cloned in 1978 from a histamine 
releasing subline of RBL-1, a basophilic leukemia cell line from Wistar rats basophilic 
cells that were maintained as tumors. These cells present typical characteristics of both 
MMC and basophils, and are an imprecise model for mast cells (49).  
1.2.8.1.4 MC/9 cells 
MC/9 is a cloned murine cell line with characteristics of mast cells that depends 
on rmIL-3 for its growth (50). It phenotypically resembles MMC isolated from a variety of 
sources, notably those of the lung and intestinal mucosa. MC/9 granules contain 
chondroitin sulphate rather than heparin. Biochemically, MC/9 cells can be stimulated by 
calcium ionophore A23187, concanavalin A, and IgE-hapten, as well as other agents. 
They can be easily grown in large numbers in suspension cultures, providing the 
opportunity to perform accurate biochemical analysis (51).  
1.2.8.2 Mast cell-deficient mice 
As the development mast cells is crucially dependent on the binding of SCF to 
Kit, mouse strains with alterations in the c-Kit gene can be mast cell-deficient and have 
been utilized for studying mast cell functions (52). The c-Kit mutant WBB6F1-KitW/W-v and 
C57BL/6J-KitW-sh/W-sh mice are the most widely used models. KitW/W-v mice have truncated 
and point-mutated W and WV alleles, respectively, leading to reduced Kit expression, 
signal transduction and severe mast cell deficiency. However, as Kit is important for the 
development of other cell lineages, KitW/W-v mice are also deficient in erythrocytes, 
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neutrophils, and certain T cells. As a result, these mice develop macrocytic anemia and 
neutropenia, and sterility (53). KitW-sh/W-sh mice have an insertion upstream of the c-Kit 
that leads to selective reduction in Kit expression and hence mast cell deficiency. These 
mice bear abnormalities, including splenic myeloid and megakaryocytic hyperplasia, but 
are generally milder than KitW/W-v as these mice are neither anemic nor sterile, and have 
normal blood neutrophils (54). Both strains can be reconstituted with immature 
progenitor mast cells derived in vitro IURP ERQH PDUURZ FHOOV LQ ³NQRFN-LQ´ PRGHOV WR
define mast cell-specific contributions in experimental models. Engraftment of mast cells 
by intradermal, intraperitoneal or intravenous injections can result in mast cell numbers, 
which, dependent on the route of transfer and the anatomical site, can approach normal 
mast cell density, but often remain considerably lower with significant variability (55).  
Other approaches to investigate in vivo functions of mast cells include the use of 
transgenic mice expressing Cre-UHFRPELQDVH XQGHU WKH FRQWURO RI ³PDVW FHOO-VSHFLILF´
promoters. Such mast-cell-Cre mice can be crossed with other strains in which the gene 
RI LQWHUHVW LV ³IOR[HG´ (56) :KHQ D JHQH VHTXHQFH LV ³IODQNHG E\ loxP VLWHV´ IOR[HG
Cre-recombinase can excise the specific segment from the genetic sequence. For 
example, Mcpt5-Cre transgenic mice (Cre expressed under the control of the mast cell 
protease 5 promoter) delete loxP-flanked genomic DNA in mast cells alone, whereas no 
deletion occurV LQRWKHUFHOO W\SHV7KLVDSSURDFKKDVJHQHUDWHG ³LPSURYHG´PDVWFHOO-
deficient mouse model, permitting direct analyses of the extent to which mast cells 
represent important source of mediators that can also be derived from other cells (56).  
1.2.8.3 Human mast cells  
1.2.8.3.1 Primary human mast cells 
Human mast cells can be cultured from CD34+ progenitors isolated from 
peripheral or umbilical cord blood in the presence of rhSCF. Human peripheral blood 
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CD34+ cell-derived mast cells (HuMC) are relatively mature with a condensed non-
segmented nucleus and nuPHURXVJUDQXOHVH[SUHVV)Fİ5,DQGDUHWU\SWDVH+ chymase+ 
(8) (Figure 1.5). By contrast, cord blood-derived mast cells (CBMC) are relatively 
immature with a segmented nucleus and less abundant granules. They are tryptase+ 
chymase- and do not express significant DPRXQWV RI )Fİ5, EXW LQFXEDWLRQ IRU  GD\V
with IgE and rhIL-4 induces )Fİ5, H[SUHVVLRQ (57). Human mast cells can also be 
isolated from tissues such as skin, lung, intestine, spleen, kidney, and uterus (58). 
Phenotypic differences exist between tissue-derived mast cells depending on their 
origin. For instance, skin mast cells are MCTC, whereas lung mast cells are largely MCT 
(17)  
Although primary human mast cells are preferred over cell lines to study mast 
cell biology, current culture protocols are unable to achieve complete mast cell 
maturation as determined by functional studies and expression of cell surface markers. 
Other limitations include the time and cost associated with culturing progenitors for 6-12 
weeks in the presence of various cytokines and growth factors, only to attain limited 
numbers of mast cells per culture. Isolation and purification of mast cells from tissues is 
labor intensive, requires large quantities of fresh tissue specimens and yields only 1-4 x 
105 mast cells per gram of tissue (59). Moreover, the response of mast cells varies with 
time as cells used immediately after isolation usually respond better to physiological 
stimuli, such as IgE-antigen (P. Pundir, personal observation).    
1.2.8.3.2 Human mast cell lines  
Due to the scarcity of tissue mast cells and the costly purification procedures, 
human mast cell research mainly relies on the use of mast cell lines. Currently three 
human mast cell lines have been established: (i) HMC-1, (ii) LAD and (iii) LUVA.  
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HMC-1 is a SCF-independent, fast -growing, immature mast cell line established 
in 1988 from the peripheral blood of a patient with mast cell leukemia (60). In fact, two 
subclones, HMC1.1 and HMC1.2 have been characterized. HMC1.1 cells harbor the 
V560G c-Kit mutation, while HMC1.2 cells harbor both the V560G and D186V c-Kit 
mutations, with both making the Kit receptor active even in the absence of SCF. While 
these cells contain classical mast cell-associated markers such as histamine, tryptase, 
heparin and Kit, they lack native expression of )Fİ5,, limiting their functional application 
(61)7KHODFNRI)Fİ5,KDVOHGUHVHDUFKHUVWRHPSOR\³less physiologic´ stimuli, such as 
calcium ionophores and phorbol esters to assess mast cell function using HMC-1 cells.  
LAD (Laboratory of allergic diseases) is a SCF-dependent, slow-growing mast 
cell line developed from a patient with mastocytosis and characterized in 2003. LAD1 
and LAD2 cells possess many well-estabOLVKHGPDVW FHOOPDUNHUV LQFOXGLQJ)Fİ5,DQG
retain characteristics of mature tissue mast cells (heavily granulated, intracytoplasmic 
histamine and tryptase+ chymase+) (62) (Figure 1.6). Since LAD2 cells persist in long-
term cultures, this offers an invaluable model for studies with mast cells.  However, their 
widely variable doubling-time (about 1-2 weeks) and requirement for SCF-supplemented 
medium makes them poorly suitable for experiments requiring large number of cells.  
LUVA is a new cell line characterized in 2011 which was derived from peripheral 
blood CD34+ cells of a patient with aspirin-exacerbated respiratory disease. These cells 
are granulated and tryptase+ chymase+ and although having a normal c-Kit, their growth 
is SCF-independent. While they ZHUH LQLWLDOO\ )Fİ5,+ and able to release mast cell 
mediators (63), it seems that the cell line loses its expression RI)Fİ5,Xpon long term 
culture (Dr. T.C. Moon, personal communication, February 2013).  
1.2.8.4 In vitro stimulation of mast cells 
)Fİ5,-mediated activation of mast cells can be mimicked experimentally using 
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Figure 1.5 Primary human mast cells stained with toluidine blue. Peripheral blood CD34+ cells 
were cultured in SCF for 7 weeks. Substantial amounts of purple granules are seen, suggesting 
HuMC present significant amounts of histamine and heparin. X 100. (Original image).  
 
 
Figure 1.6 LAD2 human mast cells stained with toluidine blue. Presence of purple granules 
suggests LAD2 cells express histamine and heparin. X 100. (Original image).  
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monoclonal IgE/anti-IgE or antiserum specific for IgE which can crosslink membrane 
bound IgE. Calcium ionophores A23187 and ionomycin are also used as stimulants and 
can induce mast cell degranulation and mediator release. Other non-immunological 
stimuli for mast cell activation include c48/80, SP, vasoactive intestinal peptide, C5a, 
C3a, morphine, codeine, adenosine, and platelet-activating factor (PAF). Pathogen-
associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), flagellin, 
lipotechoic acid, peptidoglycans and double-stranded RNA are also used to stimulate 
mast cells to mimic their response to pathogens in vitro. The various stimuli have 
differential effects on mast cell responses depending on the type of mast cell (Table 1.1 
and 1.2) (64, 65). 
1.2.8.5 In vivo stimulation of mast cells 
The presence/activation of human mast cells in vivo can be examined by various 
methods, including measuring the release/presence of mast cell mediators in bodily 
fluids, histology and immunohistochemistry of tissue biopsies, as well as determining 
physiological effects of ligands/drugs/stimuli with specificity for mast cells.  
1.2.9 Mast cells in health 
Signs and symptoms of mast cells mediators are generally associated with 
sneezing, wheezing, itching, and other inflammatory events often referred to as 
hypersensitivity. However, it has now become clear that mast cells not only release 
histamine, leukotrienes and prostaglandins, but also many other mediators not readily 
associated with inflammation. Mast cell mediators can enhance or suppress the 
development, survival, proliferation, migration, maturation, or function of other immune 
cells. For example, histamine can promote Th1 cell activation through activation of the H1 
receptor but conversely can suppress both Th1 and Th2 cell activation through activation 
of the H2 receptor (66). Mast cell-derived cytokines can influence the polarization and 
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function of T cell subpopulations (67), and IL-4, IL-5, IL-6, and IL-13 can influence B cell 
development and function, including IgE production (68, 69).  
Mast cells are involved in immunity against extracellular parasitic infection. For 
example, KitW/W-v mast cell-deficient mice infected with Trichinella spiralis show greater 
and persistent peak larval counts and slower worm expulsion than wild-type normal 
mice. Reconstitution of mast cells effectively restores protective antiparasite immune 
responses in these mice (70). In a model of cutaneous parasite infection by Leishmania 
major, mast cells contribute to the control of skin lesions by priming antigen-specific T 
cells and enhancing the recruitment of proinflammatory neutrophils, macrophages and 
dendritic cells (71). Mast cell function is also necessary for mice to survive infections by 
other pathogens including bacteria. Reconstitution in mast cell-deficient mice 
substantially reduces mortality and morbidity from ceacal ligation and puncture. This 
protection by adoptive transfer of mast cells can be inhibited by using anti-TNF 
neutralizing antibodies suggesting that mast cell-derived TNF induces neutrophil 
recruitment which is crucial for host defense against bacteria (72). Mast cells can also 
recognize and respond to viruses and viral products through the release of cytokines 
(73), recruitment of CD8+ T cells, production of IFNĮDQG WKHVXEVHTXHQWFOHDUDQFHRI
viral infection (74). Their numbers are also seen to increase in the lungs following 
respiratory viral infection (75). Mast cell proteases are also involved in maintaining 
homeostasis by degrading toxins, such as endothelin-1 (76) and snake venom (77).  
Mast cells are important in homeostasis of organs that undergo continuous 
growth and remodeling, such as hair follicles and bones. Hair follicle cycling is severely 
impaired in mast cell-deficient mice, resulting in hair growth disorders (78). Mast cells 
produce osteopontin (79); mast cell-deficient mice have thinner, lighter and fragile 
femurs. Mast cell-derived IL-1, TGF-ȕ ,/-6 and histamine can influence osteoclast 
recruitment and development (80). Mast cells play a major role in wound healing and 
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tissue repair. Growth factors, such as NGF, platelet-derived growth factor (PDGF), 
VEGF, fibroblast growth factor 2 (FGF2), histamine and tryptase increase vascular 
permeability, promote proliferation of epithelial cells and fibroblasts, initiate collagen 
deposition and remodeling of the matrix. Moreover, mast cells recruit other inflammatory 
cells to the site of injury, facilitating degradation and/or production of extracellular matrix 
proteins, and promoting angiogenesis by producing angiogenic mediators TNF, IL-8, 
FGF and VEGF (81). In many tissues, mast cells are found in close association with 
nerve endings, where they can communicate with neurons though the release of 
mediators. Histamine, serotonin and tryptase can influence neuronal activity, and in 
return neurons can release neuropeptides which activate mast cells (82). In the gut, 
mast cells and neurons play a role in maintaining homeostasis by regulating ion 
transport, secretion of acid, electrolytes and mucus by epithelial cells, and 
gastrointestinal motility (83).  
1.2.10 Mast cells in disease 
Mast cells are triggers of the allergic or Type I hypersensitivity responses. The 
importance of mast cells in allergic reactions is emphasized by their increased numbers 
in affected tissues. In patients with asthma, their numbers are increased following 
allergen exposure and are localized within the airway smooth muscle (ASM), epithelium, 
and mucous glands (84). This critical localization in proximity to key anatomical 
structures involved in asthma and evidence for direct interaction between mast cells and 
ASM cells (85) suggest they play a significant role in the pathophysiology of this disease. 
ASM can recruit mast cells by secreting CXCL8 and CXCL1, and can enhance survival 
and induce degranulation. Mast cells can induce TGF-ȕ H[SUHVVLRQ LQ $60 FHOOV YLD
UHOHDVHRIȕ-tryptase, resulting in tissue remodeling (86). Mucosal mast cells under the 
influence of IL-4 and IL-9 are highly responsive to inhaled allergens causing 
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bronchoconstriction. The initial rapid release of mediators such as histamine, LTC4 and 
PGD2 contributes to the acute signs and symptoms associated with early-phase 
asthmatic reactions and may range from mild rhinitis to anaphylactic shock and death. 
These mediators induce vasodilation, contraction of the bronchial smooth muscle 
(producing airflow obstruction and wheezing) and increased mucosal secretions 
(exacerbating airflow obstruction in the lower airways and producing a runny nose). Mast 
cells also have a role in late-phase asthmatic reaction by mediating local accumulation 
and activation of T cells, dendritic cells, neutrophils, eosinophils and monocytes. Mast 
cell-produced Th2 cytokines IL-4, IL-5 and IL-13 which regulate IgE synthesis by B cells, 
development of eosinophilc inflammation, and secretion of cytokines (TGF-ȕDQG)*)-2) 
associated with tissue remodeling in asthma.  
Mast cells are also active modifiers of autoimmune diseases. Disease-associated 
increases in mast cell numbers, along with mast cell degranulation and secretion of 
mediators at sites of inflammation are commonly observed in many autoimmune 
diseases, including multiple sclerosis, rheumatoid arthritis, type I diabetes, and bullous 
pemphigoid. Histamine, PAF, TNF, CXCL2, and IL-8 released within minutes of mast cell 
activation initiate the influx of neutrophils, thus contributing to neutrophil-driven tissue 
damage in autoimmune diseases. In addition, activation of mast cells through PRRs, 
)Fİ5, DQG )FȖ5 DSSHDUV WR EH WKH FRPPRQ PHFKDQLVP OLQNLQJ DXWRLPPXQLW\ DQG
allergy.  
Mast cells also play pivotal roles in cardiovascular diseases. Pathological studies 
have shown increased presence of mast cells in perivascular tissue during 
atherosclerotic plaque progression, while plaque rupture is associated with myocardial 
infarction and stroke. Mast cells promote lipid accumulation, matrix degeneration, 
apoptosis, leukocyte influx into the plaque, and microvascular leakage, all resulting in 
plaque destabilization and rupture. Mast cell-deficient atherosclerotic LDLr-/- mice have 
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reduced atheroscelorsis compared to control mice, while repopulation of these mice with 
BMMC reverses the beneficial effect of mast cell absence. Mast cell numbers are also 
found to increase during heart failure, especially in patients with ischemic and idiopathic 
cardiomyopathy (87).  
Mast cells play a dual role in cancer, as their presence in tumor tissue may affect 
prognosis both positively and negatively. Mast cell infiltrates surround tumor and secrete 
mediators that act as growth factors, facilitating tumor growth, angiogenesis, and 
metastasis. These include heparin, IL-8 and VEGF, which induce neovascularization, 
histamine, an immunesuppressant, mitogenic factors such as NGF, SCF, PDGF, and 
proteases, which disrupt the surrounding matrix and facilitate metastases. By contrast, 
IL-4, IL-5, IL-6 and TNF can induce apoptosis of tumor cells, thus limiting tumor growth. 
High mast cell density together with angiogenesis is a poor predictor of clinical outcome 
in colorectal cancer, lung cancer, and pancreatic cancer. In contrast, mast cell infiltration 
has been reported to be detrimental to tumor growth in breast cancer (88, 89).  
To sum up, mast cell responses are essential in both innate and acquired 
immunity. They are also involved in the pathogenesis of inflammatory diseases. Mast 
cells are continuously communicating with each other, various immune cells and the 
surrounding environment in orchestrating diverse functions. These interactions require a 
molecular framework and a mechanism for transmission of information across the cell 
membrane. The molecular framework consists of receptors located in the plasma 
membrane, such as GPCRs, transducers of G protein signaling mechanisms.   
 
1.3 G PROTEIN-COUPLED RECEPTORS 
The 2012 Nobel Prize in chemistry recognized Drs. Lefkowitz and Kobilka for 
WKHLU ³VWXGLHV RI * SURWHLQ-FRXSOHG UHFHSWRUV *3&5V´ (90). Their groundbreaking 
discoveries revealed the signaling mechanisms initiated by endogenous substances, 
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such as adrenalin, serotonin, histamine, dopamine, and many other hormones and 
neurotransmitters through a family of versatile GPCRs. 
1.3.1 GPCR: Definition and basic characteristic  
 GPCRs are the largest and most diverse superfamily of proteins located in the 
plasma membrane of eukaryotic cells. They mediate the action of various stimuli by 
activating heterotrimeric G proteins. The human genome encodes for over 800 unique 
GPCRs (91) which can be grouped into five major families: (i) rhodoposin family, (ii) 
adhesion family, (iii) frizzled/taste family, (iv) glutamate family, and (v) the secretin family 
(92). The physiologic function of a fraction of these 800 GPCRs remains largely 
unknown and referred to as the orphan GPCRs; however, due to ongoing research 
efforts, the actual number of orphan receptors is decreasing (93). 
1.3.2 GPCR: Structure 
GPCRs are composed of seven hydrophobic transmePEUDQHĮ-helices domains 
connected by three extracellular loops and three intracellular loops (94). The 
extracellular region, which binds the ligand, includes the amino terminus and the 
LQWUDFHOOXODU UHJLRQ WKDW LQWHUDFWV ZLWK * SURWHLQV ȕ-arrestins and other downstream 
effectors, has the carboxyl terminus (95). The amino terminus is frequently glycosylated 
and may range in size from 7 to 595 amino acids. The carboxyl terminus is usually 
bound to the membrane by a lipid modification, such as palmitoylation, and ranges in 
size from 12 to 359 amino acids. A disulphide bond between two highly conserved 
cysteines links the second and third extracellular loops of most GPCRs (96). 
1.3.3 GPCR: Ligand interaction 
Ligands bind within the transmembrane domain or extracellular binding sites of 
GPCR. In protease-activated receptors, the ligand is generated by proteolytic cleavage 
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of amino terminus of the receptor (97). The binding of a ligand on GPCR depends on 
two basic properties: affinity and efficacy. Affinity refers to the ability of a ligand to bind to 
the receptor and efficacy describes the effect of a ligand on the functional properties of 
the receptor and its associated signaling network. Based on these attributes, there are 
two types of ligands for GPCR: agonist and antagonists. Agonists are ligands that have 
positive efficacy and fully activate the receptor, while partial agonists induce submaximal 
activation of the G protein even at saturating concentrations. Inverse agonists have 
negative efficacy as they inhibit basal activity. Antagonists have neutral efficacy, but 
competitively block binding of other ligands, thus preventing any signaling (98).  
1.3.4 Receptor activation: Interaction with G proteins  
Binding of an agonist induces a conformational change in the receptor protein 
that is then transferred as a signal to its intracellular carboxyl terminus, where the GPCR 
interacts with G proteins. Heterotrimeric G proteins are the molecular switches that turn 
on signaling cascades and are composed of three subunits, guanosine diphosphate 
(GDP) nucleotide-ELQGLQJ Į-VXEXQLW *Į DQG D GLPHU FRQVLVWLQJ RI ȕ- DQG Ȗ-subunits 
*ȕȖ(99). In humans, there are 21 GĮZKLFKDUHGLYLGHGLQWRIRXUFODVVHVL*Įs, (ii) 
*Įi*ĮoLLL*Įq*Į11DQGLY*Į12*Į13 (100) (Table 1.4), 6 *ȕDQG*ȖVXEXQLWV,Q
WKH LQDFWLYH IRUP *Į LV ERXQG WR *'3 DQG WLJKWO\ DVVRFLDWHG ZLWK *ȕȖ $FWLYDWLRQ RI
GPCR promotes the exchange of GDP for GTP (guanosine triphosphate) and the 
GLVVRFLDWLRQRI*Į-*73IURP*ȕȖGLPHU$FWLYDWHG*ĮDQG*ȕȖVXEXQLWVFan modulate 
the activity of various effectors, which transduce the signal to different kinds of second 
messengers (99) (Figure 1.7).  
1.3.5 Activated GPCR: Phosphorylation and internalization 
Given the diversity of the GPCR superfamily, the general process by which a cell 
regulates the magnitude and duration of GPCR signaling is surprisingly well conserved. 
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Table 1.4 &KDUDFWHULVWLFVRI*SURWHLQĮVXEXQLW 
 Family Subtype Gene Expression Effectors 
*Įs *Įs Gnas Ubiquitous $&Ĺ9'&&Ĺ 
 *Įolf Gnal Olfactory epithelium, brain $&Ĺ 
*Įi/o *Įi1 Gnai1 Wide $&Ļ*,5.Ĺ 
 *Įi2 Gnai2 Ubiquitous $&Ļ*,5.Ĺ 
 *Įi3 Gnai3 Wide $&Ļ*,5.Ĺ 
 *Įo Gnao Neuronal, neuroendocrine 9'&&Ļ*,5.Ĺ 
 *Įt-rod Gnat1 Retinal rods, taste cells cGMP-3'(Ĺ 
 *Įt-cone Gnat2 Retinal cones cGMP-3'(Ĺ 
 *Įgust Gnat3 Taste/brush cells 3'(Ĺ" 
 *Įz Gnaz Neuronal, platelets $&Ļ 
*Įq/11 *Įq Gnaq Ubiquitous 3/&ȕĹ 
 *Į11 Gna11 Ubiquitous 3/&ȕĹ 
*Į12/13 *Į12 Gna12 Ubiquitous RhoGEF, Btk, cadherin 
 *Į13 Gna13 Ubiquitous RhoGEF, cadherin 
 
AC, adenylyl cyclase; cGMP, cyclic guanosine monophosphate; GIRK, G protein-regulated inward rectifier 
potassium channel; PDE, phosphodiesterase; PLC, phospholipase C; RhoGEF, Rho-specific guanine 
nucleotide exchange factor; VDCC, voltage-dependent calcium channel 
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Figure 1.7 GPCR signaling cascade. 7KH DFWLYH *Į-GTP subunit stimulates phospholipase C 
3/&ȕ ZKLFK K\GURO\]HV SKRVSKDWLG\OLQRVLWRO -biphosphate (PIP2) into diacylglycerol (DAG) 
and inositol 1,4,5-triphosphate (IP3). IP3 binds to IP3 receptors present on the surface of internal 
Ca2+ stores, mainly smooth endoplasmic reticulum, and opens Ca2+ channels. Release of Ca2+ 
leads to degranulation. DAG activates PKC which in turn stimulates generation of lipid mediators 
through cytosolic phospholipase A2 (PLA2*ȕȖGLPHUDFWLYDWHV5DV-Raf, which phosphorylates 
mitogen-activated protein kinases (MAPK), and extracellular signal regulated kinases (ERK). 
7KHVHWRJHWKHUZLWK3/&ȕDQGSKRVSKRLQRVLWRO-kinase (PI3K) lead to cytokine and chemokine 
generation. (Original image). 
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GPCR function can be regulated by several different mechanisms. GPCR become 
GHVHQVLWL]HGZKHQH[SRVHGWRDQDJRQLVWIRUDSURORQJHGSHULRGRIWLPH µ+RPRORJRXV¶
desensitization is mediated by agonist-induced activation of the same GPCR, whereas 
µKHWHURORJRXV¶ GHVHQVLWL]DWLon is mediated by repeated stimulation of a GPCR by one 
agonist resulting in unresponsiveness of unrelated GPCR to other agonists. Besides, G 
proteins may terminate their own activation by the intrinsic GTPase activity of *ĮZKLFKO
hydrolyzes *73 WKHUHE\ DOORZLQJ *Į-*'3 WR UHXQLWH ZLWK *ȕȖ DQG IRUP DQ LQDFWLYH
heterotrimer (101). As this reaction proceeds at a slow rate (101), cofactors such as 
regulator of G protein signaling proteins (102) come into play that aid in desensitization.  
Rapid desensitization of GPCR can also be facilitated by phosphorylation-
dependent uncoupling of the receptor from heterotrimeric G proteins by the GPCR 
kinase (GRK)-arrestin pathway. There are seven GRKs in humans (GRK1-7) and four 
arrestins (arrestin 1-4). Most GPCRs are regulated by only four GRKs: GRKs 2, 3, 5, or 
6, and two arrestins: arrestin-ȕ-arrestin1) and arrestin-ȕ-arrestin2) (103). Just as G 
proteins recognize activated GPCR, GRKs also recognize activated GPCR, which leads 
to receptor phosphorylation at various serine/threonine residues on the intracellular 
loops and the carboxyl-terminal tail (104). Upon phosphorylation by GRK, G3&5¶V
affinity for arrestin proteins is increased, which prevents the receptor from activating 
DGGLWLRQDO * SURWHLQV 7KH ȕ-arrestins interact with clathrin and the adaptor protein 
complex AP-2 and target the agonist-occupied receptors to pre-existing clathrin-coated 
pits for internalization. Thus GRK phosphorylation and arrestin binding result in 
termination of GPCR signaling, despite the continued presence of agonist (105, 106).  
 
1.4 GPCRs AND MAST CELL FUNCTION 
Host- and pathogen-derived GPCR agonists regulate innate inflammatory 
responses through modulating mast cell chemotaxis, survival, and activation. GPCR-
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activated physiological responses are important for maintaining homeostasis, but in 
some cases, disregulation leads to the development of pathological conditions. 
Nevertheless, activation of GPCR by extracellular stimuli enhances the motile phenotype 
of mast cells, which results from the activation of numerous signaling cascades involving 
proteins, such as GTPases (107), kinases (108)DQGȕ-arrestins (109). These ultimately 
act in concert to regulate remodeling of the actin cytoskeleton and cell migration. In 
many cases, these GPCRs also control the activated state of the recruited cells (110). 
Chemokines are small molecular weight proteins that bind to their cognate receptors to 
elicit chemotaxis. The activation of receptors, such as CXCR2, plays an important role in 
mast cell migration, mediator release, wound healing, angiogenesis and inflammation 
(111). Activation of CXCR4, another chemokine receptor, on mast cells plays an 
important role in hematopoiesis as well as in the development, and organization of the 
immune system (112). Several biolipids such as sphingosine-1 phosphate (S1P), 
cysteinyl leukotrienes (CysLTs), and prostaglandins also regulate mast cell functions via 
GPCRs. S1P1 receptor induces mast cell chemotaxis, whereas S1P2 receptor stimulates 
degranulation and release of cytokines/chemokines (113). CysLT receptor 1-2 (114, 
115) and prostaglandin receptors, EP 1-4, (116, 117) modulate mast cell responses in 
infected/inflamed tissues by increasing mast cell numbers, degranulation, and release of 
mediators. Neuropeptide SP releases histamine from mast cells and the effect is 
believed to occur through neurokinin GPCRs (118). Also, adenosine, an endogenous 
nucleoside released from metabolically active cells and generated exogenously by 
degradation of released ATP, can inhibit or enhance mediator release from mast cells 
depending upon which adenosine receptor is engaged on the cell surface (119).  
Mast cells accumulate within hours at sites of acute inflammation. They express 
abundant adhesion molecules for the rapid binding to inflammation-induced counter-
receptors on activated endothelial cells, and their chemoattractant receptors sense the 
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release of tissue-derived signals and PAMPs. Mast cells become activated and release 
products that in turn promote vascular permeability and leukocyte recruitment (21, 22). 
Numerous chemoattractants are capable of inducing chemotaxis in mast cells. Some of 
them, and their corresponding receptors, are summarized in Table 1.5. In the following 
sections we focus on the N-formyl peptide receptors, the complement fragment 
receptors, and the adenosine receptor and describe how human mast cell function is 
modified by these GPCRs. 
 
1.5 THE N-FORMYL PEPTIDE RECEPTORS, THE COMPLEMENT 
RECEPTORS AND THE ADENOSINE RECEPTORS 
The classical chemoattractants have dominated the study of leukocyte 
chemotaxis owing to their potency in vitro and in vivo, and to their induction by 
proinflammatory stimuli. In addition, most of these molecules also activate the 
antimicrobial functions of leukocytes, including degranulation and oxidative burst. The 
classical chemoattractants include N-formyl-methionyl-leucyl-phenylalanine (fMLF), C3a, 
C5a, and adenosine. The primary structures of chemoattractant receptors for these 
classical chemoatrractants have been deduced from cloned cDNAs; all of them are high 
affinity GPCRs (120).   
1.5.1 The N-formyl peptide receptor (FPR) family 
The human FPR is a GPCR that was first defined pharmacologically in 1976 as a 
high affinity binding site on the surface of neutrophils for the prototypical N-formylated 
peptide, fMLF (121). The receptor was then cloned in 1990 from cDNA library from 
differentiated HL-60 myeloid leukemia cells (122). Two additional genes, FPR-like 1 
(FPRL1) and FPR-like 2 (FPRL2), were subsequently cloned by low-stringency 
hybridization using FPR cDNA as a probe (123, 124). Although all three receptors in  
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Table 1.5 Different mast cell chemoattractants and their receptors 
Chemoattractant Receptor Mast cell model 
SCF c-Kit (CD 117) BMMC, PMC, CBMC, HMC-1 
IgE-antigen )Fİ5, MC/9, BMMC 
S1P SIPR1, S1PR2 BMMC, RBL-2H3, CBMC, 
LAD2 
PGE2 EP3 BMMC 
PGD2 DP1, DP2 (CRTH2) BMMC 
LTB4 BLT1, BLT2 BMMC, CBMC, HMC-1 
LTD4, LTC4 CysLT1R, CysLT2R CD34+ hematopoietic 
progenitors 
CCL3 (MIP-Į&&/5$17(6
CCL7 (MCP-3), CCL14 (HCC-1), 
CCL15 (MIP-į&&/+&&-
4), CCL23 (MPIF-1) 
 
CCR1 BMMC, LMC, CBMC, HMC-1 
CCL5 (RANTES), CCL7 (MCP-3), 
CCL8 (MCP-2), CCL1 (eotaxin), 
CCL13 (MCP-4), CCL15 (MIP-
į&&/HRWD[LQ-2), CCL26 
(eotaxin-3), CCL28 (MEC) 
 
CCR3 BMMC, LMC, CBMC, SMC 
CCL5 (RANTES) CCR4 LMC, CBMC 
CCL3 (MIP-Į&&/0,3-ȕ
CCL5 (RANTES), CCL11 
(eotaxin) 
 
CCR5 CBMC 
CCL16 (HCC-4), CCL20 CCR6 IMC 
CCL19 (MIP-ȕ&&/&NLQH CCR7 BMMC, LMC, IMC 
CCL1 CCR8 IMC 
CXCL6 (GCP-2), CXCL8 (IL-8) CXCR1 BMMC, LMC, CBMC, IMC 
CXCL8 (IL-8) CXCR2 CBMC, IMC 
CXCL9 (MIG), CXCL10 (IP-10), 
CXCL11 (I-TAC) 
CXCR3 BMMC, CBMC, IMC, synovial 
MC, HMC-1 
CXCL12 (SDF-Į CXCR4 BMMC, CBMC, LMC, IMC 
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CXCL16 (GCP-2) CXCR6 BMMC, LMC, IMC 
CX3CL1 (fractalkine) CX2CR1 BMMC, IMC 
TNF TNF receptor PMC 
TGF-ȕ 7*)ȕ-I and II receptors PMC, CBMC, HMC-1 
Adenosine Adenosine receptors BMMC 
C1q cC1q-R, gC1q-R HMC-1 
C3a C3aR CBMC, SMC, HMC-1 
C5a C5aR CBMC, SMC, HMC-1 
PAF PAF-receptor BMMC, CBMC, HMC-1 
5-Hydroxytryptamine 5-HT receptors BMMC, HuMC 
Histamine Histamine receptor BMMC 
fMLF n.d. PMC 
Catestatin n.d. HuMC, LAD2 
Cathelicidin LL-37 n.d. LAD2 
ȕ-defensins n.d. PMC, LAD2 
 
BMMC, bone marrow-derived mast cells; C3a, complement component C3a; C5a, complement component 
5a; CBMC; cord blood-derived mast cells; fmlp, N-formyl-methionyl-leucyl-phenylalanine; HMC-1, human 
mast cell line-1; HuMC, human peripheral blood CD34+ cells-derived mast cells; IgE, immunoglobulin E; IL, 
interleukin; IMC, intestinal mast cells; LAD2, Laboratory of Allergic Diseases 2; LMC, lung mast cells; LT, 
leukotriene; MC/9, murine mast cell line; MCP, monocyte-specific chemokine; MIG, monokine induced by 
interferon gamma; MIP, macrophage inflammatory protein; PG, prostaglandin; PMC, peritoneal mast cells 
RANTES, regulated on activation, normal T cell expressed and secreted; RBL-2H3, rat basophilic-like 
human mast cell line; SCF, stem cell factor; SDF-1, stromal cell-derived factor-1; SMC, skin-derived mast 
FHOOV7*)ȕWUDQVIRUPDWLRQJURZWKIDFWRUEHWD71)WXPRUQHFURVLVIDFWRUQGQRWGHWHUPLQHG 
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FPR family play a critical role in the regulation of inflammatory process associated with 
host defense, FPRL1 will be discussed further because of its relevance to this thesis. 
1.5.1.1 FPRL1 receptor 
Unlike FPR which binds fMLF with high affinity (Kd < 1 nM), FPRL1 exhibits low 
affinity (efficacy ~1000 fold lower than FPR) for fMLF (125). FPRL1 was initially termed 
as ALX because of its high affinity for arachidonic acid-derived Lipoxin A4 (LXA4) (126). 
Thereafter, a number of ligands were described, making FPRL1 an exceptionally 
promiscuous receptor, responding to numerous ligands of different origins and 
structures. These include serum amyloid A (SAA), annexin 1 and its derived peptides, 
antimicrobial peptides, chemokines, HIV peptides, as well as synthetic peptides 
WKYMVM and WKYMV (W peptides), and numerous chemical compounds (C43) (127).  
1.5.1.1.1 Structure 
FPRL1 comprises a 350-amino acid polypeptide chain. The receptor clusters on 
chromosome 19q13.3, and shares 69% sequence homology with FPR (125) and 83% 
with FPRL2. (128). The structural domain that mediates FPRL1 binding to agonists has 
yet to be identified. Studies from FPR have suggested that the second and the fifth 
transmembrane domains may be involved in ligand binding; however, stimulation of 
FPRL1 by ligands which have the ability to also activate FPR, is not affected by two 
FPR-specific antagonists. This indicates that although certain agonists are recognized 
by both FPR and FPRL1, binding of these agonists to the two receptors involve different 
binding sites (129).  
1.5.1.1.2 Expression.  
FPRL1 is expressed in a large variety of cells and tissues, including monocytes, 
macrophages, neutrophils, T cells, B cells, microglial cells, platelets, hepatocytes, 
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epithelial cells, microvascular endothelial cells, fibroblasts, spleen, lung, testis, placenta, 
brain, astrocytoma, and neuroblastoma cells (130).  
1.5.1.1.3 Signaling.  
)35/LVFRXSOHGWR*Įi proteins and upon activation signals through G protein-
dependent signaling pathways described earlier (122, 131, 132). The synthetic peptide 
WKYMVM can activate FPRL1 to induce various cellular functions, such as calcium flux, 
chemotaxis, lipid mediator production through cPLA2, MAPK, PI3K and Akt activation, 
and superoxide production. WRW4 peptide is an antagonist of FPRL1; it has no effect 
on FPR signaling but blocks activation by most FPRL1 agonists (133).  
1.5.1.1.4 Biological role.  
FPRL1 is strongly associated with host defense, and its ability to convey both 
pro- and anti-inflammatory signaling makes it an intriguing GPCR. Bacteria-derived 
peptides activate chemotactic and antimicrobial responses in neutrophils via FPRL1. 
Antimicrobial peptides produced during microbial invasion interact with FPRL1 leading to 
recruitment of neutrophils, monocytes, eosinophils, and T cells; therefore, amplifying 
innate immune response. The receptor can also act during human immunodeficiency 
virus (HIV)-1 infection as HIV-1 envelope proteins gp41 and gp120 are chemotactic 
DJRQLVWV IRU )35/ &KHPRNLQH V&.ȕ-1, a splice variant of CCL23, elicits FPRL1-
mediated Ca2+ mobilization and chemotaxis in neutrophils. FPRL1/SAA have been 
implicated in the pathogenesis of inflammatory arthritis attributable to their ability to 
chemoattract monocytes, neutrophils, and T cells and stimulate production of 
metalloproteases, cytokines and increased expression of cytokine receptors. In contrast, 
FPRL1/LXA4 has a role in anti-inflammatory pathways; it inhibits neutrophil chemotaxis, 
cytokine production, and superoxide generation. (128, 130, 133, 134).  
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1.5.1.1.5 Mast cell functions 
Previous studies have shown that antimicrobial peptides are capable of 
chemoattracting mast cells. Antimicrobial peptides are a unique and diverse group of 
gene-encoded proteins, which are highly conserved in their structure, function and 
mechanism of action (135). The major antimicrobial peptides found in humans are 
defensins and cathelicidins. A variety of cathelicidins have been identified in animals 
(136); however, humans express only one cathelicidin, hCAP-18/LL-37 (137), produced 
mainly by neutrophils (138), monocytes, mast cells (139), natural killer cells, B cells 
(140), squamous epithelia (141), keratinocytes of inflamed skin (142), and airway 
epithelia (143). Apart from their direct antimicrobial functions, cathelicidins have been 
reported to evoke a number of mast cell activities including migration, proliferation, and 
cytokine and chemokine production. LL-37 stimulates mast cell degranulation and the 
release of PGD2 (144-146); it also chemoattracts mast cells (146-148) and activates 
them to release histamine, which in turn increases vascular permeability in the skin. This 
requires phosphorylation of MAPK and ERK1/2 (146, 149). LL-37 induces production of 
the Th1 cytokine IL-2, Th2 cytokines IL-4 and IL-5, and proinflammatory cytokines TNF 
and IL-ȕE\KXPDQPDVWFHOOV(145), suggesting that it can mediate both pro- and anti-
inflammatory effects in mast cells. In addition, LL-37 has the ability to stimulate the 
secretion of the pruritogenic mediator IL-31 from mast cells (150), indicating a role for 
antimicrobial peptide-mast cell interactions in the pathogenesis of skin disorders. The 
majority of the studies describing mast cell activation through a GPCR have utilized 
pharmacological antagonists of different signaling cascades, such as pertussis toxin 
LQKLELWRURI*Įi), wortmannin (inhibitor of PI3K), U-73122 (inhibitor of PLC), and Ro-31-
8220 (inhibitor of PKC). Indeed, LL-37-mediated mast cell activation could be blocked by 
pertussis toxin and wortmannin (144, 146-148), indicating antimicrobial peptides 
potentiate mast cell responses through the G protein signal transduction. Many GPCRs 
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have been theorized to bind and be activated by antimicrobial peptides, but the identities 
of these receptors on mast cells is largely unknown (151). The ability of cathelicidins to 
induce Ca2+ mobilization in FPRL1-transfected HEK(293) cells have suggested that 
FPRL1 may be a receptor for LL-37 (152). However, whether LL-37 is an agonist for 
FPRL1 in human mast cells remains uncertain. Furthermore, the expression and 
function of FPRL1 in human mast cells remain elusive.  
1.5.2 The complement receptors 
The complement system is a biochemical cascade of the innate immune system, 
comprised of more than 30 humoral and membrane-associated proteins, normally 
present as zymogens. PRRs in the complement system, such as specific antibody, C1q, 
C3, mannose-binding lectin, and ficolins recognize exogenous as well as endogenous 
PAMPs leading to the activation of complement (153) by four different pathways: 
classical, alternative, lectin and extrinsic protease pathways. Each of these pathways 
culminate in activation of C3, the central step in complement activation. The complement 
proteins C3a, C4a and C5a are generated as part of the complement cascade. C3a is a 
 NLOR'DOWRQ N'D SHSWLGH IUDJPHQW UHOHDVHG GXULQJ SURWHRO\WLF FOHDYDJH RI WKH & Į
chain by a C3 convertase of the classical or the alternative pathway. C4a is a 8.7 kDa 
SHSWLGHUHOHDVHGIURPWKHĮFKDLQRI&E\&a cleavage in an early step of the classical 
SDWKZD\&DLVDQN'DSHSWLGHUHOHDVHGIURPWKHĮFKDLQRI&E\DFWLRQRIHLWKHU
classical or alternative pathway C5 convertase (154) (Figure 1.8).  
C3a, C4a and C5a are potent anaphylatoxins with diverse activities on many cell 
types. They act as chemoattractants for neutrophils, eosinophils, monocytes, and mast 
cells, recruiting them to sites of injury or inflammation. They induce oxidative burst in 
neutrophils, histamine release from mast cells and basophils, production of eosinophil 
cationic protein (ECP) from eosinophils, and production of proinflammatory cytokines 
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Figure 1.8 Complement activation. All three pathways that activate the complement cascade 
converge at the formation of a C3 convertase. This complex cleaves C3 into components C3a, 
C4a, and C5a and C3b, ultimately leading to pathogen opsonization, release of inflammatory 
mediators, and formation of terminal complement components which form the membrane attack 
complex. (Original image). 
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from monocytes, B cells and T cells. Characterization of the inflammatory activities 
indicate relative potency in the order of C5a > C3a > C4a on most tissues examined 
(155). C3a and C5a exert their pleiotropic effects by binding to a family of three 
receptors belonging to the GPCR superfamily. These receptors are C3a receptor 
(C3aR), C5a receptor (C5aR) and C5a receptor-like 2 (C5L2). 
1.5.2.1 C3a receptor (C3aR) 
C3aR is a membrane glycoprotein of approximately 54 kDa (156) displaying high 
affinity for C3a with a Kd of about 1 nM, but not for C3a desArg or C5a (157). Human 
platelets express a high molecular weight (95-105 kDa) variant of C3aR that binds C3a 
with Kd of 8 x 10-10 M.   
1.5.2.1.1 Structure 
C3aR contains seven transmembrane domains within its 482-amino acids 
sequence. It distinctively possesses a large second extracellular loop between the fourth 
and fifth transmembrane domain required for ligand binding. This loop contains 175 
amino acid residues; in most GPCRs the corresponding extracellular loop is 30-40 
amino acids long. Sulfation of tyrosine 174 in this loop is essential for binding C3a (158). 
The genes encoding C3aR have been mapped to q13.2-3 of chromosome 12 in humans 
and 6F1 in mice (159). C3aR displays 50-60% homology between various species, with 
65% sequence identity between the human and murine counterparts (159).  
1.5.2.1.2 Expression  
C3aR is expressed on cells of myeloid origin, including monocytes/macrophages, 
neutrophils, eosinophils, basophils, mast cells, dendritic cells, and microglia. It is also 
expressed on non-myeloid cells, such as astrocytes, endothelial cells, epithelial cells, 
smooth muscle cells, and activated T cells. 
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1.5.2.1.3 Signaling 
C3aR exerts its effect via coupling to the pertussis toxin-sensitive and ±
LQVHQVLWLYH*SURWHLQV*Įi DQG*Į16, respectively. In endothelial cells, C3aR also couples 
to pertussis toxin-LQVHQVLWLYH*Į12 and *Į13 (160). Downstream signaling events involve 
DFWLYDWLRQ RI3,.ȖZKLFK LQ WXUQDFWLYDWHV3/&ȕDQG3/&Ȗ ZKLFKJHQHUDWHV ,33 and 
DAG, leading to Ca2+ mobilization and PKC activation, respectively. PI3K can also 
activate the Ras-Raf-MEK-ERK1/2 cascade.  
1.5.2.1.4 Biological role  
C3aR mediates chemotaxis of eosinophils (161), mast cells (162), dendritic cells 
(163), and monocytes but not neutrophils (161). It triggers an oxidative burst in 
macrophages, neutrophils, and eosinophils (164). In addition, basophils (165) and mast 
cells (166, 167) undergo degranulation and release histamine upon C3a-C3aR 
interaction. It stimulates ECP production from eosinophils (168), as well as upregulation 
RI ȕ2-integrins and shedding of L-selectins, thereby promoting eosinophil adhesion to 
endothelial and epithelial cells (169). Human monocytes and mast cells exhibit increased 
intracellular Ca2+ levels when stimulated with C3a (167). C3a also stimulates smooth 
muscle contraction (170), lysozyme release from immune cells (171), platelet 
aggregation (172) and triglyceride synthesis in adipocytes (173) .  
1.5.2.2 C5a receptor (C5aR or CD88) 
First cloned in 1991 (174, 175), C5aR is a membrane glycoprotein of 
approximately 42 kDa (176), displaying high affinity for C5a and C5a desArg. Human 
C5aR binds C5a with a Kd of 1 nM, and C5a desArg with 10 to 100-fold lower affinity (Kd 
of 412-660 nM), whereas C3a and C3a desArg are not recognized (177). 
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1.5.2.2.1 Structure  
The C5aR gene is localized to q13.3-13.4 of human chromosome 19 (178). 
Murine C5aR exhibits 65% sequence homology with its human counterpart (179). The 
N-terminus is required for high affinity binding of C5a, but not for receptor activation 
(180, 181). A second distinct binding site is formed by charged residues in the second 
and third extracellular loops and the external faces of the transmembrane helical bundle 
and hydrophobic residues in the core of the C5aR. Unlike the N-terminal binding site, the 
second site is responsible for receptor activation (182).  
1.5.2.2.2 Expression  
C5aR is expressed on cells of myeloid origin, such as neutrophils, eosinophils, 
basophils, mast cells, dendritic cells, and monocytes, as well as on non-myeloid cells, 
including bronchial and alveolar epithelial cells, endothelial cells, Kupffer cells, stellate 
cells, astrocytes, and microglial cells (177).  
1.5.2.2.3 Signaling  
&D5 PDLQO\ FRXSOHV WR *Įi (183); however, ectopically expressed C5aR and 
C5aR on cells of the hematopoietic lineage, can also couple to pertussis toxin-
LQVHQVLWLYH *Į16 (184, 185). C5a-C5aR interaction leads to activation of several 
components of signaling pathway, including PI3KȖ 3/&ȕ DQG 3/' (127). It can 
activate the transcription factor CREB by phosphorylation at the convergence of two 
pathways, PI3K/Akt and ERK (186). CREB activation has been proposed to be a part of 
the mechanism by which C5a can delay neutrophil apoptosis and prolong an 
inflammatory response  (187). In neutrophils, C5a causes downstream activation of p21-
activated kinases (PAK), which are involved in altering cell morphology/chemotaxis, 
activation or potentiation of several distinct MAPK cascades and the activation of nuclear 
factor (NF)-ț%LQPDFURSKDJHV(188). 
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1.5.2.2.4 Biological role  
C5aR is a powerful chemoattractant receptor for monocytes (189), neutrophils 
(190), eosinophils (191), basophils (192), B cells (193), and T cells (194). It also 
stimulates mast cell degranulation (195), chemotaxis in specific mast cell subtypes (196, 
197), oxidative burst and production of reactive oxygen species (ROS) in neutrophils 
(198), secretion of lysosomal enzymes (199), as well as proinflammatory mediators from 
monocytes, eosinophils (200), and mast cells (196).  
1.5.2.3 C5a receptor-like 2 (C5L2 or GPR77) 
First discovered in 2000 as a putative orphan receptor, C5L2 has since been 
identified as a second C5a receptor (201). It is a 37 kDa protein and binds C5a with high 
affinity (Kd of 2.5 nM). Unlike C5aR, C5L2 binds C5a desArg with a 20-30 fold higher 
affinity (202).  
1.5.2.3.1 Structure  
C5L2 consists of 337 amino acids and shares 58% sequence homology with 
C5aR and 55% homology with C3aR (203). Unlike C5aR, C5L2 uses critical residues in 
its N-terminal domain for binding only to C5a desArg. C5L2 has been considered a 
binding partner for C3a, C3a desArg (204), C4a and C4a desArg; however the available 
data is not very convincing  (205, 206). Although C5L2 has the conventional structure of 
a GPCR, studies have shown that C5L2 does not couple to the known G proteins. This 
may be due to a structural difference in the third transmembrane domain. In GPCRs, a 
highly conserved DRY (Aspartic acid-Arginine-Tyrosine) motif in the third 
transmembrane domain is important for its interaction with the corresponding G proteins. 
The DRY motif is DRC in C3aR and DRF in C5aR, but DLC in C5L2. Mutation of DLC in 
human C5L2 to DRC has been shown to increase coupling to GĮ16 in co-transfected 
HEK-293 cells and induce a functional response (206). In contrast, no functional 
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response occurs in RBL-2H3 cells using a C5L2-mutant where the DRY-motif and two 
additional regions typically involved in G protein coupling are replaced by the 
corresponding C5aR sequences (207).  
1.5.2.3.2 Expression 
C5L2 is expressed in various tissues of myeloid and non-myeloid origin and 
transcripts have been detected in brain, placenta, ovary, testis, spleen, and colon. 
Surface expression of C5L2 has been detected in lung, liver, heart, kidney, adipose 
tissue, skin fibroblasts, neutrophils, and immature, but not mature dendritic cells (177). 
1.5.2.3.3 Signaling and biological role  
C5L2 is an enigmatic receptor as available data suggests opposing roles either 
as a non-signaling decoy receptor for C5a and C5a desArg or as a functional receptor. 
In support of the first argument, no mobilization of intracellular Ca2+ occurs in C5L2-
transfected cells after C5a administration (202, 206), in neutrophils from C5aR-deficient 
mice after stimulation with C5a (208), or in C5L2-expressing epithelial and myeloid cell 
lines (205). C5L2-transfected RBL-2H3 cells fail to degranulate with C5a or C5a desArg 
(202). On the contrary, C5L2 has also been demonstrated to be functional in vitro and in 
vivo. Neutrophils and macrophages from C5L2-deficient mice produce increased levels 
of TNF and IL-6 in response to C5a and LPS relative to their wildtype counterparts (209). 
Similarly, C5L2-deficient mice suffer from augmented inflammatory responses and 
higher numbers of infiltrating neutrophils in a model of pulmonary immune complex injury 
(210), indicating an anti-inflammatory role for C5L2. In contrast, a strong reduction in IL-
1ȕ, MIP-1Įand MIP-2 levels are observed in C5L2-deficient mice compared to wildtype 
controls. Furthermore, C5L2-deficient mice, like C5aR-deficient mice, or mice in which 
either of the receptors are blocked by anti-receptor antibodies, show a higher survival 
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rate in mid-grade sepsis (211), supporting a proinflammatory role of C5L2. Overall, the 
studies point to a more complex function of C5L2 in inflammation. 
1.5.2.4 The complement receptors and mast cell function 
Human skin mast cells, HMC-1, HuMC and LAD2 cells express C3aR via which 
C3a causes sustained Ca2+ mobilization, degranulation and chemokine production (167, 
212). C3a induces chemotaxis of HMC-1, CBMC and skin mast cells, and these 
responses are inhibited by receptor specific-antibodies or pertussis toxin (162, 196). The 
ability of C3a to induce degranulation and chemokine production involves the activation 
of distinct signaling pathways including PI3K, PLC, PKC and ERK1/2 (167, 212). In 
contrast to C3a, the effects of C5a on human mast cells are poorly understood. Human 
skin mast cells express C5aR and release mediators in response to C5a (212). 
However, lung mast cells are unresponsive to C5a, possibly due to the fact that while 
MCTC are predominant cell types present in the skin they are the minority cell type found 
in the lung (17, 213, 214). It has been shown recently that MCT cells in the lungs do not 
express C5aR whereas MCTC cells do and that this correlates with C5a-induced 
degranulation in MCTC cells (215). Studies with LAD2 cells have generated conflicting 
data; some have shown that C5a degranulates LAD2 cells (195), while others have 
demonstrated no degranulation with C5a (167, 216). Moreover, the expression of C5aR 
on the LAD2 cell surface has not been reported. C5L2 is a novel receptor for C5a (217); 
its expression and function in human mast cells are yet to be defined.  
1.5.3. The adenosine receptors 
Adenosine plays a dual role in modulating homeostasis. First, extracellular 
adenosine acts as an alarm molecule that reports tissue injury to surrounding tissue. 
Second, extracellular adenosine generates a range of tissue responses that are organ-
protective thereby mediating homeostasis (218). Adenosine elicits its physiological 
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responses by activation of adenosine receptors. Four subtypes of adenosine receptors 
have been identified, termed A1, A2A, A2B and A3. They have different affinities for 
adenosine - A1 and A2A are high affinity receptors (Km <30 nm), whereas the A3 and 
particularly the A2B are low affinity receptors (Km 1-20 ȝ0(219, 220).  
1.5.3.1 Structure  
All four subtypes are members of the GPCR superfamily. Among the human 
adenosine receptors, the most similar are the A1 and A3 (49% sequence homology) and 
the A2A and A2B (59% homology).  
1.5.3.2 Expression 
Adenosine receptors are ubiquitously expressed throughout the body, with 
virtually all cells expressing one or more subtypes. They are expressed on cells of 
myeloid origin, such as monocytes/macrophages, dendritic cells, neutrophils, mast cells 
and T cells, as well as non-myeloid cells including fibroblasts, smooth muscle cells, 
osteoblasts, astrocytes, myocardial cells, endothelial cells, and epithelial cells (218). 
1.5.3.3 Signaling  
Adenosine receptors are all coupled to G proteins. A1 and A3 subtypes are 
DVVRFLDWHG ZLWK *Įi proteins and signal through inhibition of adenylyl cyclase and 
decrease in cAMP. A2A and A2B VXEW\SHVDUHDVVRFLDWHGZLWK*Įs proteins and signal 
through stimulation of adenylyl cyclase and increases in cAMP. Adensoine receptors are 
also linked to various kinase pathways including PI3K, PLC, PKC and MAPKs (221).  
1.5.3.4 Biological role 
Adenosine receptors are crucial initiators of pro- and anti-inflammatory 
responses in immune cells depending on the receptor subtype involved. While activation 
of A2A and A2B limits TNF production following macrophage activation (222), A2A 
49 
 
augments IL-10 production by macrophages exposed to E. coli (223). Adenosine 
promotes the recruitment of immature dendritic cells to sites of inflammation via A1 or A3 
receptors (224, 225). At these sites adenosine induces, via A2A, an anti-inflammatory 
dendritic cell phenotype, driving T cell response towards Th2 profile (226). Adenosine is 
a potent modulator of neutrophil function; A2A inhibits superoxide generation by fMLP-
stimulated neutrophils (227). In addition, A2A inhibits adhesion of neutrophils to the 
endothelium, whereas A1 promotes neutrophil adhesion (228). A1 and A3 promote 
migration of neutrophils in response to C5a, formylated peptides and chemokines (229, 
230). Adenosine receptors also regulate the inflammatory environment in asthma, 
ischemia, arthritis, sepsis, inflammatory bowel disease and wound healing. Lymphocyte 
function is potently regulated by the anti-inflammatory effects of A2A in animal models of 
autoimmunity and ischemia (218). Due to their dual role, adenosine receptors have 
emerged as novel therapeutic targets in inflammation.  
1.5.3.5 Mast cell function 
Adenosine has been long implicated in allergic inflammation. Inhaled adenosine 
provokes bronchoconstriction in atopic and asthmatic individuals, but not in normal 
subjects (231). Furthermore, elevated levels of adenosine are found in BAL fluid and 
exhaled breathe condensates of allergic inflammation patients (232, 233). Although the 
mechanisms of how adenosine mediates bronchoconstriction remain elusive, there is 
overwhelming evidence that mast cell-derived cytokines, leukotrienes and histamine 
may have a key role in evoking airway constriction in response to adenosine (234, 235). 
Adenosine potentiates IgE-induced mediator release from rodent mast cells (236). Mast 
cell express adenosine receptor subtypes, however which specific adenosine receptor(s) 
mediate(s) adenosine triggered mast cell responses remains uncertain. A1 and A2B 
receptors in general appear to mediate proinflammatory effects by enhancing the 
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release of mediators. By contrast, A2A and A3 elicit anti-inflammatory effects (237). 
Exposure of CBMC to an A2A agonist results in inhibition of tryptase release (238). In the 
same CBMC model, while activation of A1 and A3 potentiates IgE-induced degranulation, 
activation of A2B leads to inhibition of the degranulation (239). A2B stimulation of HMC-1 
cells induces secretion of the Th2 cytokines IL-4 and IL-13 (240). Studies employing 
human lung mast cells have demonstrated a dual effect, low concentrations of 
adenosine potentiate IgE-mediated degranulation, whereas higher concentrations inhibit 
degranulation (241, 242). Taken together, these studies illustrate that the mast cells 
phenotype and the adenosine receptor(s) expressed on its cell surface may alter the 
pathophysiological responses of adenosine. Which adenosine receptors are expressed 
in LAD2 human mast cells and whether adenosine can activate LAD2 cells by itself, or 
induce pro- or anti-inflammatory responses remain unexplored.  
 
1.6 RATIONALE, CONCEPTUAL MODEL AND CENTRAL HYPOTHESIS 
As evident, mast cells respond to chemoattractants through the corresponding 
cell surface GPCRs, and responses elicited by these are quite divergent, ranging from 
induction of chemotaxis and adhesion to mediator release. Sub-populations of GPCR 
can either induce mast cell activation or modify antigen-dependent mast cell activation, 
depending on the particular G protein utilized for relaying signal. Transduction of signals 
YLD*Įi alone is sufficient for the GPCRs to promote degranulation of mast cells, whether 
in the presence or absence of antigen, as evidenced by their sensitivity to pertussis 
toxin. The ability of specific GPCRs to downregulate antigen-induced mast cell activation 
is dependent on the fact that these receptors induce adenylyl cyclase-dependent cAMP 
SURGXFWLRQ YLD *Įs. cAMP has been demonstrated to negatively regulate mast cell 
function although the precise mechanisms controlling this response still remains unclear. 
7KH EDODQFH EHWZHHQ *Įi- DQG *Įs-dependent signaling pathways keeps mast cell 
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degranulation in check, which is of critical importance in the pathophysiology associated 
with mast cell activation. It has also been proposed that the GPCRs crosstalk to produce 
diverse responses in mast cells. Activation of one particular signaling pathway by a 
GPCR can modulate signaling via another GPCR; however, such interactions are yet to 
be clearly defined in human mast cells (243).  
To better understand the role of stimulatory and inhibitory GPCRs in human mast 
cell function, we utilized novel chemoattractant receptors evolutionary conserved in the 
immune system as our conceptual model: (i) the FPRL1 receptor which is known to 
FRXSOH ZLWK VWLPXODWRU\ *Įi. Its expression and function in human mast cells are 
unknown, (ii) the C5a receptors, C5aR and C5L2. Although C5aR is known to couple 
ZLWK VWLPXODWRU\ *Įi in human mast cells, the expression, function and signaling 
mechanism of C5L2 are unknown, and (iii) the C3a receptor and the adenosine 
receptor(s). As the expression, function and signaling mechanism of C3a are well-
defined in human mast cells, it was chosen as a model for stimulatory GPCR. The effect 
of adenosine receptor(s) stimulation on C3a-activated human mast cell function was 
investigated to determine whether the interaction between adenosine and C3a GPCRs 
was stimulatory or inhibitory (Figure 1.9).  
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We hypothesized that human mast cells express both stimulatory and inhibitory 
GPCR which signal via *Įi RU*Įs, respectively, and that these receptors are important 
in chemotaxis and mast cell migration. To address this hypothesis, the following sub-
hypotheses were generated: 
1. 3OHXURFLGLQVQRYHOĮ-cationic antimicrobial peptides, activate human mast cells 
WKURXJK)35/D*Įi-linked stimulatory GPCR. To address this hypothesis we 
tested if HuMC and LAD2 cells expressed FPRL1, and if pleurocidin stimulated 
activation of mast cells as demonstrated by chemotaxis, adhesion, degranulation, 
cytokine, and chemokine production (Chapter 2). 
2. &D VWLPXODWHV KXPDQ PDVW FHOOV WKURXJK &D5 DQG &/ ERWK *Įi-linked 
stimulatory GPCRs. To address this hypothesis we tested if HuMC and LAD2 
cells expressed C5aR and C5L2, and if C5a stimulated activation of mast cells as 
demonstrated by chemotaxis, adhesion, degranulation, cytokine, and chemokine 
production (Chapter 3) 
3. $GHQRVLQH PRGXODWHV KXPDQ PDVW FHOO IXQFWLRQ WKURXJK *Įs-linked inhibitory 
(A2ARU*Įi-linked stimulatory (A2B, A3) GPCRs. To address this hypothesis we 
tested if LAD2 cells expressed adenosine receptors, and if adenosine activated 
human mast cells alone or in conjunction with a known stimulatory GPCR, C3aR 
(Chapter 4).  
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CHAPTER 2. PLEUROCIDIN, A NOVEL ANTIMICROBIAL 
PEPTIDE, INDUCES HUMAN MAST CELL ACTIVATION 
THORUGH THE FPRL1 RECEPTOR 
 
This chapter has been published as: 
P Pundir, A Catalli, C Leggiadro, SE Douglas, M Kulka. Pleurocidin, a novel 
antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor. 
Mucosal Immunology. 2014;7:177-187; doi:10.1038/mi.2013.37.1 
 
2.1 ABSTRACT 
3OHXURFLGLQVDUHDQRYHOIDPLO\RIĮ-helical cationic antimicrobial peptides (CAPs) 
that are structurally and functionally similar to cathelicidins, one of the major CAP 
families. As cathelicidins stimulate mast cell chemotaxis and mediator release, we 
postulated that pleurocidins similarly activate mast cells. A screen of 20 pleurocidin 
peptides revealed that some were capable of degranulating the human mast cell line 
LAD2 (Laboratory of Allergic Diseases 2). Pleurocidin NRC-04 caused LAD2 to adhere, 
migrate, degranulate and release cysteinyl leukotrienes and prostaglandin D2. Moreover, 
pleurocidin increased intracellular Ca2+ mobilization in mast cells and induced the 
production of proinflammatory chemokines such as monocyte chemotactic protein-1/C-C 
motif chemokine ligand 2 (CCL2) and macrophage inflammatory protein-ȕ&&/2XU
evaluation of possible cellular mechanisms suggested that G proteins, phosphoinositol 
3-kinase (PI3K), phospholipase C (PLC) and protein kinase C (PKC) were involved 
in pleurocidin-induced mast cell activation as evidenced by the inhibitory effects of 
pertussis toxin (G protein inhibitor), wortmannin (PI3K inhibitor), U-73122 (PLC inhibitor) 
                                                            
1
 P Pundir designed and performed the experiments, analyzed the data and wrote the chapter; A 
Catalli screened the pleurocidin peptides; C Leggiadro assisted with the electron microscopy; 
SE Douglas provided the pleurocidin peptides; M Kulka helped design the study and 
experiments, and edited the writing 
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and Ro-31-8220 (PKC inhibitor), respectively. We also found that human mast cells 
expressed the N-formyl-peptide receptor-like 1 (FPRL1) receptor and FPRL1-specific 
inhibitor affected pleurocidin-mediated activation of mast cells. Our finding that the novel 
CAP pleurocidin activated human mast cells through G protein-coupled receptor 
signaling suggests that this peptide might have immunomodulatory functions. 
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2.2 INTRODUCTION 
The innate immune system is the first line of defense against invading pathogens 
and is dependent upon invariant receptors that recognize pathogen-associated 
molecular patterns. Mast cells are immune cells resident in tissues throughout the body 
but most common at sites exposed to the external environment, i.e. skin, mucosa of 
airways and intestine (1, 2, Chapter 1.2.4). Considered key players in asthma and 
allergy pathology, recent studies have highlighted their importance in the protection 
against infection (3, Chapter 1.2.9). They promote innate immune responses by rapidly 
and selectively producing proinflammatory mediators which are divided into three major 
categories: (i) preformed mediators: i.e. histamine, heparin, proteoglycans, and 
antimicrobial peptides; (ii) de novo generated lipid mediators: i.e. prostaglandins, 
leukotrienes, and platelet activating factor; and (iii) cytokines, chemokines, and growth 
factors (1, Chapter 1.2.6). Stimulation with G protein-coupled receptor (GPCR) ligands 
can dramatically potentiate mast cell mediator release against pathogenic organisms, 
thus helping to limit the pathology associated with infection (4, Chapter 1.4).  
Given the need for alternate sources of multifunctional antibiotics and vaccine 
adjuvants, a number of novel GPCR ligands have recently been investigated for their 
potential to activate mast cells. Cationic antimicrobial peptides (CAPs) including 
defensins and cathelicidins are compounds mainly expressed in epithelial cells and 
cause functional changes in mast cells. Defensins and cathelicidins induce mast cell 
chemotaxis, degranulation, and chemokine production (5-7) in a pertussis toxin-sensitive 
manner which indicates that they may use GPCRs to exert their effects (6, 8). Mast cells 
are not only a target but are also a source of cathelicidins (9); therefore, the expression 
and release of CAPs, and their subsequent action is likely an important autocrine 
mechanism in the innate immune functions of mast cells (Chapter 1.5.1.1.5).  
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In 2003, 20 pleurocidin-like CAPs (NRC-01 to -20) were identified in various 
Atlantic flounder species and screened for antimicrobial activity (10). Structurally similar 
to cathelicidins, pleurocidins are mucus-derived CAPs constituting a large family of 
OLQHDU SRVLWLYHO\ FKDUJHG Į-helical cationic peptides found in flatfish (11). Recent 
findings provide evidence that these proteins are important as a first line of defense in 
vertebrates. As with cathelicidins, pleurocidins are generated in epithelial surfaces in 
response to infection and exert a potent, broad-spectrum antibacterial and antifungal 
activity (12). Furthermore, pleurocidin has been localized to circulating cells resembling 
mast cells in winter flounder, where it resides in cytoplasmic granules (13). Related 
CAPs in the piscidin family also have been detected in fish mast cells (14). Fish mast 
cells are similar to their mammalian counterparts in being filled with metachromatic 
granules containing a diverse array of proinflammatory mediators that are released 
during degranulation (15). As pleurocidin can be found in mast cells of winter flounder, 
we were interested to see if they can initiate innate defenses in human mast cells. 
Given the structural and functional similarities between pleurocidins and 
cathelicidin, we postulated that the pleurocidins family of CAPs also activates diverse 
functions of human mast cells in a G protein-dependent manner. The aims of our study 
were to determine: (i) the ability of pleurocidin variants in stimulating mast cell 
degranulation, (ii) if pleurocidins stimulate eicosanoids, cytokine and chemokine 
production, (iii) if pleurocidins influence mast cell adhesion and migration, and (iv) 
whether pleurocidin-mediated mast cell activation is GPCR-dependent. This study 
addressed the overall hypothesis of this thesis which is that human mast cells express 
both stLPXODWRU\DQGLQKLELWRU\*3&5ZKLFKVLJQDOWKURXJK*Įi RU*Įs, respectively, and 
that these receptors are important in chemotaxis and mast cell migration. We chose 
FPRL1 receptor as our model of activating GPCR. Although FPRL1 is known to couple 
with stimulatory *Įi, its expression and function in human mast cells are unknown. 
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2.3 METHODS 
2.3.1 Pleurocidin peptides 
The amino acid sequences were predicted from nucleic acid sequences and 
those predicted to contain a C-terminal glycine were amidated. Peptides NRC-01 to 
NRC-20 were synthesized by N-9-fluorenylmethoxycarbonyl (Fmoc) chemistry at Dalton 
Chemical Laboratories (Toronto, ON, Canada). Peptide purity (95%) was confirmed by 
high-performance liquid chromatography and mass spectrometry. All peptide stocks 
were prepared in phosphate-buffered saline (PBS) and stored at -80°C.  
2.3.2 Cell culture 
LAD2 (Laboratory of Allergic Diseases 2) human mast cells (16) were cultured in 
serum-free medium (StemPro-34 SFM, Life Technologies, Burlington, ON, Canada) 
supplemented with 2 mM L-JOXWDPLQH8POSHQLFLOOLQȝJPOVWUHSWRP\FLQDQG
µg/ml recombinant human stem cell factor (rhSCF) (Peprotech, Rocky Hill, NJ, USA). 
The cells were maintained at 0.1 × 106 cells/ml at 37°C/5% CO2. Cells were periodically 
WHVWHGIRUH[SUHVVLRQRI.LWDQG)Fİ5,E\IORZF\WRPHWU\+XPDQSHULSKHUDOEORRG&'+ 
cell-derived mast cells were kindly provided by Dr. Dean Befus. These cells were 
cultured in StemSpanSFEM (StemCell Technologies, Vancouver, BC, Canada) 
supplemented with 2 mM L-JOXWDPLQH  8PO SHQLFLOOLQ  ȝJPO VWUHSWRP\FLQ 
µg/ml rhSCF, and 0.1 µg/ml rhIL-6 (Peprotech). rhIL-3 (0.03 µg/ml) was added for the 
first week. At 8-10 weeks, cultures consisted of >99% mast cells. 
2.3.3 Degranulation 
Cells were washed, resuspended in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (10 mM HEPES, 137 mM NaCl, 2.7 mM 
KCl, 0.38 mM Na2HPO4.7H2O, 5.6 mM glucose, 1.8 mM CaCl2.H2O, 1.3 mM 
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MgSO4.7H2O, 0.4% bovine serum albumin (BSA), pH 7.4) at 2.5 × 104 cells per well and 
stimulated for 30 min with serial dilutions (0.0001-ȝ0RIHDFKSOHXURFLGLQDW&
CO2 ȕ-hexosaminidase released into the supernatants and in total cell lysates 
solubilized with 0.1% Triton X-100 was quantified by hydrolysis of p-nitrophenyl N-acetyl-
ȕ-D-glucosamide (Sigma-Aldrich, Oakville, ON, Canada) in 0.1 M sodium citrate buffer 
(pH 4.5) for 90 min at 37°C/5% CO27KHSHUFHQWDJHRIȕ-hexosaminidase release was 
calculated as a percent of total content.   
In some experiments, LAD2 cells were pretreated for 30 min with wortmannin 
(0.1-ȝ06LJPD-Aldrich), U-73122 (0.1-ȝ0&DOELRFKHP%LOOHULFD0$86$5R-
31-8220 (0.01-ȝ06LJPD-Aldrich) or vehicle (0.1-1% dimethyl sulfoxide); or for 2 h 
with pertussis toxin (0.1-10 nM, Sigma-Aldrich), WRW4 (0.5-ȝ0>Biotrend Chemicals, 
Zurich, Switzerland]), KN-62 (10-100 nM; Sigma-Aldrich), or vehicle. Cells were then 
stimulated for 30 min with NRC-DQGȕ-hexosaminidase release was measured.  
2.3.4 Electron microscopy  
LAD2 cells were treaWHGIRUPLQZLWKȝ015&-04 at 37°C/5% CO2 and fixed 
for 20 min in glutaraldehyde fixative (2.5% glutaraldehyde in 0.05 M cacodylate buffer 
with 0.1 M NaCl, pH 7.5) at room temperature. Sections were cut using a microtome and 
observed by using a S300N transmission electron microscope (Hitachi, Tokyo, Japan).  
2.3.5 Intracellular Ca2+ mobilization 
LAD2 cells were loaded for 30 min with 1 ȝM fura-2 acetoxymethyl (AM) (Life 
Technologies) in HEPES buffer, washed and incubated for 15 min in BSA-free HEPES 
at 37°C/5% CO2. A total of 4 × 106 cells were placed in a glass-bottom culture dish under 
an inverted microscope (Axiovert 200, Carl Zeiss Canada Ltd., Canada). Fura-2 was 
excited at 340 and 380 nm alternatively. The Ca2+ response was recorded at 100 ms 
intervals using SlideBook for Stallion, version 4.26.04 software (Intelligent Imaging 
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Innovations, USA). In all,  ȝ0 15&-04 was added at 70 s time point and  ȝJ/ml 
compound 48/80 (c48/80, Sigma-Aldrich) at the256 s time point. The Ca2+ response of 
20 randomly selected cells was analyzed for each experiment and plotted as 340/380 
ratio vs. time. 
2.3.6 ELISA 
In each, 1 × 106 cells were stimulated for either 3 or 24 h with ȝJPOhuman 
myeloma immunoglobulin E (IgE, CalELRFKHP ȝJPO UDELELW DQWL-IgE (Dako, 
&DUSLQWHULD&$86$ȝJPO cRUȝ0SOHXURFLGLQVDW&&22. Cell-free 
supernatants were isolated and analyzed for cysteinyl leukotrienes (CysLTs), 
prostaglandin D2 (PGD2) or chemokine using the following commercial competitive EIA 
kits: correlate-EIA cysteinyl leukotriene kit (Assay Designs, Ann Arbor, MI, USA), 
prostaglandin D2 EIA kit (Cayman Chemicals, Ann Arbor, MI, USA), human CCL2 (C-C- 
motif chemokine ligand 2; monocyte chemoattractant protein-1 [MCP-1]) ELISA kit 
(eBioscience, San Diego, CA, USA) and quantikine human macrophage inflammatory 
protein (MIP)-1beta/CCL4 ELISA kit (R&D Systems, Minneapolis, MN, USA).  The 
minimum detection limits were 78.1 pg/ml for CysLT, 200 pg/ml for PGD2, 7 pg/ml for 
MCP-1 and 4 pg/ml for MIP-ȕ 
2.3.7 Isolation of RNA and generation of cDNA by reverse transcritption 
CHOOVZHUHVWLPXODWHG IRUKZLWKȝ015&-04 oUȝJPO c48/80. Total RNA 
was isolated using the Tri Reagent method (Sigma-$OGULFK ,QDOOȝJRIWRWDOFHOOXODU
RNA was reverse-transcribed to cDNA using M-MLV Reverse Transcriptase (Life 
Technologies) in a 20-ȝOUHDFWLRQPL[DFFRUGLQJWRWKHPDQXIDFWXUHU¶VUHFRPPHQGDWLRQ 
2.3.8 Reverse transcription PCR (RT-PCR) 
RT-PCR was performed on a Peltier Thermal Cycler System (Bio-Rad, Hercules,  
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CA, USA) with Life Technologies reagents. FRPL1, P2X7 DQGȕ-actin primers (Table 2.1) 
were designed using the Primer Express software (Applied Biosystems, Foster City, CA, 
USA). Amplification was carried out for 30 cycles of denaturation for 45 s at 94°C, 
annealing for 30 s at 56°C for FPRL1, P2X7DQG&IRUȕ-actin and extension for 60 s 
at 72°C. PCR amplicons were analyzed by 1% agarose gel electrophoresis and 
visualized by ethidium bromide staining.   
2.3.9 Real-time qPCR 
Gene expression was analyzed using qPCR on a StepOnePlus system (Applied 
Biosystems). For each qPCR assay, a total of 50 ng of cDNA was used. Primer sets 
(Table 2.1) for PCR amplifications were designed using Primer Express software. All 
UHDFWLRQV ZHUH SHUIRUPHG LQ WULSOLFDWH IRU  F\FOHV DV SHU WKH PDQXIDFWXUHU¶V
recommendation. All data were normalized to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) internal controls (17) and are reported as fold-change in 
expression over untreated cells. 
2.3.10 Cytometric bead array 
In each, 1 × 106 cells were stimulated for 24 h wLWK  ȝ0 15&-04 or  ȝJPO 
c48/80 at 37°C/5% CO2. Cell-free supernatants were isolated and analyzed for human 
cytokine and chemokine content using the following commercial cytometric bead array 
kits: human inflammatory cytokine kit and human chemokine kit (BD Biosciences). The 
minimum detection levels for the cytokines and chemokines are IL-ȕSJPO ,/-6, 
2.5 pg/ml; IL-10, 3.3 pg/ml; TNF, 3.7 pg/ml; IL-12p70, 1.9 pg/ml; IL-8, 0.2 pg/ml; 
RANTES (regulated on activation, normal T cell expressed and secreted)/CCL5, 1.0 
pg/ml; monokine induced by interferon-Ȗ 0,*&;&/  SJPO 0&3-1/CCL2, 2.7 
pg/ml; and inducible protein -10 (IP-10)/CXCL10, 2.9 pg/ml. 
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Table 2.1 Sequences of oligonucleotides used for PCR 
Gene Forward primer Reverse primer Probe: FAM/TAMRA (GAPDH: 
MAX/BHQ) 
GAPDH 5'-TCG TGG AAG GAC TCA 
TGA C-3' 
5'-CCA TCA CGC CAC AGT TT-3' 5'-/5MAXN/AGT CCA TGC CAT 
CAC TGC CAC/3IABlk_FQ/-3' 
GM-SCF 5'-CAG CCC TGG GAG CAT 
GTG-3' 
5'-ATT CAT CTC AGC AGC AGT 
GTC TCT A-3' 
5'-/56-FAM/AGG CCC GGC 
GTC TCC TGA ACC/36-
TAMSp/-3' 
IL-ȕ 5'-TGA GCT CGC CAG TGA 
AAT GA-3' 
5'-TGA GCT CGC CAG TGA AAT 
GA-3' 
5'-/56-FAM/GAA GCT GAT 
GGC CCT AAA CAG ATG AAG 
TGC T/36-TAMSp/-3' 
IL-4 5'-CTG CAA ATC GAC ACC 
TAT TAA TGG-3' 
5'-GCA CAT GCT AGC AGG AAG 
AAC A-3' 
5'-/56-FAM/ TCT CAC CTC 
CCA ACT GCT TCC CCC/36-
TAMSp/-3' 
IL-6 5'-AGC CAC TCA CCT CTT 
CAG AAC GAA-3' 
5'-AGT GCC TCT TTG CTG CTT 
TCA CAC-3' 
5'-/56-FAM/ACG GCA TCT CAG 
CCC TGA GAA AGG AGA/36-
TAMSp/-3' 
IL-8 5'-CTG GCC GTG GCT CTC 
TTG-3' 
5'-TTG GCA AAA CTG TTT AGC 
ACT CC-3' 
5'-/56-FAM/CAG CCT TCC TGA 
TTT CTG CAG CTC TGT 
GT/36-TAMSp/-3' 
IP-10 5'-CGA TTC TGA TTT GCT 
GCC TTA TC-3' 
5'-TGA TTA CTA ATG CTG ATG 
CAG GTA CA-3' 
5'-/56-FAM/TGG CAT TCA AGG 
AGT ACC TCT CTC TAG AAC 
CGT/36-TAMSp/-3' 
MCP-1 5'-TCT CTG CCG CCC TTC 
TGT-3' 
5'-GCC TCT GCA CTG AGA TCT 
TCC-3' 
5'-/56-FAM/CTG CTC ATA GCA 
GCC ACC TTC ATT 
CCC/36TAMSp/-3' 
MIG 5'-GGA GTG CAA GGA ACC 
CCA GTA-3' 
5'-TCT TTC AAG GAT TGT AGG 
TGG ATA GTC-3' 
5'-/56-FAM/TCG CTG TTC CTG 
CAT CAG CAC CA/36-TAMSp/-
3' 
MIP-Į 5'-CTA CAC CTC CCG GCA 
GAT TC-3' 
5'-CCG GCT TCG CTT GGT TAG-
3' 
5'-/56-FAM/CAG TGC TCC AAG 
CCC GGT GTC 
ATC/36TAMSp/-3' 
MIP-ȕ 5'-CAG CGC TCT CAG CAC 
CAA-3' 
5'-TTC CTC GCG GTG TAA GAA 
AAG-3' 
5'-/56-FAM/CTC AGA CCC TCC 
CAC CGC CTG C/36-TAMSp/-3' 
RANTES 5'-TCG CTG TCA TCC TCA 
TTG CTA -3' 
5'-GCA CTT GCC ACT GGT GTA 
GAA A-3' 
5'-/56-FAM/CTG GGA CAC 
CAC ACC CTG CTG C/36-
TAMSp/-3' 
TGF-ȕ 5'-CTC TCC GAC CTG CAA 
CAG A-3' 
5'-AAC CTA GAT GGG CGC GAT 
CT-3' 
5'-/56-FAM/CCC TAT TCA AGA 
CCA CCC ACC TTC TGG T/36-
TAMSp/-3' 
TNF 5'-TCT GGC CCA GGC AGT 
CA-3' 
5'-GCT TGA GGG TTT GCT ACA 
ACA TC-3' 
5'-/56-FAM/ CTT CTC GAA 
CCC CGA GTG ACA AGC 
C/36T-AMSp/-3' 
FPRL1 5'-TGT GAG TCT GGC CAT 
GAA GGT GAT-3' 
5'-AGC TCG TTG GGT TAA CCA 
GGA TGT-3' 
 
P2X7 5'-TAC AGC TGC TTA GAA 
AGG AGG CGA-3' 
5'-ACT GCC CTT CAC TCT TCG 
GAA-3' 
 
ȕ-actin 5'-ATC TGG ACC ACA CCT 
TCT ACA ATG AGC TGC G-3' 
5'-CGT CAT ACT CCT GCT TGC 
TGA TCC ACA TCT GC-3' 
 
 
FPRL1, N-formyl-peptide receptor 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GM-CSF, 
granulocyte macrophage colony-stimulating factor; IL, interleukin; IP-10, inducible protein-10; MCP-1, 
monocyte chemotactic protein-1; MIG, monokine induced by interferon-Ȗ 0,3 PRQRF\WH LQIODPPDWRU\
protein; RANTES, regulated on activation, normal, T cell-expressed, and secreted; TGF-ȕ WUDQVIRUPLQJ
growth factor-beta; TNF, tumor necrosis factor.  
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2.3.11 Adhesion assay 
Maxisorp 96-well plates (NUNC, Naperville, IL, USA) were coated for 16 h with 
 ȝJPO KXPDQ ILEURQHFWLQ 6LJPD-Aldrich) in PBS at 4°C, washed three times with 
PBS, blocked for 1 h with 3% BSA in HEPES bufIHUDWÛ&&22, then washed three 
times with HEPES buffer. LAD2 cells were washed with HEPES buffer, suspended at 1 × 
106 FHOOVPO DQG ODEHOHG IRU  PLQ ZLWK  ȝ0 FDOFHLQ-AM (Life Technologies) at 
37°C/5% CO2. After labeling, cells were washed and resuspended at 1 × 106 cells/ml in 
HEPES buffer. Cell suspension (5 × 104 FHOOV+(3(6EXIIHUFRQWDLQLQJȝ015&-04 
or 0.1 µg/ml SCF was added and incubated for 2 h at 37°C/5% CO2. After incubation, 
non-adherent cells were washed away with warm HEPES buffer. Fluorescence emission 
at 530 nm (485 nm excitation) was measured using a fluorescence plate reader 
(Varioskan Flash Multimode Reader, Thermo Fisher Scientific, Nepean, ON, Canada). 
The number of adhered cells was calculated from a standard curve consisting of 
increasing LAD2 cell numbers. 
2.3.12 Chemotaxis assay 
Chemotaxis was performed using a 96-well monocyte cell migration kit 
(Calbiochem) with slight modifications. LAD2 cells were incubated overnight in SCF-free 
media, washed with HEPES buffer and suspended at 0.25 × 106 cells/ml. Agonists (0.1 
JPO6&)RUȝ015&-04) were added to the lower chamber of the 96-well tray and 
cell suspension (2.5 × 104 cells) was added to the insert (upper chamber). Cells were 
allowed to migrate towards the agonists for 6 h at 37°C/5% CO2. After incubation, the 
insert was washed twice with warm HEPES buffer. Cells were labeled for 30 min with 5 
ȝ0FDOFHLQ-AM at 37°C/5% CO2. After labeling, the cells that had migrated across the 
insert membrane were lysed using 0.1% Triton X-100. Fluorescence emission was 
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measured at 530 nm (485 nm excitation). The number of migrated cells was calculated 
from a standard curve consisting of increasing LAD2 cell numbers. 
2.3.13 Cell viability assay 
&HOOV ZHUH SUHWUHDWHG ZLWK  ȝ0 15&-04 for 30 min, 3 or 24 h, followed by 
incubation for 2 h with resazurin dye (In vitro toxicological assay kit, Sigma-Aldrich) at 
37°C/5% CO2. Fluorescence emission was measured at 590 nm (560 nm excitation).  
2.3.14 Flow cytometric analysis 
LAD2 cells were washed, suspended at 2 × 105 cells/ml in 0.1% BSA/PBS and 
incubated for 1 h with a phycoerythrin (PE)-anti-FPRL1 antibody or a PE-isotype control 
antibody (R&D Systems) at 4°C. Cells were washed twice, resuspended in 0.1% 
BSA/PBS and analyzed on a FACSArray (BD Biosciences). 
2.3.15 FRET analysis 
FPRL1-*Į-NFAT-bla CHO-K1 cells (Life Technologies) were cultured in 
growth medium (DMEM (high-glucose), with GlutaMAXTM (Life Technologies) 
supplemented with 10% dialyzed fetal bovine serum, 0.1 mM NEAA, 25 mM HEPES, 
8PO SHQLFLOOLQ ȝJPO VWUHSWRP\FLQ ȝJPO ]HRFLQ ȝJPO EODVWLFLGLQ DQG
ȝJPOJHQHWLFLQ&HOOVZHUHZDVKHGUHVXVSHQGHGLQSODWLQJPHGLXP'0(0[high-
glucose], with GlutaMAXTM + 10% charcoal-stripped fetal bovine serum) and plated at 
5000 cells/well in a 384-well plate; and incubated at 37°C/5% CO2 for 16 h. After 
incubation the plating media was removed and replenished with assay medium (DMEM 
[high-glucose], with GlutaMAXTM). Cells were pretreated for 2 h with the antagonists 
(WRW4 or pertussis toxin) followed by stimulation for 4 h with either 5 nM WKYMVM 
(W(M)) peptide (Phoenix Pharmaceuticals, Burlingame, CA, USA) RU ȝ015&-04 at 
37°C/5% CO2. Following stimulation, cells were loaded in the dark for 2 h at room 
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temperature with LiveBLAzerTM-FRET B/G substrate (Life Technologies). Fluorescence 
emissions were measured at 460 nm (409 nm excitation, Blue channel) and 530 nm 
(409 nm excitation, Green channel).  
2.3.16 Statistical analysis 
Each experiment was performed at least three separate times. Statistical 
significance was determined by two-WDLOHG 6WXGHQW¶V SDLUHG t-test and P<0.05 was 
considered significant. The results are shown as mean ± S.E.M. 
 
2.4 RESULTS 
2.4.1 Effect of pleurocidin peptides on mast cell degranulation 
Twenty different pleurocidin peptides (NRC-01 to NRC-20) were screened for 
their ability to induce human mast cell degranulation using a degranulation assay. The 
peptides differ in their total length and amino acid sequence (Table 2.2). Following 
stimulation of LAD2 cells with various concentrations of each of the pleurocidin peptides, 
we observed that not all were capable of degranulating LAD2 cells, as assessed by the 
UHOHDVHRIȕ-hexosaminidase enzyme, a marker of histamine release (Chapter 1.2.6.1). 
Only 11 of the tested peptides, including NRC-02, -03, -04, -07, -10, -12, -13, -16, -17, -
18, and -20, LQGXFHGVLJQLILFDQWGHJUDQXODWLRQDWDFRQFHQWUDWLRQRIȝ0Figure 2.1A).  
To determine whether these peptides had any cytotoxic effects on mast cells, we 
LQFXEDWHGFHOOVZLWKȝ0RIHDFKSHSWLGHDQGPHDVXUHGWKHPHWDEROLFDFWLYLW\RIFHOOV
using the resazurin assay. There was no change in cell metabolic activity following 30 
min, 3, or 24 h stimulation (data not shown).  
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Table 2.2 Amino acid sequences and lengths of the pleurocidin peptides tested  
Code Amino-acid sequence No. of residues 
NRC-01 GKGRWLERIGKAGGIIIGGALDHL-NH2 24 
NRC-02 WLRRIGKGVKIIGGAALDHL-NH2 20 
NRC-03 GRRKRKWLRRIGKGVKIIGGAALDHL-NH2 26 
NRC-04 GWGSFFKKAAHVGKHVGKAALTHYL-NH2 25 
NRC-05 FLGALIKGAIHGGRFIHGMIQNHH-NH2 24 
NRC-06 GWGSIFKHGRHAAKHIGHAAVNHYL-NH2 25 
NRC-07 RWGKWFKKATHVGKHVGKAALTAYL-NH2 25 
NRC-08 RSTEDIIKSISGGGFLNAMNA-NH2 21 
NRC-09 FFRLLFHGVHHGGGYLNAA-NH2 19 
NRC-10 FFRLLFHGVHHVGKIKPRA-NH2 19 
NRC-11 GWKSVFRKAKKVGKTVGGLALDHYL-NH2 25 
NRC-12 GWKKWFNRAKKVGKTVGGLAVDHYL-NH2 25 
NRC-13 GWRTLLKKAEVKTVGKLALKHYL-NH2 23 
NRC-14 AGWGSIFKHIFKAGKFIHGAIQAHND-NH2 26 
NRC-15 GFWGKLFKLGLHGIGLLHLHL-NH2 21 
NRC-16 GWKKWLRKGAKHLGQAAIK-NH2 19 
NRC-17 GWKKWLRKGAKHLGQAAIKGLAS-NH2 23 
NRC-18 GWKKWFTKGERLSQRHFA-NH2 18 
NRC-19 FLGLLFHGVHHVGKWIHGLIHGHH-NH2 24 
NRC-20 GFLGILFHGVHHGRKKALHMNSERRS-NH2 26 
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2.4.2 Mast cell degranulation in response to pleurocidin NRC-04 is 
concentration- and time-dependent  
Out of the 11 pleurocidin peptides that activated mast cell degranulation, NRC-04 
stimulated the highest amount of degranulation and it was chosen for further studies. 
NRC-04 degranulated LAD2 cells in a concentration-dependent manner, with maximum 
GHJUDQXODWLRQ    DW  ȝ0 Figure 2.1B). NRC-04 also notably caused 
degranulation of human peripheral blood CD34+ cell-derived mast cells (HuMC, Figure 
2.1B); however, these cells had a weaker response (21.89 ± 1.1%) to NRC-04 when 
compared with LAD2 cells. We further characterized the kinetics of NRC-04-mediated 
LAD2 degranulation and found that degranulation reached a maximum (71.07 ± 3.03%) 
within 5 min of stimulation (Figure 2.1C). Since the degranulation reached its maximum 
by 5 min, we evaluated the effect of NRC-04 at shorter time periods. NRC-04 induced 
gradual degranulation in LAD2 cells from 1-5 min (Figure 2.1D). 
To study the morphological changes associated with pleurocidin activation, we 
used electron microscopy to analyze intracellular changes in granularity and 
tomography. As shown in Figure 2.1E, stimulation with NRC-04 caused marked 
changes in the surface configuration of LAD2 cells, with loss in membrane integrity and 
the appearance of pores leading to the interior of the cell. 
2.4.3 Pleurocidin NRC-04 induces intracellular calcium mobilization  
As increase in intracellular Ca2+ is necessary for the induction of mast cell 
degranulation, we next tested whether NRC-04 had the capacity to mobilize intracellular 
Ca2+. LAD2 cells loaded with the Ca2+-sensing fluorescent dye fura-2 AM showed a rapid 
increase in intracellular Ca2+, reaching a peak within 60 s after NRC-04 exposure. As 
expected, c48/80 (positive control) caused additional Ca2+ influx (Figure 2.2A, B). 
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Figure 2.1 Pleurocidin peptides degranulate human mast cells. (A) LAD2 cells were stimulated 
IRUPLQZLWKȝ0SOHXURFLGLQSHSWLGHV15&-01 to NRC-DQGȕ-hexosaminidase release 
was measured (n=4). (B) Human peripheral blood CD34+ cell-derived mast cells (HuMC) and 
LAD2 cells were stimulated for 30 min with NRC-04 at indicated concentrations or (C-D) LAD2 
FHOOVZHUHVWLPXODWHGZLWKȝ015&-IRULQGLFDWHGWLPHVDQGȕ-hexosaminidase release was 
measured (n=3). (E) Electron micrograph showing morphological changes in LAD2 cells either 
unstimulated (left) or stimulated (righW IRU  PLQ ZLWK  ȝ0 15&-04. * P<0.05, ** P<0.01 
compared with untreated. 
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Figure 2.2 Pleurocidin NRC-04 mediates intracellular Ca2+ mobilization. (A) Fura-2 AM loaded 
/$'FHOOVZHUHVWLPXODWHGZLWKȝ015&-04 at time point VIROORZHGZLWKȝJPOF
at time point 256 s and mobilization of intracellular Ca2+ was measured (n=4). (B) Calcium 
response in 20 randomly selected individual LAD2 cells reported as mean ± S.E.M. of ratio 
340/380 (n=4). * P<0.05, ** P<0.01 compared with untreated. 
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2.4.4 Pleurocidin NRC-04 induces the release of lipid mediators CysLTs and 
PGD2 
Following degranulation, activated mast cells release arachidonic acid-derived 
lipid mediators (Chapter 1.2.6.2). As NRC-04 induced mast cell degranulation, we 
examined its ability to initiate the release of leukotrienes and prostaglandins. NRC-04 
induced significant release of CysLTs (147.11 ± 4.55 pg/ml) and PGD2 (935.48 ± 75.6 
pg/ml) from LAD2 cells. IgE/anti-IgE stimulated similar amounts of CysLTs and PGD2 
release while the G protein agonist c48/80 had no significant effect (Figure 2.3A, B). 
Although LAD2 cells showed high spontaneous release of PGD2, this was not 
attributable to any cell medium component as shown by low PGD2 concentrations in the 
cell-free medium control (Figure 2.3B) and NRC-04 in medium alone control (data not 
shown). 
2.4.5 Pleurocidin NRC-04 stimulates gene expression and protein production of 
chemokines 
We further measured the expression of cytokines and chemokines by LAD2 cells 
using qPCR analysis. Although no effect was observed on mRNA expression of 
cytokines (Figure 2.4A), mRNA expression levels of chemokines MCP-1/CCL2 and 
MIP-ȕ&&/ LQFUHDVHG VLJQLILFDQWO\ Figure 2.4B). In addition to the cytokines and 
chemokines examined in Figure 2.4A, B, we also tested if NRC-04 induced the 
expression of IL-4, IL-17, granulocyte macrophage colony-stimulating factor (GM-CSF), 
IP-10/CXCL10, IL-ȕ0,*&;&/5$17(6&&/RU,/-8. There was no change in the 
mRNA expression levels of these mediators following NRC-04 stimulation (data not 
shown). After observing the enhanced expression of MCP-1 and MIP-ȕWKHVWLPXODWRU\
effects on protein production of the respective chemokines was confirmed using ELISA, 
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Figure 2.3 Pleurocidin NRC-04 mediates the release of lipid mediators. LAD2 cells were 
VWLPXODWHG ZLWK  ȝJPO ,J( ȝJPO DQWL-,J(  ȝJPO F RU  ȝ0 15&-04. After 3 h 
treatment, the levels of (A) CysLTs, (B) PGD2 in cell-free supernatants was measured by enzyme 
immunoassay (n=5). * P<0.05, ** P<0.01 compared with untreated.  
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showing that NRC-04 enhanced the production of both MCP-1/CCL2 (Figure   2.4C) and 
MIP-ȕ&&/ Figure 2.4D). Interestingly, the effect of NRC-04 on chemokine 
production was comparable to that of IgE/anti-IgE, but considerably lower than c48/80. 
To further support our hypothesis that NRC-04 preferentially activates chemokine 
production, we performed CBA for IL-12p70, TNF, IL-10, IL-6, IL-ȕ ,3-10/CXCL10, 
MCP-1/CCL2, MIG/CXCL9, RANTES/CCL5, and IL-8. NRC-04 induced the production of 
MCP-1/CCL2 only (data not shown). We next evaluated the effect of NRC-04 on HuMC 
and observed no production of TNF, MCP-1/CCL2, or MIP-ȕ&&/ Figure 2.4E). In 
comparison, NRC-05 did not result in mast cell degranulation, and also failed to 
stimulate the production of TNF, MCP-1/CCL2 and MIP-ȕ&&/E\/$'FHOOV7KHVH
cells were responsive to c48/80 which was used a positive control (Figure 2.4F). 
2.4.6 Pleurocidin NRC-04 induces mast cell adhesion and chemotaxis 
Activation of mast cell degranulation in response to infection requires mast cell 
migration and accumulation at sites of infection (Chapter 1.2.7). As CAPs evoke mast 
cell adhesion, chemotaxis, and subsequent degranulation (Chapter 1.5.1.1.5), we 
evaluated whether NRC-04 could also promote these functions. Comparable with SCF, 
NRC-04 activated LAD2 cells to adhere to fibronectin, an extracellular matrix protein 
(Figure 2.5A). Since adhesion is closely related to cytoskeletal reorganization and 
migration, we measured LAD2 chemotaxis to either SCF or NRC-04. Results showed 
that similar to SCF, NRC-04 activated LAD2 chemotaxis (Figure 2.5B).  
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Figure 2.4 Pleurocidin NRC-04 induces the production and release of proinflammatory mediators. 
After 3 h treatment, mRNA expression of (A) TNF, TGF-ȕ DQG ,/-6, (B) MCP-1, MIP-Į DQG
MIP-ȕZDVPHDVXUHGE\T3&5 (n=3). Data was normalized to GAPDH mRNA levels and are 
expressed as fold increase over unstimulated controls. After 24 h treatment, production of (C) 
MCP-1, and (D) MIP-ȕ
 
in cell-free supernatants was measured by ELISA (n=3). Production of 
TNF, MCP-1, and MIP-ȕLQFHOO-free supernatant from (E) c48/80 or NRC-04-treated HuMC and 
(F) c48/80 or NRC-05-treated LAD2 cells was measured by ELISA (n=3). * P<0.05, ** P<0.01, *** 
P<0.001 compared with untreated. ND, not detectable.  
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Figure 2.5 Pleurocidin NRC-04 mediates human mast cell adhesion and migration. (A) LAD2 
cells were allowed to adhere for 2 h to fibronectin-coated wells in the presence of medium alone, 
ȝJPO6&)RUȝ015&-04 and number of adherent cells was assessed as described in 
Methods section (n=3). (B) LAD2 cells were allowed to migrate for 6 h across inserts towards 
PHGLXP DORQH  ȝJPO 6&) RU  ȝ0 15&-04 and migration was assessed as described in 
Methods section (n=3). * P<0.05, ** P<0.01 compared with untreated. 
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2.4.7 Human mast cell activation by pleurocidin NRC-04 is sensitive to inhibitors 
of G protein signaling  
Although the signaling pathways responsible for cathelicidin activation of mast 
cells are poorly understood, a number of specific secondary messengers such as G 
proteins and lipid kinases have been implicated (Chapter 1.5.1.1.5). We examined 
whether G protein, phosphoinositol 3-kinase (PI3K), phospholipase C (PLC) and/or 
protein kinase C (PKC) pathways were involved by pretreating the cells with pathway 
specific inhibitors, pertussis toxin, wortmannin, U-73122 and Ro-31-8220, respectively 
before activation with NRC-04. All four inhibitors significantly inhibited NRC-04-activated 
mast cell degranulation (Figure 2.6A-D), and pertussis toxin significantly suppressed 
NRC-04-induced intracellular Ca2+ mobilization in LAD2 cells (Figure 2.6E, F).  
2.4.8 Human mast cells express N-formyl peptide receptor-like 1 (FPRL1) and 
P2X7 receptors 
Pertussis sensitivity suggested that NRC-04 was activating G protein signaling 
mediated by the activation of functional GPCR. Previous studies have shown that 
cathelicidin LL-37 activates mast cell chemotaxis via FPRL1 and mast cell cytokine 
release via purinoreceptor P2X7. We hypothesized that FPRL1 and/or P2X7 receptors 
might therefore be involved in NRC-04-mediated mast cell activation. RT-PCR analysis 
showed that LAD2 cells expressed mRNA for both FPRL1 and P2X7 receptors (Figure 
2.7A), and flow cytometric analysis confirmed cell surface expression of FPRL1 (Figure 
2.7B). 
To determine if NRC-04 activation was FPRL1 and P2X7 dependent, we 
pretreated LAD2 cells with WRW4 (FPRL1 antagonist) or KN-62 (P2X7 antagonist) prior 
to activation with NRC-04. WRW4 inhibited NRC-04-induced degranulation (Figure 
2.7C), whereas KN-62 had no effect (Figure 2.7D).  
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Figure 2.6 Pleurocidin NRC-04-induced human mast cell degranulation is G protein-, PI3K-, PLC- 
and PKC-dependent. LAD2 cells were treated with the indicated concentrations of (A) pertussis 
toxin (PTx), (B) wortmannin, (C) U-73122, or (D) Ro-31-SULRUWRVWLPXODWLRQZLWKȝ015&-
04 and the percentageVRIȕ-hexosaminidase release were measured (n=3). (E) LAD2 cells were 
pretreated for 2 h with 5 nM PTx, loaded with fura-VWLPXODWHGZLWKȝ015&-04 at time point 
VIROORZHGZLWKȝJPOFDWWLPHSRLQWVDQGPRELOL]DWLRQRILQWUDFHOOXODU&D2+ was 
measured. (F) The Ca2+ response in 20 randomly selected individual LAD2 cells reported as 
mean ± S.E.M. of ratio 340/380 (n=5). * P<0.05, ** P<0.01 compared with untreated. 
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Figure 2.7 FPRL1 and P2X7 receptors in NRC-04-mediated human mast cell activation. (A) Total 
RNA was isolated from LAD2 cells, and FPRL1 and P2X7 receptor mRNA expression was 
examined by RT-3&5ȕ-actin was used as a positive control. (B) The expression of FPRL1 on 
LAD2 cell surface was evaluated by flow cytometry. LAD2 cells were pretreated for 2 h with (C) 
WRW4, (D) KN-62, or vehicle, stimulated with 1 µM NRC- DQG SHUFHQWDJH RI ȕ-
hexosaminidase release was measured (n=3). ** P<0.01 compared with untreated. 
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2.4.9 Fluorescence-resonance energy transfer (FRET)-based detection of FPRL1 
activation by pleurocidin NRC-04 
To determine whether NRC-04 could directly activate the FPRL1 receptor, we 
XVHG D UHSRUWHU DVVD\ LQ ZKLFK )35/ LV VWDEO\ LQWHJUDWHG LQWR WKH *Į-NFAT-bla 
CHO-K1 cell line. This cell line contains a beta-lactamase (bla) reporter gene under the 
control of a NFAT (nuclear factor of activated T-cell) response element and a 
SURPLVFXRXV*SURWHLQ*ĮVWDEO\ LQWHJUDWHG LQWR&+2-K1 cells.  In the absence of 
bla expression (unstimulated) cells appear green fluorescent (530 nm emission); 
however, in the presence of bla expression (stimulated), the FRET-enabled substrate is 
cleaved and cells appear blue fluorescent (460 nm emission). Incubation of cells with 
NRC-04 resulted in a significant increase in 460/530 (Blue/Green) emission ratio in a 
concentration-dependent manner. WKYMVM (W(m)) peptide was used a positive 
control. WRW4 and pertussis toxin were able to inhibit NRC-04 activity (Figure 2.8), 
indicating a specific interaction between NRC-04 and FPRL1.   
 
2.5 DISCUSSION 
In the present study, we investigated the pleurocidin family of CAPs in innate 
immune responses based on their abilities to activate human mast cells. We 
demonstrated that pleurocidin NRC-04 induced mast cell migration, adhesion, 
degranulation, release of lipid mediators, and the production of chemokines. By contrast, 
NRC-05 did not activate LAD2 cell degranulation and chemokine production, suggesting 
that these two functions are controlled by similar signaling pathways. Our data further 
showed that pleurocidins activated G proteins and PI3K, PLC and PKC signaling 
pathways in human mast cells. A specific GPCR, FPRL1, was expressed in human mast 
cells and likely to be functional in pleurocidin-induced mast cell activation.  
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Figure 2.8 Pleurocidin NRC-04 couples to FPRL1 receptor. FPRL-1-*Į-NFAT-bla CHO-K1 
cells were incubated for 4 h with WRW4 or pertussis toxin (PTx), stimulated with W(m) or NRC-04 
and FRET assay was performed as described in Methods section (n=3). * P<0.05, ** P<0.01, *** 
P<0.001 compared with untreated. 
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Among the mucus-derived fish AMPs, the pleurocidin family is probably the best 
characterized and has been under investigation by several research groups. A study by 
Chiou et al. reported the potential immunoregulatory effects of pleurocidin on the 
expression of immune-relevant genes, IL-1 and cyclooxygenase (COX)-2, in a fish 
macrophage cell line (18), suggesting a proinflammatory role of pleurocidin in vertebrate 
immune system. In other studies, pleurocidin CAPs exhibited cytolytic activity against 
breast cancer cells and multiple myeloma cells and impaired the growth of tumor 
xenografts in immune-deficient mice (19), indicating that these peptides may also 
stimulate an antitumor immune response. Similar to cathelicidins, a family of mammalian 
CAPs, pleurocidin genes share highly conserved N-terminal signal peptide (pre) and C-
terminal acid peptide (pro) sequences, in addition to the mature pleurocidin sequences 
(20-22), this results in an initial pre-pleurocidin-pro peptide, which is the precursor of 
mature and fully bioactive pleurocidin. Both mature cathelicidins (20) and mature 
SOHXURFLGLQV IRUP Į-helixes and kill Gram-positive and Gram-negative bacteria by 
forming pores in their membranes (12, 23), causing cell lysis (11, 24). Different peptides 
belonging to the pleurocidin family are only found in pleuronectid flatfish (Winter 
flounder, Yellowtail flounder, American plaice, and Halibut) and share a common signal 
and proregion amino acid sequences but differ in core antimicrobial sequences 
(10). Pleurocidin family peptides exhibit a wide range of antimicrobial activities, ranging 
from highly potent (minimum inhibitory concentration   ȝJPO WR LQDFWLYH 3HSWLGHV
NRC-03, -04, -06, -07, -11, -12, -13, -15, -16, and -17, exhibit significant inhibitory 
activities against pathogens, and  the peptide sequences of NRC-04, -07, -11, -12, and -
13 CAPs consist of an XVGK motif, where X is H, K, or T, all of which are relatively bulky 
residues. In the case of NRC-04, the motif is even doubled as HVGKHVGK, which is 
probably compatible with a highly bactericidal amphipathic helix (10). Interestingly, the 
widely divergent antimicrobial activities of pleurocidins extend also to their ability to 
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activate mast cells. Our initial screen of the twenty pleurocidin peptides revealed that 
some peptides were capable of degranulating human mast cells. Eleven of the twenty 
pleurocidin peptides tested (NRC-02, -03, -04, -07, -08, -12, -13, -16, -17, -18, and -20) 
induced significant LAD2 degranulation. Pleurocidin NRC-04 showed the highest 
degranulation activity, and since it is also a potent CAP with maximum antimicrobial 
activity as compared with the other 19 peptides, it was used for subsequent studies.  
A hallmark of mast cell activation is the rise in intracellular Ca2+ upon agonist 
stimulation and polybasic compounds such as c48/80 are potent activators of mast cell 
degranulation and calcium influx (25, Chapter 1.2.5.2). Intracellular Ca2+ is thought to 
play a key role in mast cell migration, release of histamine and lipid mediators (26). Ca2+ 
influx is required for histamine release by huPDQ ȕ-defensin-2 and LL-37 (7). In this 
study, pleurocidin increased intracellular Ca2+ mobilization in mast cells, causing them to 
degranulate and release proinflammatory mediators.  
De novo-synthesized lipid mediators are mainly secreted by activated mast cells, 
and are mediators of proinflammatory reactions (27, Chapter 1.2.6.2). We showed that 
pleurocidin activated the release of CysLTs and PGD2 in human mast cells, in contrast 
with LL-37 which does not induce PGD2 production (7). However, the study involving LL-
37 used rat peritoneal mast cells; thus, differences in mast cell phenotypes should be 
considered. Our results with c48/80 were consistent with a previous report that in mast 
cells, c48/80 induced intracellular Ca2+ mobilization, high secretion of histamine and low 
release of PGD2 (28). The failure of c48/80 to induce secretion of lipid mediators, 
suggests that, unlike c48/80, which activates human mast cells in a receptor-
independent manner by directly acting on G proteins, pleurocidins utilize a receptor for 
their action.  
Our findings demonstrated that pleurocidins activated the production of 
chemokines MCP-1 and MIP-ȕ EXW QRW F\WRNLQHV LPSO\LQJ WKDW VWLPXODWLRQ PD\ EH 
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selective for a limited number of proinflammatory chemokines. MCP-1 and MIP-ȕDUH
involved in recruitment and activation of various immune cells such as neutrophils, 
basophils, eosinophils, monocytes, and T cells to sites of tissue injury, infection, and 
inflammation (29, Chapter 1.2.6.3). Taken together, our results suggest that in addition 
to histamine and lipid mediator release, pleurocidins may also participate in the 
regulation of inflammatory immune response by the induction of chemokines and 
subsequent immune cell recruitment.  
During inflammation, localized increases in the numbers of mast cells occurs, 
and their accumulation requires directed migration of these cells (1, 2, Chapter 1.2.7). 
The present study showed that pleurocidins can serve as a potent chemoattractant for 
human mast cells. Moreover, it promoted mast cell adhesion to fibronectin, indicating its 
importance in tissue localization of mast cells and a possible role in processes such as 
wound healing and fibrosis.  
 To understand the molecular mechanisms underlying the activities of 
pleurocidin, we investigated the requirement for G proteins, PI3K, PLC and PKC as their 
roles in CAPs-stimulated mast cell activation has been previously reported (4, Chapter 
1.5.1.1.5). The G protein inhibitor pertussis toxin, the PI3K inhibitor wortmannin, the PLC 
inhibitor U-73122 and the PKC inhibitor Ro-31-8220 showed inhibitory effects on 
pleurocidin-mediated mast cell degranulation. In addition, pertussis toxin also inhibited 
the increase in intracellular Ca2+ mobilization. Cationic peptide stimulation of G proteins 
lead to the activation of PLC and PI3K; activated PLC catalyzes the generation of 
inositol triphosphate and diacylglycerol leading to Ca2+ mobilization and PKC activation 
respectively (25, Chapter 1.3, Figure 1.7). Among isoenzymes of PLC identifLHGRQO\ȕ
VXEW\SH 3/& LV DFWLYDWHG E\ * SURWHLQV W\SLFDOO\ *Įq ,Q DGGLWLRQ ȕȖ VXEXQLWV RI *
proteins which have GLVVRFLDWHG IURP *Įi/o DOVR UHJXODWH 3/& ȕ DFWLYLW\ (30, 31); and 
VLQFHSHUWXVVLVWR[LQLVNQRZQWRLQKLELW*Įi/o EXWQRW*Įq (32), our findings suggest that 
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*Įi DQGRU*Įo type G proteins are involved in pleurocidin-induced activation of PLC in 
mast cells. Thus, the activation of G protein-FRXSOHG3/&ȕSDWKZD\OLNHO\SOD\VDUROHLQ
the pleurocidin-elicited intracellular Ca2+ mobilization leading to mast cell activation. We 
also tested the effect of fluticasone propionate, salmeterol xinafoate, and tranilast on 
NRC-04-activated mast cell degranulation but found that none of these inhibitors had an 
effect on mast cell activation (data not shown). 
Next we identified a functional receptor for pleurocidin in mast cells. LL-37 
chemoattracts immune and inflammatory cells, including neutrophils, monocytes, and T 
cells via the action on a low affinity formyl peptide receptor, FPRL1 (33, Chapter 
1.5.1.1). LL-37 also interacts with the purinoreceptor P2X7, that is predominantly 
expressed on monocytes, macrophages and dendritic cells and induces the processing 
and release of the potent cytokine IL-ȕ(34) and IL-8 in human gingival fibroblasts (35). 
Thus, we addressed the question as to whether the pleurocidin-induced mast cell 
degranulation was mediated by FPRL1 and/or P2X7. We found that both FPRL1 and 
P2X7 were expressed by human mast cells. The FPRL1 antagonist WRW4 inhibited 
pleurocidin-induced mast cell degranulation but the P2X7 antagonist KN-62 had no 
effect. Thus, pleurocidin utilizes FPRL1 as a receptor to activate mast cellss. In a 
IOXRUHVFHQW UHSRUWHU DVVD\ XWLOL]LQJ )35/ VWDEO\ LQWHJUDWHG LQWR WKH *Į-NFAT-bla 
CHO-K1 cell line under the control of beta-lactamase reporter gene, we showed that 
pleurocidin activated a conformational change in FPRL1 which was sensitive to a 
pharmacological inhibitor of FPRL1 and pertussis toxin. FPRL1 belongs to the GPCR 
superfamily that activates host defense mechanisms in immune cells including migration, 
adhesion, and degranulation. It mediates these cellular functions in a pertussis toxin-
sensitive manner, indicating coupling to one or more members of the GĮi subfamily of G 
proteins.  The novel ability of FPRL1 to convey both pro and anti-inflammatory signaling 
makes it an intriguing, yet unusual GPCR (36). Not surprisingly numerous peptide 
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ligands of FPRL1 have been identified as potential therapeutic interventions for human 
disease (Chapter 1.5.1.1.4). Our study describes a novel, naturally-occurring 
proinflammatory agonist for FPRL1.                                                                                                                 
In conclusion, our studies show that pleurocidin could effectively recruit and 
activate human mast cells by binding and signaling through the *Įi-coupled stimulatory 
FPRL1 receptor. Pleurocidin activation of mast cells not only induced degranulation and 
release of preformed granule mediators, but it also induced the production of 
chemokines. Pleurocidin-induced release of mast cell mediators could potentially lead to 
recruitment and activation of T lymphocytes, eosinophils, and other inflammatory cells 
that contribute to innate and adaptive immune responses. With the global emergence of 
many new infectious diseases, as well as concerns about the antibiotic resistance of an 
increasing number of microbial pathogens, the peptide antibiotics group of antimicrobials 
warrants attention and further studies. Our data may prove useful in suggesting novel 
ways of activating mast cells to boost immune responses.  
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CHAPTER 3.  THE COMPLEMENT COMPONENT C5a ACTIVATES 
HUMAN MAST CELLS VIA THE NOVEL C5a RECEPTOR, C5L2 
 
A version of this chapter has been submitted for publication in The Journal of 
Immunology as follows: 
P Pundir, C MacDonald, M Kulka. The novel receptor C5L2 is required for C5a-mediated 
human mast cell adhesion, migration, cytokine and chemokine production.2 
 
3.1 ABSTRACT 
Mast cells are tissue-resident immune effector cells that upon activation can 
initiate inflammatory responses to infectious insult or allergens by releasing a multitude 
of biologically-active mediators. The complement component C5a can regulate mast cell 
functions. However, the signaling pathways through which it acts remain unclear. C5a 
functions though two identified receptors C5a receptor (C5aR) and C5a receptor-like 2 
(C5L2). C5aR is a classical G protein-coupled receptor known to mediate most mast cell 
responses associated with C5a, but the role of C5L2 has yet to be defined. We 
hypothesized that C5a activates human mast cells via the C5aR and C5L2 receptors. 
The human mast cell line, LAD2 (Laboratory of Allergic Diseases 2), expressed C5L2 
receptor but not C5aR, whereas human peripheral blood CD34+ cell-derived mast cells 
showed no surface expression of C5aR or C5L2. Although, C5a did not induce 
degranulation, it caused LAD2 to adhere, migrate, and release cytokines and 
chemokines. Silencing C5L2 using lentiviral short hairpin RNA rendered the cells 
unresponsive to C5a. Adhesion of mast cells could be blocked partially by pertussis toxin 
(G protein inhibitor) and wortmannin (phosphoinositol-3 kinase inhibitor); however, U-
73122 (phospholipase C inhibitor) and Ro-31-8220 (protein kinase C) had no effect. 
                                                            
2
 P Pundir designed and performed the experiments, analyzed the data and wrote the chapter; M 
Kulka helped design the study and experiments, and edited the manuscript 
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Moreover, C5a caused extracellular signal-regulated kinases (ERK)-1/2 phosphorylation 
in LAD2 cells. Exposure to C5a caused ~60% internalization of cell surface C5L2 
receptor. Culture in the presence of interleukin (IL)-4 or human fibroblasts led to 
upregulation of C5L2 receptor in human mast cells which correlated with enhanced 
adhesion and migration in response to C5a. These findings suggest that C5L2 receptor, 
which couples with pertussis toxin-sensitive signaling pathways, activates adhesion, 
migration and mediator release by human mast cells.  
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3.2 INTRODUCTION 
Mast cells play a central role in the pathophysiology associated with asthma and 
allergic diseases (1, Chapter 1.2.10). The classical activation of mast cells occurs via the 
FHOOVXUIDFHKLJKDIILQLW\LPPXQRJOREXOLQ,J(UHFHSWRU)Fİ5,)ROORZLQJFURVV-linking of 
)Fİ5,E\DOOHUJHQVPDVWFHOOVDUHDFWLYDWHGDQGVHFUHte a multitude of biologically active 
mediators such as histamine, leukotrienes and prostaglandins, as well as proteases, 
cytokines and chemokines, which are all pivotal to the development of allergic 
inflammation (2, Chapter 1.2.5.1) %HVLGHV )Fİ5, RWKHU IgE-independent mechanisms 
have been described for mast cell activation which can be initiated by a variety of 
peptides, secretagogues, and pathogen-associated molecular patterns (PAMPs) (2-4, 
Chapter 1.2.5.2, Figure 1.3) 
The complement system is an evolutionarily conserved part of the innate immune 
system playing an important role in the host defense against pathogens (5, Chapter 
1.5.2). After encountering PAMPs, activation of the complement system occurs through 
a proteolytic cascade. During the cascade numerous biologically active fragments are 
generated from zymogens, including the anaphylatoxic peptides C3a (6), C4a (7), and 
C5a (6, Figure 1.9). C5a causes very potent pathophysiologic responses, including 
smooth muscle contraction, enhanced vascular permeability (6, 8), and chemotaxis of 
macrophages, neutrophils, activated lymphocytes, basophils, and eosinophils (9-12, 
Chapter 1.5.2.2.4). C5a activates various immune cells through interaction with two 
different receptors, the C5a receptor (C5aR) and C5a receptor-like 2 (C5L2) (Chapter 
1.5.2). C5aR and C5L2 are co-expressed on a wide variety of immune cells, including 
neutrophils, monocytes, mast cells, and immature dendritic cells and in tissues, such as 
testis, spleen, lung, liver, kidney, heart, and brain (13-16). C5aR is a classical G protein-
coupled receptor (GPCR) through which most of the functional effects of C5a occur, 
such as chemotaxis, oxidative burst, degranulation, and release of proinflammatory 
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mediators (Chapter 1.5.2.2). C5L2 is also a 7-transmembrane protein that shares 58% 
sequence homology with the C5aR (13). It is a second high affinity receptor for C5a. 
which also binds C5a desArg with a much higher affinity than the C5aR (16). Some 
studies have also demonstrated that the C5L2 has the ability to bind C3a desArg (17-
19). The functional role of C5L2 remains much more enigmatic, but some studies 
suggest that it may act as a non-signaling decoy receptor that regulates the 
bioavailability of C5a and thus limits C5aR-dependent cell activation. On the contrary, 
other studies suggest a functional role for C5L2 in controlling both proinflammatory and 
anti-inflammatory responses of C5a in different disease settings (17, Chapter 1.5.2.3). 
Mast cells have long been considered a target for the action of anaphylatoxins 
and studies have shown that C5a induces mediator release by human mast cells (20), 
as well as chemotaxis of neoplastic human mast cells (HMC-1), cord blood-derived mast 
cells (CBMC) and skin mast cells (21, 22). In addition to chemotaxis and degranulation, 
C5a also induces cytokine and chemokine gene expression in mast cells (23, 24) and 
C5a-induced responses are inhibited by receptor-specific antibodies and pertussis toxin, 
DQ LQKLELWRU RI WKH *Įi family of G proteins. Rat basophilic-like (RBL-2H3) cells 
transfected with the C5aR release mediators in response to C5a stimulation (25). 
Therefore, the C5aR signaling cascade has been implicated in C5a-induced mast cell 
functions. However, a role for C5L2 has yet to be defined (Chapter 1.5.2.3). We 
hypothesized that C5a activates human mast cells through their C5aR and C5L2 
receptors. The aims of our study were to determine: (i) the expression of C5aR and 
C5L2 by human mast cells, (ii) the ability of C5a in activating mast cells, (iii) whether 
C5a-mediated mast cell activation is C5aR- and C5L2-dependent, and (iv) the signaling 
pathway(s) used for the activation of mast cells by C5a. These studies addressed the 
overall hypothesis of this thesis which is that human mast cells express both stimulatory 
DQG LQKLELWRU\ *3&5 ZKLFK VLJQDO WKURXJK *Įi RU *Įs, respectively, and that these 
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receptors are important in chemotaxis and mast cell migration. We chose C5a receptors 
as our model of activating GPCRs. &D5FRXSOHVZLWKVWLPXODWRU\*Įi; the expression, 
function and signaling mechanism of C5L2 in human mast cells are unknown. 
 
3.3 METHODS 
3.3.1 Cell culture  
LAD2 (Laboratory of Allergic Diseases 2) human mast cell line was cultured in 
serum-free medium (StemPro-34 SFM, Life Technologies, Burlington, ON, Canada) 
supplemented with 2 mM L-JOXWDPLQH8POSHQLFLOOLQȝJPOVWUHSWRP\cin and /ml 
0.1 µg/ml recombinant human stem cell factor (rhSCF; Peprotech, Rocky Hill, NJ, USA). 
The cells were maintained at a density of 0.1 × 106 cells/ml at 37°C/5% CO2. The cells 
ZHUHSHULRGLFDOO\WHVWHGIRUH[SUHVVLRQRI.LWDQG)Fİ5,E\IORZF\WRPHtry.  
Human peripheral blood CD34+ cells-derived mast cells were kindly provided by 
Dr. Dean Befus. These cells were cultured in StemSpan SFEM (StemCell Technologies, 
Vancouver, BC, Canada) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 50 
ȝJPO streptomycin, 0.1 µg/ml rhSCF, and 0.1 µg/ml rh(interleukin) IL-6 (Peprotech); 
0.03 µg/ml rhIL-3 (Peprotech) was added for the first week. At 8-10 weeks, the cultures 
consisted of >99% c-Kit+ )Fİ5,+ mast cells, as tested by flow cytometry. 
The 1079SK human fibroblast cell line (ATCC CRL-2097) was cultured in 
Minimum Essential Medium (Life Technologies) supplemented with 2 mM L-glutamine, 
1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 
8POSHQLFLOOLQȝJPOVWUHSWRmycin and 10% FBS. 
3.3.2 Isolation of RNA and generation of cDNA by reverse transcription 
Total RNA was isolated using the Tri Reagent method (Sigma-Aldrich Canada, 
2DNYLOOH21&DQDGD,QDOOȝJRIWRWDOFHOOXODU51$ZDVUHYHUVH-transcribed to cDNA 
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using M-MLV Reverse Transcriptase (Life Technologies) in a 20-ȝO UHDFWLRQ PL[, 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VUHFRPPHQGDWLRQ 
3.3.3 Reverse transcription PCR (RT-PCR) 
RT-PCR was performed using a Peltier Thermal Cycler System (Bio-Rad, 
Hercules, CA, USA) with Life Technologies reagents. C5a receptor (C5aR), C5a 
receptor-like 2 (C5L2), DQGȕ-actin primers (Table 3.1) were designed using the Primer 
Express software (Applied Biosystems, Foster City, CA, USA). Amplification was carried 
out for 30 cycles including denaturation for 45 s at 94°C, annealing for 30 s at 52°C for 
C5aR, 58°C for C5L2, DQG & IRU ȕ-actin, and extension for 30 s at 72°C. PCR 
amplicons were analyzed by 1% agarose gel electrophoresis and visualized by ethidium 
bromide staining.   
3.3.4 Real-time qPCR 
Gene expression was analyzed using real-time qPCR on a StepOnePlus system 
(Applied Biosystems). For each qPCR assay, a total of 50 ng of cDNA was used. Primer 
sets (Table 3.1) for PCR amplifications were designed using the Primer Express 
software. All reactions were performed in triplicate for 40 cycles as per the 
PDQXIDFWXUHU¶V UHFRPPHQGDWLRQ $OO GDWD ZHUH QRUPDOL]HG WR JO\FHUDOGHK\GH -
phosphate dehydrogenase (GAPDH) internal controls (26) and are reported as fold 
change in expression over untreated cells.  
3.3.5 Flow cytometric analysis 
Cells were washed, suspended at 0.2 × 106 cells/ml in 0.1% bovine serum albumin 
(BSA)/PBS and/or permeabilized  with 0.4% saponin and stained for 1 h with either 
phycoerythrin (PE)-labeled anti-C5aR antibody (R&D Systems, Minneapolis, MN, USA), 
PE-anti-C5L2 antibody (Abcam, Cambridge, MA, USA), or PE-isotype control antibody at  
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Table 3.1 Sequences of oligonucleotides used for PCR 
Gene Forward primer Reverse primer Probe: FAM/TAMRA (GAPDH: 
MAX/BHQ) 
 
GAPDH 
 
5'-TCG TGG AAG GAC TCA 
TGA C-3' 
 
 
5'-CCA TCA CGC CAC AGT 
TT-3' 
 
5'-/5MAXN/AGT CCA TGC CAT CAC 
TGC CAC/3IABlk_FQ/-3' 
C5aR 5'-TGA CTG AAG AGT CCG 
TGG TTA GG -3' 
5'-CTG GGT CTT CTG GGC 
CAT AG-3' 
5'-/56-FAM/ AGA GCA AGT CAT TCA 
CGC GCT CCA C/36-TAMSp/-3' 
 
C5L2 5'-CCA GGG CCA GGA CGA 
AA-3' 
5'-CTC CAG CCT ACA CCT 
CCA TCT C-3' 
5'-/56-FAM/ TGG ACA GCA AGA AAT 
CCA CCA GCC A/36-TAMSp/-3' 
 
GM-CSF 5'-CAG CCC TGG GAG CAT 
GTG-3' 
5'-ATT CAT CTC AGC AGC 
AGT GTC TCT A-3' 
5'-/56-FAM/AGG CCC GGC GTC TCC 
TGA ACC/36-TAMSp/-3' 
IL-ȕ 5'-TGA GCT CGC CAG TGA 
AAT GA-3' 
5'-TGA GCT CGC CAG TGA 
AAT GA-3' 
¶-/56-FAM/GAA GCT GAT GGC CCT 
AAA CAG ATG AAG TGC T/36-
TAMSp/-3' 
 
IL-6 5'-AGC CAC TCA CCT CTT 
CAG AAC GAA-3' 
5'-AGT GCC TCT TTG CTG 
CTT TCA CAC-3' 
5'-/56-FAM/ ACG GCA TCT CAG CCC 
TGA GAA AGG AGA /36-TAMSp/-3' 
 
IL-8 5'-CTG GCC GTG GCT CTC 
TTG-3' 
5'-TTG GCA AAA CTG TTT 
AGC ACT CC-3' 
5'-/56-FAM/ CAG CCT TCC TGA TTT 
CTG CAG CTC TGT GT /36-TAMSp/-3' 
 
IP-10 5'-CGA TTC TGA TTT GCT 
GCC TTA TC-3' 
5'-TGA TTA CTA ATG CTG 
ATG CAG GTA CA-3' 
5'-/56-FAM/TGG CAT TCA AGG AGT 
ACC TCT CTC TAG AAC CGT /36-
TAMSp/-3' 
 
MIP-ȕ 5'-CAG CGC TCT CAG CAC 
CAA-3' 
5'-TTC CTC GCG GTG TAA 
GAA AAG-3' 
5'-/56-FAM/ CTC AGA CCC TCC CAC 
CGC CTG C/36-TAMSp/-3' 
MCP-1 5'-TCT CTG CCG CCC TTC 
TGT -3' 
5'- GCC TCT GCA CTG AGA 
TCT TCC T-3' 
5'-/56-FAM/ CTG CTC ATA GCA GCC 
ACC TTC ATT CCC  /36TAMSp/-3' 
 
RANTES 5'-TCG CTG TCA TCC TCA 
TTG CTA-3' 
5'-GCA CTT GCC ACT GGT 
GTA GAA A-3' 
5'-/56-FAM/ CTG GGA CAC CAC ACC 
CTG CTG C  /36-TAMSp/-3' 
 
TGF-ȕ 5'-CTC TCC GAC CTG CCA 
CAG A-3' 
5'-AAC CTA GAT GGG CGC 
GAT CT-3' 
5'-/56-FAM/ CCC TAT TCA AGA CCA 
CCC ACC TTC TGG T /36-TAMSp/-3' 
 
TNF 5'-TCT GGC CCA GGC AGT 
CA-3' 
5'-GCT TGA GGG TTT GCT 
ACA ACA TG-3' 
5'-/56-FAM/ CAG TGC TCC AAG CCC 
GGT GTC ATC /36TAMSp/-3' 
C5aR 5'-ATG GAT CCT AAC ATA 
CCT GCG GAT G-3' 
5'-TCT ACA CCG CCT GAC 
TCT TCC G-3' 
 
C5L2 5'-AAC CAC ACC ACC AGC 
GAG TAT TAT G-3' 
5'-AGC CCT CTT GCC TAC 
ACC GGC-3' 
 
ȕ-actin 5'-ATC TGG ACC ACA CCT 
TCT ACA ATG AGC TGC G-
3' 
5'-CGT CAT ACT CCT GCT 
TGC TGA TCC ACA TCT GC-
3' 
 
 
C5aR, C5a receptor; C5L2, C5a receptor-like 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GM-CSF, 
granulocyte macrophage colony-stimulating factor; , IL, interleukin; IP-10, inducible protein-10; MIP, monocyte 
inflammatory protein; MCP-1, monocyte chemotactic protein-1; RANTES; regulated upon activation, normal T cell 
expressed and secreted; TGF-ȕWUDQVIRUPDWLRQJURZWKIDFWRU-beta; TNF, tumor necrosis factor. 
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4°C. Cells were washed twice, resuspended in 0.1% BSA/PBS and analyzed on a 
FACSArray or FACSCalibur (BD Biosciences, Mississauga, ON, Canada). 
3.3.6 Degranulation assay 
Cells were washed, resuspended in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (10 mM HEPES, 137 mM NaCl, 2.7 mM 
KCl, 0.38 mM Na2HPO4.7H2O, 5.6 mM glucose, 1.8 mM CaCl2.H2O, 1.3 mM 
MgSO4.7H2O, 0.4% BSA, pH 7.4) at 2.5 × 104 cells per well and stimulated for 30 min 
with serial dilutions of C3a (Calbiochem, Billerica, MA, USA) or C5a (Biovision, Milpitas, 
CA, USA) at 37°C/5% CO2 ȕ-hexosaminidase released into the supernatants and in 
total cell lysates solubilized with 0.1% Triton X-100 was quantified by hydrolysis of p-
nitrophenyl N-acetyl-ȕ-D-glucosamide (Sigma-Aldrich) in 0.1 M sodium citrate buffer (pH 
4.5) for 90 min at 37°C/5% CO2 7KH SHUFHQWDJH RI ȕ-hexosaminidase release was 
calculated as a percent of total content.   
,Q VRPH H[SHULPHQWV /$' FHOOV ZHUH VHQVLWL]HG RYHUQLJKW ZLWK  ȝJPO
biotinylated immunoglobulin E (IgE, Abbiotec. San Diego, CA, USA). Cells were washed 
with HEPES, preincubated for 30 min with C5a, stimulated for 30 min with streptavidin 
/LIH 7HFKQRORJLHV DQG WKHQ ȕ-hexosaminidase release was measured. In other 
experiments, LAD2 cells were treated for 30 min with C5a followed by stimulation for 30 
min with compound 48/80 (c48/80; Sigma-$OGULFK RU 6&) DQG ȕ-hexosaminidase 
release was measured. 
3.3.7 Intracellular Ca2+ mobilization  
LAD2 cells were loaded for 30 min with 1 ȝM fura-2 AM (Life Technologies) in 
HEPES buffer, washed and incubated for 15 min in BSA-free HEPES at 37°C/5% CO2. 
A total of 4 × 106 cells were placed in glass-bottom culture dish under an inverted 
microscope (Axiovert 200, Carl Zeiss Canada Ltd., Canada). Fura-2 was excited at 340 
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and 380 nm alternatively. The Ca2+ response was recorded at 100 ms intervals using 
SlideBook for Stallion, version 4.26.04 software (Intelligent Imaging Innovations, USA). 
In all,  ȝJPO &D was added at the 70 s time point and  ȝ0 LRQRP\FLQ (Sigma-
Aldrich) at the 256 s time point. The Ca2+ response of 20 randomly selected cells were 
analyzed for each experiment and plotted as the ratio 340/380 vs. time. 
3.3.8 ELISA 
1 × 106 cells were stimulated for 3 h either ZLWKȝJPO,J(ȝJPODQWL-IgE 
RUȝJPO&DDW&&22. Cell-free supernatants were isolated and analyzed for 
cysteinyl leukotrienes (CysLTs), prostaglandin D2 (PGD2) or cytokine content using the 
following commercial competitive enzyme immunoassay (EIA) kits: correlate-EIA 
cysteinyl leukotriene kit (Assay Designs, Ann Arbor, MI, USA), prostaglandin D2 EIA kit 
(Cayman Chemicals, Ann Arbor, MI, USA), human tumor necrosis factor (TNF)-alpha 
quantikine ELISA kit, and human granulocyte-macrophage colony-stimulating factor 
(GM-CSF) quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).  The minimum 
detection limits were CysLT, 78.1 pg/ml; PGD2, 200 pg/ml; TNF, 5.5 pg/ml; and GM-
CSF, 3 pg/ml. 
3.3.9 Cytometric bead array 
0.3 × 106 cells were stimulated for 24 h with 0.0001-ȝJPO&DDW&
CO2. Cell-free supernatants were isolated and analyzed for chemokine content using the 
human chemokine cytometric bead array kit (BD Biosciences). The minimum detection 
levels are inducible protein-10/CXCL10 (IP-10), 2.9 pg/ml; monocyte chemoattractant 
protein-1/CCL2 (MCP-1), 2.7 pg/ml; monokine induced by interferon-Ȗ&;&/0,*
pg/ml; RANTES/CCL5 (regulated on activation, normal T cell expressed and secreted), 1 
pg/ml; and IL-8, 0.2 pg/ml. 
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3.3.10 Adhesion assay 
Maxisorp 96-well plates (NUNC, Naperville, IL, USA) were coated for 16 h with 
 ȝJPO KXPDQ ILEURQHFWLQ 6LJPD-Aldrich) in PBS at 4°C, washed three times with 
PBS, blocked for 1 h with 3% BSA in HEPES buffer at 37°C/5% CO2 and then washed 
three times with HEPES buffer. Cells were washed with HEPES buffer, suspended at 1 × 
106 FHOOVPO DQG ODEHOHG IRU  PLQ ZLWK  ȝ0 FDOFHLQ-AM (Life Technologies) at 
37°C/5% CO2. After labeling, cells were washed and resuspended at 1 × 106 cells/ml in 
HEPES buffer. Cell suspension (5 × 104 cells) ± HEPES buffer containing 0.1 µg/ml SCF 
or 0.01-1 µg/ml C5a was added and incubated for 2 h at 37°C/5% CO2. In some 
experiments, cells were pretreated for 30 min with 10 nM wortmannin (Sigma-Aldrich), 
10 nM U-73122 (Calbiochem), 10 nM Ro-31-8220 (Sigma-Aldrich) or vehicle, or for 2 h 
with 5-10 nM pertussis toxin (Sigma-Aldrich). After incubation, non-adherent cells were 
washed away with warm HEPES buffer. Fluorescence emission at 530 nm (485 nm 
excitation) was measured using a fluorescence plate reader (Varioskan Flash Multimode 
Reader, Thermo Fisher Scientific, Nepean, ON, Canada). 
3.3.11 Chemotaxis assay 
Chemotaxis was performed using a 96-well monocyte cell migration kit 
(Calbiochem) with slight modifications. Briefly, cells were incubated overnight in SCF-
free media, washed with HEPES buffer, and suspended at 0.25 × 106 cells/ml. Agonists 
(0.1 µg/ml SCF or 0.01-ȝJPO&DZHUHDGGHG WR WKH ORZHUFKDPEHURI the 96-well 
tray and cell suspension (2.5 × 104 cells) was added to the insert (upper chamber). The 
cells were allowed to migrate towards the agonists for 6 h at 37°C/5% CO2. After 
incubation, the insert was washed twice with warm HEPES buffer. Cells were labeled for 
PLQZLWKȝ0FDOFHLQ-AM at 37°C/5% CO2. After labeling, the cells that had migrated 
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across the insert membrane were lysed using 0.1% Triton X-100. Fluorescence emission 
was measured at 530 nm (485 nm excitation). 
3.3.12 Lentivirus-mediated knockdown of C5L2 
C5L2 small hairpin RNA (shRNA) lentiviral particles and scrambled control 
shRNA lentiviral particles (Santa Cruz Biotechnology, Dallas, TX, USA), which do not 
bind to any known human mRNAs, were transduced into LAD2 cells according to the 
manufacturer's protocol. Briefly, 2 × 106 LAD2 cells were infected by aGGLQJ  ȝO
VK51$OHQWLYLUDOSDUWLFOHVPXOWLSOLFLW\RILQIHFWLRQLQWKHSUHVHQFHRIȝJPOSRO\EUHQH
(Santa Cruz Biotechnology). cop-green fluorescent protein (GFP) control lentiviral 
particles were used to confirm the transduction of LAD2 cells. At 72 h post-infection, the 
medium was changed to virus-IUHHFRPSOHWHPHGLXPDQGDQWLELRWLFVHOHFWLRQ ȝJPO
puromycin, Santa Cruz Biotechnology) was initiated 7 days later. Cells were analyzed for 
C5L2 knockdown by flow cytometry and used for subsequent assays following initiation 
of puromycin selection. 
3.3.13 Receptor internalization 
Cells (0.25 × 106ZHUHH[SRVHGWR%6$3%6EXIIHURUȝJPO&DIRU
min at 37°C, washed twice with ice-cold 0.1% BSA/PBS buffer, stained with PE-anti-
C5L2 antibody or PE-isotype control antibody and incubated on ice for 1 h. After 
washing twice with cold 0.1% BSA/PBS, the cells were fixed in a 2% formaldehyde 
solution and analyzed using flow cytometry. The percentage of receptor internalization 
was calculated from the mean fluorescent intensity as follows: 
(MFI[exp.]-MFI[0% control])/(MFI[100% control]-MFI[0% control]) *100 
MFI: mean fluorescent intensity; 100% control corresponds to C5L2 expression on the 
cell surface of untreated cells; 0% control refers to cells incubated with isotype control 
antibody. 
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3.3.14 Western blot 
Mast cells (1 × 106) were stimulated with 0.1 µg/ml C5a for 0, 1, 5, 10, 20, or 30 
min and were lysed in buffer containing loading dye solution (lithium dodecyl sulfate) 
VDPSOH EXIIHU /LIH 7HFKQRORJLHV  ȕ-mercaptoethanol (Sigma-Aldrich), 5 mM 
dithiothreitol (Sigma-Aldrich) and protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN). Whole cell lysates were separated on 4-12% Bis-Tris SDS-PAGE gels 
(Life Technologies) and transferred onto nitrocellulose membranes. The membranes 
were blocked with 4% BSA in Tris-buffered saline (TBS)-0.05% Tween overnight and 
then probed with primary antibodies against phospho-ERK1/2 (Thr202/Tyr204; Cell 
Signaling Technology Inc.) in 4% BSA-TBS-Tween for 1 h at room temperature. The 
membranes were washed with TBS-Tween four times and then incubated with the 
horseradish peroxidase-linked secondary antibody (donkey anti-mouse IgG-HRP; R&D 
6\VWHPVIRUK7KHPHPEUDQHZDVVWULSSHGDQGUHSUREHGZLWKȕ-actin antibody. The 
membranes were developed with chemiluminescence reagent (Life Technologies) for 1 
min and exposed to chemiluminescence film for 1 to 5 min. 
3.3.15 Co-culture of mast cells with fibroblasts 
The 1079SK fibroblasts were seeded in 6-well tissue culture plates at 5000 cells 
per well. After 7 days, the medium was replaced with StemPro-34SFM containing 3 × 
104 LAD2 cells per ml. The cells were incubated for 7 days after which the culture was 
trypsinized with 0.025% trypsin-EDTA to detach LAD2 cells from fibroblasts. Detached 
cells were incubated for 30 min in T75 flasks to remove any contaminating fibroblasts as 
only the fibroblasts were attached to the bottom, and most of the mast cells were 
recovered from the supernatants. The non-adherent mast cells were harvested, 
characterized for cell surface Kit expression by flow cytometry and used in subsequent 
studies.  
119 
 
3.3.16 Statistical analysis 
Each experiment was performed at least three separate times. Statistical 
significance was determined by two-WDLOHG 6WXGHQW¶V SDLUHG t-test and P<0.05 was 
considered significant. The results are shown as mean ± S.E.M. 
 
3.4 RESULTS 
3.4.1 Characterization of C5aR and C5L2 receptors in human mast cells 
C5aR and C5L2 mRNA are abundantly expressed in several tissues and in 
peripheral blood granulocytes (13). We used qPCR to assess the expression of C5aR 
and C5L2 mRNA by LAD2 cells. The LAD2 human mast cell line was originally obtained 
from a patient with mastocytoma and the cells have many features common with primary 
CD34+ cells-derived human mast cells. As shown in Figure 3.1A, LAD2 cells expressed 
C5aR and C5L2 mRNA. We next assessed the protein expression of these receptors 
using flow cytometry. Interestingly, no C5aR was detected on the cell surface. LAD2 
cells expressed greater C5L2 receptor on their surface (Figure 3.1B). As shown in 
Figure 3.1C, the mean fluorescence intensity (MFI) of anti-C5L2 antibody-stained LAD2 
cells was significantly higher (MFI 829 ± 3.6) compared with the cells stained with 
isotype control antibody (MFI 52 ± 5.5) or anti-C5aR antibody (MFI 53.3 ± 1.3). Since we 
could not find surface C5aR expression, we hypothesized perhaps C5aR was expressed 
internally in intracellular vesicles. Therefore, we determined the intracellular expression 
of C5aR and C5L2 by permeabilizing LAD2 cells with saponin and performing flow 
cytometry using antibodies specific to each receptor. Our data showed that LAD2 cells 
displayed a weaker expression of C5aR intracellularly in contrast to abundant 
expression of C5L2 (Figure 3.1D). 
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Figure 3.1 Expression of C5a receptors by human mast cells. (A) Total RNA was isolated from 
LAD2 cells, and expression of C5aR and C5L2 mRNA was examined by qPCR. Data was 
normalized to GAPDH mRNA levels and are expressed as fold expression over GAPDH 
expression. (B) The surface expression of C5aR and C5L2 by LAD2 was measured using flow 
cytometry and a phycoerythrin (PE)-labeled mouse IgG isotype control (red histogram), PE-anti-
C5aR (green histogram), or PE-anti-C5L2 antibody (green histogram). (C) Summary of flow 
cytometric analysis expressed as differences in MFI between LAD2 cells stained with PE-isotype 
control, PE-anti-C5aR, or PE-anti-C5L2 antibody (n=3). (D) Intracellular expression of C5aR and 
C5L2 was analyzed in permeabilized LAD2 cells using flow cytometry. *** P<0.001 compared 
with isotype control. 
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Since LAD2 are sometimes considered to possess a neoplastic phenotype, we 
determined the expression of C5aR and C5L2 by human peripheral blood CD34+ cells-
derived mast cells (HuMC), which resemble the connective tissue-type mast cell
 
phenotype, are considered to have a more mature mast cell phenotype and are often 
used as a model of skin mast cells. HuMC were identified by the expression of Kit 
receptor. Similar to LAD2 cells, HuMC did not express C5aR on their surface (Figure 
3.2A). However, they expressed C5aR and significant amounts of C5L2 which were 
mostly located within intracellular compartments (Figure 3.2B).  
To make sure that the anti-C5aR and anti-C5L2 antibodies that we used for our 
flow cytometry analysis were capable of recognizing C5aR and C5L2 on human mast 
cells, we tested HMC-1 cells, a mast cell line known to express C5aR and C5L2, for their 
expression of both receptors. As expected, our antibodies detected expression of both 
C5aR and C5L2 on the surface HMC-1 cells (Figure 3.2C). Based on the overall results, 
we focused on C5aR- C5L2+ LAD2 cells for subsequent analyses.  
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Figure 3.2 C5a receptors expression by HuMC and HMC-1 cells. (A) Cell surface and (B) 
intracellular expression of Kit, C5aR and C5L2 by HuMC and (C) cell surface expression of Kit, 
C5aR and C5L2 by HMC-1 cells was measured using flow cytometry and a phycoerythrin (PE)-
labeled mouse IgG isotype control (red histogram), PE-anti-Kit, PE-anti-C5aR, or PE-anti-C5L2 
antibody (green histograms). 
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3.4.2 (IIHFWVRILQWHUIHURQ,)1ȖDQGLQWHUOHXNLQ,/-4 on C5a receptors expression 
Although some mast cells do not constitutively express C5aR, it is possible to induce 
its expression with certain stimuli.  For example, mouse bone marrow-derived mast cells 
(BMMC) neither express cell surface C5aR nor respond to C5a, but preincubation of these 
cells with antigen, ionomycin, or phorbol 12-myristate 13-acetate (PMA) upregulates surface 
C5aR and makes BMMC responsive to C5a, inducing Ca2+ flux and chemotaxis (27). We 
thus assessed if incubation of mast cell with cytokines would modulate C5aR and C5L2 
expression. First, we treated LAD2 cells with different concentrations RI ,)1Ȗ IRU YDU\LQJ
WLPH SRLQWV ,)1Ȗ LV D 7K1 F\WRNLQH WKDW JHQHUDOO\ LQKLELWV )Fİ5,-mediated mast cell 
activation. qPCR analysis showed that culturing LAD2 cells in different concentrations of 
,)1Ȗ IRU  h upregulated the expression of C5aR (Figure 3.3A), however there was no 
significant effect on the expression of C5L2 at any of the concentrations and time points 
tested (Figure 3.3B). Then, we incubated LAD2 cells in different concentrations of IL-4 for 
similar time periods. IL-4  is a Th2 cytokine whicK KDV EHHQ VKRZQ WR SRWHQWLDWHV )Fİ5,-
mediated mast cell activation (29). Culture in the presence of IL-4 for 3-9 h increased mast 
cell expression of C5L2 mRNA after which the expression returned to basal level (Figure 
3.3D). The expression of C5aR remained unchanged (Figure 3.3C). Flow cytometric 
analysis confirmed that preincubation with IL-4 increased cell surface expression of C5L2 in 
a concentration-dependent manner (Figure 3.3E).  
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Figure 3.3 Effect of Th1 and Th2 cytokines on C5aR and C5L2 expression. LAD2 cells were 
cultured with (A, B) ,)1Ȗor (C, D) IL-4 for 3, 6, 9, 12, 24, and 96 h and (A, C) C5aR or (B, D) 
C5L2 expression was measured by qPCR and (E) flow cytometry (n=3) ** P<0.01. *** P<0.001 
compared with untreated.  
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3.4.3 Effect of C5a on mast cell degranulation and intracellular Ca2+ mobilization 
Previous studies have shown that anaphylatoxins may contribute to 
hypersensitivity reactions by degranulating eosinophils, basophils as well as mast cells, 
but the studies with C5a on human mast cells have led to variable and inconclusive data. 
For instance, C5a has been found to degranulate skin mast cells but not lung and 
tonsillar mast cells. Some authors have reported that C5a degranulates LAD2 cells (30), 
while others have shown no effect (24). We compared the ability of C5a and C3a 
(another complement component established as a human mast cell secretogogue; 
Chapter 1.5.2.3) to degranulate human mast cells. LAD2 cells were treated with various 
concentrations of C3a and C5a, and degranulation was assessed by the release of ȕ-
hexosaminidase enzyme. As shown in Figure 3.4A, C5a was unable to stimulate LAD2 
cell degranulation at any of the concentrations tested. C3a degranulated LAD2 cells in a 
concentration-dependent manner, with maximum degranulation (47.95 ± 1.65%) at 0.1 
ȝJ/ml.  
As we demonstrated that LAD2 cells express higher C5L2 in the presence of IL-
4, we thus determined the functional consequences of C5L2 upregulation. LAD2 cells 
were incubated in the absence or presence of 100 ng/ml IL-4 for up to 4 days and 
degranulation assay was performed with C5a. c48/80 was used as a positive control. 
Similar to IL-4-negative LAD2 cells, while IL-4-positive mast cells degranulated in 
response to c48/80, C5a failed to stimulate degranulation (Figure 3.4B).  
Integrated signaling pathways have been suggested for mast cell activation. Mast 
FHOO VWLPXODWLRQ ZLWK &D RU DGHQVRLQH SRWHQWLDWHV )Fİ5,-mediated degranulation. We 
thus determined if concurrent stimulation of mast cells viDWKH)Fİ5,-, Kit- or G protein- 
signaling pathways would modulate C5a signal transduction. For the first set of 
experiments, we sensitized LAD2 cells overnight with 0.5 µg/ml biotinylated IgE prior to 
stimulation for 30 min with 0.5 µg/ml streptavidin and 0.1 µg/ml C5a, and determined the 
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UHOHDVHRIȕ-hexosaminidase enzyme. As shown in Figure 3.4C, while IgE alone did not 
induced degranulation, treatment with IgE-VWUHSWDYLGLQLQGXFHGUHOHDVHRIȕ-
hexosaminidase. Stimulation with C5a alone or in combination with IgE and IgE-
streptavidin did not potentiate degranulation of mast cells. We then determined the effect 
of simultaneous activation of G protein on C5a function by utilizing c48/80. We treated 
LAD2 with c48/80 in the absence or presence of 0.1 µg/ml C5a and measured 
GHJUDQXODWLRQȝJPOFDFWLYDWHGUHOHDVHRIWRWDOȕ-hexosaminidase 
content, whereas C5a had not effect on c48/80-induced mast cell degranulation (Figure 
3.4D). Finally, we assessed the effect of Kit stimulation. We starved LAD2 cells of SCF 
by culturing them overnight in SCF-free medium followed by treatment with different 
concentrations of SCF in the absence or presence of 0.1 µg/ml C5a. As expected, 
stimulation with SCF failed to induce degranulation of mast cells. C5a was also unable to 
elicit degranulation in SCF-negative as well as SCF-positive mast cells (Figure 3.4E).  
An increase in intracellular Ca2+ is necessary for the induction of mast cell 
degranulation, and C5a has been shown to mobilize intracellular Ca2+ to mediate its 
biological responses in various immune cells. As C5a failed to degranulate LAD2 cells, 
we hypothesized that C5a would not mobilize Ca2+ in LAD2 cells. Cells were loaded with 
the Ca2+-sensing fluorescent dye fura-2 AM and treated with C5a, and changes in 
fluorescence were measured as a change in ratio of A340 to A380. C5a did not cause an 
increase in intracellular Ca2+ concentration. As expected, stimulation with ionomycin 
(positive control) led to a transient increase in intracellular Ca2+ (Figure 3.4F). 
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Figure 3.4 C5a does not induce mast cell degranulation. (A) LAD2 cells were stimulated for 30 
PLQZLWK&DRU&DDQGȕ-hexosaminidase release was measured (n=3). (B) LAD2 cells were 
incubated for 4 days with 100 ng/ml IL-4, stimulated for 30 min with C5a aQGȕ-hexosaminidase 
UHOHDVHZDVPHDVXUHGQ /$'FHOOVZHUHHLWKHUVHQVLWL]HGZLWKȝJPOELRWLQ\ODWHG-IgE or 
incubated in SCF-IUHH PHGLD RYHUQLJKW WUHDWHG IRU  PLQ ZLWK  ȝJPO &D IROORZHG E\
stimulation with (C VWUHSWDYLGLQ 6$  ȝJPO (D) c48/80, or (E 6&) IRU  PLQ DQG ȕ-
hexosaminidase release was measured (n=3). Fura-2 loaded LAD2 cells were stimulated with 0.1 
ȝJPO&DDWWLPHSRLQWVIROORZHGZLWKȝ0LRQRP\FLQDWWLPHSRLQWVDQGPRELOL]DWLRQRI
intracellular Ca2+ was measured (n=3). ** P<0.01, *** P<0.001. 
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3.4.4 C5a stimulates production of cytokines and chemokines 
Mast cell-derived cytokines and chemokines propagate a proinflammatory 
reaction. We therefore measured the expression of cytokines and chemokines after 3 h 
of C5a stimulation using qPCR. mRNA expression of GM-CSF, TNF (Figure 3.5A), IP-
10/CXCL10, and MCP-1/CCL2 (Figure 3.5B) was modestly increased by C5a 
stimulation. Protein production of these mediators following 24 h stimulation with C5a 
was confirmed using cytometric bead array. C5a induced production of GM-CSF (15.1 ± 
0.4 pg/ml per 300,000 cells) (Figure 3.5C), TNF (23.17 ± 1.8 pg/ml) (Figure 3.5D), IP-10 
(32.5 ± 2.3 pg/ml) (Figure 3.5E), and MCP-1 (53.4 ± 4.5 pg/ml) (Figure 3.5F). 
3.4.5 C5a induces adhesion, chemotaxis and upregulation of CD29 expression 
by human mast cells 
Mast cell accumulation is critical in various pathophysiological conditions, 
including allergic reactions, atopic diseases, wound healing, tissue repair, and host 
defense against infection. Since C5a activates chemotaxis of HMC-1, CBMC and skin 
mast cells, we evaluated whether C5a would also promote adhesion and chemotaxis of 
LAD2 cells. Comparable to SCF, C5a activated LAD2 cells to adhere to fibronectin, an 
extracellular matrix protein, with maximum DGKHVLRQ    DW  ȝJPO
concentration (Figure 3.6A). As adhesion is closely related to cytoskeletal 
reorganization and migration, we measured LAD2 chemotaxis to either SCF or C5a. 
Similar to SCF, C5a activated LAD2 chemotaxis with maximum chemotaxis (143.1 ± 8%) 
DWȝJPOFRQFHQWUDWLRQFigure 3.6B). 
  
 
 
129 
 
G M -C S F IL -1 E IL -6 T G F -E T N F1 0 0
1 0 1
1 0 2
F
o
ld
 
e
x
p
re
s
s
io
n
 
o
v
e
r 
u
n
tr
e
a
te
d
*
*
N .D . N .D .N .D .
IL -8 IP -1 0 M C P -1 M IP -1 E R A N T E S1 0 0
1 0 1
1 0 2
F
o
ld
 
e
x
p
re
s
s
io
n
 
o
v
e
r 
u
n
tr
e
a
te
d
*
*
N .D .
0 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1
0
5
1 0
1 5
2 0
[C 5 a ]  (P g /m l)
G
M
-
C
S
F
 
(p
g
/m
l)
* * *
0 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1
0
1 0
2 0
3 0
[C 5 a ]  (P g /m l)
T
N
F
 
(p
g
/m
l)
* *
0 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1
0
1 0
2 0
3 0
4 0
[C 5 a ]  (P g /m l)
IP
-
1
0
 
(p
g
/m
l)
*
0 0 .0 0 0 1 0 .0 0 1 0 .0 1 0 .1
0
2 0
4 0
6 0
8 0
[C 5 a ]  (P g /m l)
M
C
P
-
1
 
(p
g
/m
l)
*
A B
C D
E F
 
Figure 3.5 C5a induces the production of cytokines and chemokines. After a 3 h treatment with 
0.1 µg/ml C5a, mRNA expression of (A) GM-CSF, IL-ȕ,/-6, TGF-ȕ71), (B) IL-8, IP-10, MCP-
1, MIP-ȕDQG5$17(6ZDVPHDVXUHGE\T3&5 (n=3). Data was normalized to GAPDH mRNA 
levels and are expressed as fold increase over untreated controls. After 24 h treatment of LAD2 
cells (0.3 x 106 cells) with 0.0001 ± 0.1 µg/ml C5a, production of (C) GM-CSF, (D) TNF, (E) IP-10 
and (F) MCP-1
 
in cell-free supernatants was measured by cytometric bead array (n=5). * P<0.05, 
** P<0.01, *** P<0.001 compared with untreated.  
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&'ȕLQWHJULQLVWKHILEURQHFWLQUHFHSWRULQYROYHGLQDYDULHty of cell-cell and 
cell-matrix interactions. It is broadly expressed on hematopoietic cells including mast 
cells, and is responsible for mast cell accumulation and function in inflamed tissues. As 
C5a stimulated LAD2 cell adhesion to fibronectin, we determined whether the effect was 
CD29-dependent. We treated LAD2 cells for 2 h with 0.1 µg/ml C5a and measured cell-
surface CD29 expression using flow cytometric analysis. As shown in Figure 3.6C, the 
MFI of C5a-treated anti-CD29 antibody stained LAD2 cells was significantly higher (MFI 
910 ± 31) than the untreated cells stained with either an anti-CD29 antibody or an 
isotype control antibody (MFI 650 ± 13). 
3.4.6 C5L2 expression is required for C5a-mediated induction of mast cell 
adhesion, migration, and cytokine/chemokine production 
To confirm whether C5a was stimulating mast cell responses by acting through 
the C5L2 receptor, we utilized small hairpin RNA (shRNA) lentivirus system to stably 
knockdown the expression of C5L2 in LAD2 cells.  We transduced cells with shRNA 
lentiviral particles targeting mRNA of the C5L2 gene (LAD2-C5L2kd), and as a negative 
control, we used scrambled shRNA lentiviral particles (LAD2-cntr). To confirm 
transduction of LAD2 cells and determine transduction efficiency we employed copGFP 
control lentiviral particles. Figure 3.7A (right panel) shows data in which LAD2 cells 
were stably transduced with copGFP lentiviral particles at multiplicity of infection (MOI) 
1. After transduction and selection with puromycin, flow cytometry was performed to 
evaluate C5L2 receptor knockdown. As shown in Figure 3.7B, we were able to generate 
LAD2 cells with 80% knockdown of the C5L2 expression. The MFI of anti-C5L2 
antibody-stained LAD2-C5L2kd cells was significantly lower (MFI 191.3 ± 33.9) 
compared with that of LAD2-cntr (MFI 1395.3 ± 179) (Figure 3.7C). We then compared 
the cellular phenotype of LAD2- C5L2 with LAD2-cntr by testing these cells for Kit and 
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Figure 3.6 C5a mediates human mast cell adhesion, chemotaxis and CD29 upregulation. (A) 
LAD2 cells were allowed to adhere for 2 h to fibronectin-coated wells in the presence of medium 
DORQHȝJPO6&)RU-ȝJPO&DDQGSHUFHQWDJHRIFHOODGKHVLRQRYHUXQWUHDWHGFHOOV
was assessed (n=5). (B) LAD2 cells were allowed to migrate for 6 h across inserts towards 
PHGLXP DORQH  ȝJPO 6&) RU - ȝJPO &D DQG SHUFHQWDJH RI FHOO FKHPRWD[LV RYHU
untreated cells was assessed (n=5). (C) LAD2 mast cells were treated with 0.1 µg/ml C5a for 2 h, 
fixed in 2% paraformaldehyde, incubated with PE-anti-C5L2 antibody or an isotype control and 
analyzed by flow cytometry (n=3). * P<0.05 compared to untreated. * P<0.05, ** P<0.01 
compared with untreated. 
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)Fİ5, H[SUHVVLRQ 7KHUH ZDV QR GLIIHUHQFH LQ H[SUHVVLRQ RI .LW DQG )Fİ5, EHtween 
LAD2-C5L2kd and LAD2-FQWU 6LPLODUO\ WKHUH ZDV QR VLJQLILFDQW GLIIHUHQFH LQ ȕ-
hexosaminidase release in response to c48/80 or C5a (data not shown). 
We then examined if LAD2-C5L2kd cells would express cytokines and 
chemokine after C5a stimulation. LAD2-cntr and LAD2-C5L2kd cells were exposed to 
C5a and qPCR was performed. In LAD2-cntr cells, C5a caused a significant increase in 
GM-CSF and MCP-1 expression. In contrast, when LAD2-C5L2kd cells were stimulated 
with C5a, there was no expression of GM-CSF and MCP-1 (Figure 3.8A, B). 
We further determined if C5a-induced mast cell adhesion was C5L2-dependent 
by allowing LAD2-cntr and LAD2-C5L2kd cells to adhere to fibronectin in the presence of 
C5a or SCF (positive control). When LAD2-C5L2kd cells were exposed to C5a, no 
adhesion was observed, whereas LAD2-cntr cells adhered to fibronectin (Figure 3.8C). 
Similarly, to see whether absence of C5L2 would affect C5a-induced mast cell 
chemotaxis, LAD2-cntr and LAD2-C5L2kd cells were allowed to migrate towards C5a or 
SCF (positive control). LAD2-cntr cells exhibited chemotaxis towards C5a, whereas 
LAD2-C5L2kd cells showed no chemotaxis towards C5a (Figure 3.8D). Collectively, 
these findings confirmed the role of C5L2 receptor as a mediator of C5a function in 
human mast cells. 
3.4.7 C5a stimulation of human mast cells mediates C5L2 internalization, G 
protein and PI3K activation, and ERK1/2 phosphorylation 
Agonist-induced activation of most GPCRs is followed by their desensitization 
and internalization (29). To determine whether C5L2 is internalized following C5a 
exposure, we incubated LAD2 cells for 30 min with C5a and measured the cell surface 
C5L2 expression by flow cytometry. Up to 60% of C5L2 was internalized within 15 min 
following exposure to C5a (Figure 3.9A). 
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Figure 3.7 Stable knockdown of C5L2 in human mast cells. LAD2 cells were transduced with 
copGFP control lentiviral particles (LvP), scrambled shRNA control LvP or shRNA LvP targeted 
against C5L2. (A) LAD2 cells stably transduced with copGFP LvP (right) compared with non-
transduced negative control (left). (B) Flow cytometry was performed to assess C5L2 expression 
levels on control (LAD2-cntr) and C5L2 shRNA LvP-transduced knockdown (LAD2-C5L2kd) cells. 
(C) Data is represented as MFI ± S.E.M. from three independent experiments. *** P<0.001. 
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Figure 3.8 Effects of C5L2 knockdown on C5a-induced responses in human mast cells. Control 
(LAD2-cntr) and C5L2-knockdown (LAD2-C5L2kd) LAD2 cells were stimulated with  ȝJPO
C5a. After 3 h treatment, expression of (A) GM-CSF and (B) MCP-1 was measured by qPCR 
(n=5). (C) LAD2-cntr and LAD2-C5L2kd cells were allowed to adhere to fibronectin for 2 h in the 
SUHVHQFH RI  ȝJPO 6&) RU  ȝJPO &D DQG the percentages of cell adhesion were 
determined (n=5). (D) LAD2-cntr and LAD2-C5L2kd cells were allowed to migrate for 6 h towards 
ȝJPO6&)RUȝJPO&DDQGthe percentages of cell chemotaxis were determined (n=5). * 
P<0.05, ** P<0.01, *** P<0.001. 
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Although the functional role of C5L2 in human mast cells remains unknown, 
VWXGLHVLQRWKHUFHOOW\SHVKDYHVKRZQWKDW&/PD\ZHDNO\FRXSOHWRWKH*Įi subunit, 
which is pertussis toxin-sensitive. We reasoned that the moderate response of C5a 
coupling to C5L2 in LAD2 cells could be due to G protein-dependent signal transduction. 
We tested our reasoning by performing an adhesion assay by treating cells with 
pertussis toxin prior to stimulation with C5a and measured the adhesion to fibronectin. 
As shown in Figure 3.9B, pretreatment with pertussis toxin inhibited C5a-induced 
adhesion of LAD2 cells to fibronectin. The inhibition, however, was not 100%, indicating 
that other signaling mechanism might be activated in C5a-mediated LAD2 cell adhesion.  
As sensitivity to pertussis toxin indicated involvement of G protein signaling, we 
next determined if phosphoinositol 3-kinase (PI3K), phospholipase C (PLC) and/or 
protein kinase C (PKC) signaling molecules were involved in C5a-mediated mast cell 
adhesion. For these experiments, we treated the cells with wortmannin (PI3K inhibitor), 
U-73122 (PLC inhibitor) and Ro-31-8220 (PKC inhibitor) prior to stimulation with C5a 
and measured the adhesion to fibronectin. We found that wortmannin inhibited C5a-
induced mast cell adhesion. U-73122 and Ro-31-8220 were ineffective at blocking C5a-
mediated adhesion (Figure 3.9C). 
The biological effects of many GPCRs are mediated via the activation of 
extracellular signal regulated kinase (ERK) signaling pathway. We performed western 
blot analysis to study tyrosine phosphorylation of ERK1/2 in LAD2 cells in response to 
C5a. C5a caused ERK1/2 phosphorylation within 1 min of stimulation that remained 
elevated for 5 min and was substantially eliminated at 10 min (Figure 3.9D).  
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Figure 3.9 C5a induces C5L2 internalization, G protein and PI3K activation, and ERK1/2 
phosphorylation. (A /$' FHOOV ZHUH H[SRVHG WR  ȝJPO &D IRU  PLQ IL[HG LQ 
paraformaldehyde, incubated with anti-C5aR antibody, anti-C5L2 antibody, or an isotype control 
antibody and analyzed by flow cytometry (n=3). (B-C) LAD2 cells were treated for 2 h with the 
indicated concentrations of PTx or for 30 min with wortmannin, U-73122, or Ro-31-8220 (10 nM 
HDFKSULRUWRVWLPXODWLRQIRUKZLWKȝJPOC5a and the percentages of cell adhesion were 
GHWHUPLQHGȝJPO6&)ZDVXVHGDVDSRVLWLYHFRQWUROQ D) LAD2 cells were stimulated 
ZLWK  ȝJPO &D IRU       RU  PLQ DQG SURWHLQ O\VDWHV ZHUH DQDO\]HG IRU
phospho-ERK1/2 expression by western blot (n=3). * P<0.05, ** P<0.01, *** P<0.001 compared to 
untreated. 
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3.4.8 Co-culture of human mast cells with fibroblasts upregulates C5L2 and 
potentiates C5a-mediated adhesion and chemotaxis  
Interaction of mast cells with fibroblasts leads to differentiation, maturation and 
enhanced mediator release (31-33). We questioned the effect of such interactions on 
mast cell responses to C5a. To address this, we established a culture system in which 
LAD2 cells were co-cultured with human fibroblasts 1079SK for a week in the presence 
of SCF. We examined C5a receptor expression in co-cultured LAD2 cells and found 
enhanced expression of C5L2. The MFI of anti-C5L2 antibody-stained co-cultured LAD2 
cells was significantly higher (410.3 ± 20) compared with MFI of cells that were not 
cultured in the presence of 109SK (268.3 ± 16) (Figure 3.10A). No expression of C5aR 
was detected in LAD2 cells as well as co-cultured LAD2 cells (data not shown). We next 
investigated the response of co-cultured LAD2 cells to C5a. We found that C5a amplified 
mast cell adhesion (Figure 3.10B) and chemotaxis (Figure 3.10C). These results 
suggested that C5a-C5L2 signaling may aggravate mast cell responses depending upon 
their location and interactions with other structural and immune cells.  
 
3.5 DISCUSSION 
The studies reported here represent the first characterization of the novel 
receptor for C5a, C5L2, which is a functional receptor in human mast cells. C5a is one of 
the most powerful inflammatory mediators of the innate immune system, with the ability 
to initiate multiple cellular responses such as recruitment of inflammatory cells to sites of 
infection, activation of phagocytic cells and release of granule-associated mediators (6). 
Mast cells show highly variable responsiveness to C5a; skin human mast cells are 
activated by C5a (34), whereas lung (35) and intestinal mast cells (36) do not respond. 
Moreover, within the heterogenous lung mast cell population, there are two distinct 
subpopulations; MTC that degranulate in response to C5a and MT, that do not (37). The  
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Figure 3.10 C5L2 expression, adhesion and chemotaxis by human mast cells cultured with 
fibroblasts. LAD2 cells were cultured with or without 1079SK fibroblasts for 7 days. (A) Cells were 
incubated with PE-anti-C5L2 antibody or an PE-isotype control antibody and C5L2 expression 
was analyzed by flow cytometry (n=3). (B) Cells were allowed to adhere to fibronectin for 2 h in 
the presenFH RI  ȝJPO 6&) RU  ȝJPO &D DQG the percentages of cell adhesion were 
determined (n=3). (C&HOOVZHUHDOORZHGWRPLJUDWHIRUKWRZDUGVȝJPO6&)RUȝJPO
C5a and the percentages of cell chemotaxis were determined (n=3). * P<0.05, ** P<0.01. 
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functional discrimination between these mast cell subpopulations is attributed to 
differences in protease expression and differences in expression of the receptor for C5a, 
C5aR. Tryptasehigh chymasehigh skin mast cells and lung mast cell subpopulations 
express C5aR (37, 38); whereas tryptaselow chymaselow lung mast cell populations do not 
(37). The content of tryptase and chymase are highest in skin mast cells, followed by 
LAD2 cells, and least amounts are found in lung mast cells (39). Most of the effects of 
C5a in immune cells appear to be mediated through C5aR signal transduction, a G 
protein-dependent mechanism. Although C5a-C5aR has been shown to stimulate mast 
cells, most of these studies have been performed using either mast cell lines transfected 
to express the C5aR (40), immature mast cell lines (41, 42), mucosal mast cells such as 
BMMC with no endogenous C5aR (27), or C5aR-deficient mice and present inconsistent 
data. We strived to elaborate on these studies and examined the expression and 
function of C5a receptor in human LAD2 mast cells. Interestingly, we found that human 
peripheral blood CD34+ cell-derived human mast cells (HuMC) and human mast cell line 
LAD2 cells did not express the classical C5aR on their cell surface, but expressed the 
novel C5a receptor, C5L2. The expression of C5L2 was predominantly intracellular in 
HuMC, whereas LAD2 cells expressed significant levels of C5L2 on their cell surface. 
Both the cell types expressed C5aR intracellularly. To the best of our knowledge, no 
published evidence exists on the C5aR and C5L2 expression in HuMC and LAD2 cells.  
C5L2 was identified by Ohno et al. as a cDNA with homology to the C5aR (13). 
Although C5L2 has the conventional structure of a GPCR, studies suggest that C5L2 
does not couple conventionally to the known G proteins due to an amino acid 
replacement of arginine by leucine in the DRY motif located in the third transmembrane 
domain (16). Due to this structural property C5L2 has been regarded, until recently, as a 
non-signaling decoy receptor. No mobilization of intracellular Ca2+ occurs in C5L2-
transfected cells (43, 44), neutrophils from C5aR-deficient mice after stimulation with 
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C5a (45), or in C5L2-expressing epithelial and myeloid cell lines (46). In the presence of 
C5a and C5a desArg, C5L2-transfected RBL-2H3 cells do not degranulate (43). Further, 
C5a binding to C5L2 in bone marrow cells derived from C5aR-deficient mice fails to 
induce any changes in mRNA expression (44). Recent studies, however, suggest that 
C5L2 can mediate biological activities of C5a. In a rat model of sepsis induced by cecal 
ligation and puncture, antibody blockade of C5L2 dramatically increases the level of 
circulatory IL-6 (47). C5L2-/- mice suffer from augmented inflammatory responses and 
higher numbers of infiltrating neutrophils in a model of pulmonary immune complex injury 
(48), indicating an anti-inflammatory function of C5L2. On the contrary, a strong 
reduction of other inflammatory mediators, such as IL-1ȕ, MIP-1Įand MIP-2 is observed 
in C5L2-/- mice compared to wild types control animals. Furthermore, C5L2-/- mice or 
mice in which C5aR or C5L2 are blocked by anti-receptor antibody show a higher 
survival rate in mid-grade sepsis. Additionally, signaling through C5L2 but not C5aR, 
lead to release of the inflammatory protein, high mobility group box 1 (HMGB1) (49). 
Inflammatory responses are reduced in the C5L2-/- murine models of peritonitis, 
thioglycollate-induced migration of neutrophils into dorsal air pouches, and ovalbumin-
induced airway hyperresponsiveness (50), supporting a proinflammatory role for C5L2. 
In human neutrophils, C5L2 functions as an intracellular receptor and negatively 
modulates C5aR-PHGLDWHG VLJQDOLQJ WKURXJK WKH ȕ-arrestin pathway (51). Overall the 
data points to a more complex role of C5L2 in inflammation in which C5L2 acts not only 
as a non-signaling decoy receptor but also as positive modulator of C5aR. Most cellular 
studies of C5L2 also have been performed using transfected cells. Here we utilized 
LAD2 cells that endogenously expresses the C5L2 receptor and not C5aR and 
investigated the role of C5L2 in the physiological functions of mast cells. Consistent with 
the previous reports, we found that C5a did not degranulate LAD2 human mast cells. 
C5a was also unable to induce Ca2+ mobilization. Mast cell-derived mediators are 
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classified into three categories: granule-associated preformed mediators, do novo 
synthesized lipid mediators, and cytokines and chemokines (52). The release of 
preformed and de novo synthesized mediators occurs within seconds to minutes 
following mast cell activation, whereas the production of cytokines and chemokines 
requLUHV WUDQVFULSWLRQ DQG WUDQVODWLRQ RI WKHLU P51$ DQG LV D FRPSDUDWLYHO\ µODWH¶
response (53). It is known that several ligands of GPCRs can differentially activate some 
or all of the mast cell responses (54). Indeed, incubation of LAD2 cells with C5a for 24 h 
augmented the production of cytokines and chemokines. C3a and C5a distinctly regulate 
chemokine production in mast cells by activating divergent signaling pathways (24), 
possibly by G protein-dependent and -independent mechanisms.  
In the present study, C5a induced mast cell chemotaxis, which was compared 
with chemotaxis towards the known stimuli SCF and C5a was a more potent 
chemoattractant than SCF for LAD2 cells. Chemotaxis of human mast cells towards C5a 
was found to be dependent upon binding to fibronectin, which is in agreement with the 
study of Hartmann et al, who showed that C5a-stimulated HMC-1 cells adhere to 
fibronectin and laminin (22). Fibronectin is an important extracellular matrix that binds to 
membrane-spanning receptor proteins called integrins and plays a role in cell adhesion, 
growth, migration, and differentiation (55). Preincubation of mast cells with C5a 
increased the cell surface expression of CD29 (receptor for fibronectin, also known as 
integrins) but not ICAM-1, indicating that C5a-mediated mast cell adhesion to fibronectin 
occurs through the integrins. 
To confirm the functional role of C5L2 in human mast cells, we utilized lentivirus 
shRNA to stably knockdown of expression of C5L2. Using this approach, we uncovered 
a specific role for C5L2 in modulating human mast cell functions. C5L2 was required for 
C5a enhancement of cytokine and chemokine production, since the knockdown of the 
receptor caused the expression levels to return to baseline levels (untreated cells). 
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Similarly, knockdown cells were unable to adhere to fibronectin or chemotax towards 
C5a.  
The absence of intracellular Ca2+ mobilization has suggested that C5L2 is 
uncoupled from G proteins and must therefore be a non-signaling receptor (13, 43). By 
contrast, our data showed that C5L2 is functional in mast cells and that it transduces 
signals in a G protein-dHSHQGHQWPDQQHU3HUWXVVLVWR[LQZKLFKLVDQLQKLELWRURIWKH*Įi 
subunit (56), reduced mast cell adhesion to fibronectin, though the effect was only 
partial, even at high concentrations of pertussis toxin. The fact that exceptions to the 
DRY motif paradigm have been reported and that not all the G proteins are known to us, 
support our observation. Alternatively, changes in Ca2+ levels may not be involved in the 
C5a-activated C5L2 pathway; there are many downstream effectors of G protein 
activation, many of which can be Ca2+-independent. C3a desArg mediates activation of 
PLC, PI3K, and ERK1/2 and Akt phosphorylation through C5L2 (57). Moreover, C5a 
interactions with C5L2 enhance release of G-CSF from lipopolysaccharide-activated 
mouse peritoneal elicited macrophages via Akt and MEK1/2 (58). Indeed, we showed 
that C5a-induced mast cell adhesion to fibronectin was sensitive to the inhibitor of PI3K. 
The PI3K family of lipid kinases play a crucial role in multiple mast cell biological 
responses, such as degranulation, cytokine release, mast cell homing and homeostasis 
(59). Various GPCR agonists utilize PI3K to mediate subsequent downstream signaling 
events (60). In addition to the PI3K pathway, many GPCRs utilize the mitogen-activate 
protein kinase cascade, including ERK1/2. These signaling pathways are implicated in a 
variety of cellular responses including chemotaxis, proliferation and differentiation. We 
demonstrated that C5a induced ERK1/2 phosphorylation in LAD2 cells was sustained for 
10 min, further confirming the involvement of G protein signaling in C5L2 function.  
Ligand-induced receptor internalization is a central feature of functional seven 
transmembrane receptors (61). We have clearly demonstrated that C5a stimulated C5L2 
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internalization by human mast cells. The half-life of C5L2 on the cell surface is 
considerably longer than that of C5aR and C5aR internalizes and recycles much more 
rapidly when compared to C5L2 (17, 43). In adipocytes, C5a-induced C5L2 
internalization is only detectable after 15 min, and it reaches a maximum at around 1 h in 
C5L2-HEK cells (18). PMN cells show a decrease in C5L2 protein after 3 h of C5a 
treatment (62). Consistent with these findings, we showed C5a-mediated C5L2 
internalization beginning at 15 min and reaching a maximum at 30 min.  
Not only did we demonstrated that C5a activated human mast cells via C5L2, but 
upregulation of C5L2 with no change in C5aR expression in human mast cells co-
cultured with fibroblasts resulted in augmentation of C5a-mediated adhesion and 
chemotaxis, further confirming that these functions were exerted through activation of 
C5L2 receptor. Similarly, Th2 cytokine IL-4 increased the expression of C5L2 by human 
mast cells, highlighting the importance of this receptor in propagation of inflammation.  
In summary, our study demonstrated that human mast cells express a functional 
*Įi-coupled stimulatory C5L2 receptor, activation of which promotes mast cell adhesion, 
chemotaxis, and release of cytokines and chemokines. Thus, C5L2 might be a novel 
target for modulation/regulation of mast cell responses in allergic inflammation. Given 
the potential therapeutic value of inhibiting C5L2 function to prevent inflammation as 
demonstrated in murine models of sepsis, further study of this receptor in the in vivo 
mast cell models is warranted. 
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CHAPTER 4. ADENOSINE RECEPTOR A2A INHIBITS 
COMPLEMENT-MEDIATED ACTIVATION OF HUMAN MAST 
CELLS %<$&7,9$7,1**Įs PROTEINS 
 
A version of this chapter has been submitted for publication in the Journal of Biological 
Chemistry as follows: 
P Pundir, S Stredulinsky, A Catalli, M Kulka. Adenosine receptor A2A inhibits 
complement-mediated activation of humaQPDVWFHOOVE\DFWLYDWLQJ*Įs-proteins. 3 
 
4.1       ABSTRACT 
The complement component 3a (C3a) and adenosine receptors are implicated in 
the inflammatory process associated with allergic rhinitis and asthma, although a direct 
interaction between these pathways has not been demonstrated. To investigate the 
interaction between these pathways the human mast cell line (LAD2) was stimulated 
with C3a with or without adenosine receptor agonists and antagonists. The non-selective 
adenosine receptor agonist, 5'-N-(ethylcarboxamido)adenosine (NECA;  ȝJPO
inhibited C3a-induced LAD2 cell migration, adhesion, degranulation, and production of 
monocyte chemotactic protein-1. A selective A2A receptor agonist, CGS 21680, inhibited 
C3a-mediated degranulation but the A2B and A3 receptor agonists, BAY 60-6583 and IB-
MECA, respectively, had no effect. Moreover, an A2A receptor antagonist, SCH 58261, 
blocked the inhibitory effect of NECA on C3a-induced degranulation, suggesting that 
inhibition of degranulation was mediated through the A2A receptor. Real-time PCR 
analysis showed that LAD2 expressed mRNA for A2A, A2B and A3 receptors but not the 
A1 receptor. Measurements of intracellular cyclic adenosine monophosphate (cAMP) 
showed that NECA elevated [cAMP]i levels in LAD2 cells. Treatment with an activator of 
                                                            
3
 P Pundir designed and performed the experiments, analyzed the data and wrote the chapter; A 
Catalli and S Stredulinsky assisted with the cAMP and degranulation assays; M Kulka designed 
the study and experiments, supervised the work and edited the manuscript. 
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adenylyl cyclase, forskolin, also diminished C3a-induced mast cell degranulation, 
indicating the involvement of the cAMP signaling pathway in the inhibitory effects of 
adenosine. Pertussis toxin blocked C3a-activated degranulation. The adenylyl cyclase 
inhibitor, SQ 22536, had no effect on C3a-activated degranulation but blocked the effect 
of NECA, demonstrating that C3a and NECA exert their effect through GĮi DQG *Įs 
proteins, respectively. Overall, the results suggest that adenosine inhibits complement 
DFWLYDWLRQRIKXPDQPDVWFHOOVWKURXJKD*Įs-protein pathway.     
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4.2 INTRODUCTION 
Complement component C3a is produced during the complement activation 
cascade, and belongs to the anaphylatoxin group of proteins along with C4a and C5a 
(Chapter 1.5.2, Figure 1.8). C3a is a powerful chemoattractant and activator of myeloid 
cells (1-4), inducing cytokine production, degranulation and respiratory burst in 
neutrophils, which results in enhanced vascular permeability and local blood flow (5, 6). 
It is indicated in the pathophysiology of hypersensitivity diseases. Positive correlations 
have been reported between the extent of complement activation, as assessed by 
measuring C3a levels or cleavage of C3, and the severity of systemic anaphylaxis in 
human subjects and animal models of immediate hypersensitivity. An increase in C3a 
levels have been observed in the serum of asthmatic patients following allergen-induced 
bronchospasm (7), plasma of patients with aspirin-induced asthma (8), and 
bronchoalveolar lavage fluid of asthmatic patients after segmental allergen provocation 
(9). C3a activation is also known to perpetuate the inflammatory reaction in allergic 
rhinitis (10). C3a mediates its inflammatory activities by interacting with a cell surface 
cognate G protein-coupled receptor (GPCR), C3aR, on target cells (11-13, Chapter 
1.5.2.1).  
Mast cells play a central role in the pathogenesis of allergic rhinitis, asthma, and 
other hypersensitivity/atopic diseases. Through degranulation of preformed mediators 
and de novo production of lipid mediators and cytokines, mast cells are the major cell 
type responsible for the acute and sometimes life-threatening manifestations of allergic 
disorders (14, 15, Chapter 1.2.10). Activation by C3a is important to their role in allergic 
diseases; however, C3aR expression is restricted to only certain types of mast cells. 
Human mast cell lines HMC-1 (16) and Laboratory of Allergic Diseases 2 (LAD2) (17), 
primary CD34+ cell-derived mast cells (17, 18) and skin mast cells (19) express C3aR, 
while murine bone marrow-derived mast cells (BMMC) and rat RBL-2H3 mast cell-like 
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cells (20) do not and therefore do not degranulate or produce cytokines in response to 
C3aR activation. Furthermore, mast cell contact with airway smooth muscle cells 
enhances C3aR-mediated mast cell degranulation (21), suggesting that in vitro studies 
with isolated mast cells might underestimate the in vivo importance of these pathways. 
Independent of C3aR KRZHYHU &D SHSWLGH GHULYDWLYHV FDQ ELQG WKH ȕ VXEXQLW RI WKH
)Fİ5, UHFHSWRU DQG LQKLELW LWV SKRVSKRU\ODWLRQ DQG VXEVHTXHQW VLJQDOLQJ HYHQWV (22), 
suggesting that the absence of complement receptor expression does not necessarily 
preclude complement's effects on mast cell functions. 
Like complement receptors, adenosine receptors are G-protein coupled and have 
been indicated in the pathophysiology of allergic inflammation (23, Chapter 1.5.3). 
Adenosine is an intermediate product of adenine nucleotide metabolism and serves in 
many organs as a response metabolite in hypoxia or situations where energy 
consumption is increased. Adenosine, produced in high concentrations during tissue 
injury, ischemia, or tumor growth, has been implicated in promoting innate immune 
inflammation (24). Adenosine acts through the four extracellular receptors A1, A2A, A2B, 
and A3 (25, Chapter 1.5.3). Through their ability to inhibit or enhance mediator release 
from mast cells, these receptors have emerged as novel therapeutic targets in asthma 
(26). The human mast cell line HMC-1 expresses functional A2A and A2B receptors and 
produces interleukin (IL)-8 when stimulated with adenosine (27). Studies with primary 
human mast cells have demonstrated that adenosine can potentiate mast cell 
degranulation induced by other stimuli such as immunoglobulin (Ig)E and calcium 
ionophore (28), but that it is not able to act alone. Moreover, adenosine has also been 
shown to inhibit degranulation (29) in some studies (Chapter 1.5.3.5). The role of 
adenosine in complement-mediated mast cell activation is unknown. We hypothesized 
that activation of adenosine receptors would modulate complement-mediated mast cell 
activation. This study addressed the overall hypothesis of this thesis which is that human 
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PDVW FHOOV H[SUHVV ERWK VWLPXODWRU\ DQG LQKLELWRU\ *3&5 ZKLFK VLJQDO WKURXJK *Įi or 
*Įs, respectively, and that these receptors are important in chemotaxis and mast cell 
migration. We chose C3aR as a model for a *Įi-coupled stimulatory receptor whose 
expression, function and signal transduction in human mast cell is well-established. 
Adenosine receptors were chosen as a model to study stimulatory or inhibitory receptors 
in GPCR cross-talk.   
 
4.3 METHODS 
4.3.1 Cell culture  
LAD2 human mast cell line (30) was cultured in serum-free medium (StemPro-34 
SFM, Life Technologies, Burlington, ON, Canada) supplemented with 2 mM L-glutamine, 
100 U/ml penicilOLQ  ȝJPO VWUHSWRP\FLQ DQG  JPO VWHP FHOO IDFWRU 6&)
Peprotech, Rocky Hill, NJ, USA). The cells were maintained at a density of 0.1 × 106 
cells/ml at 37°C/5% CO2DQGZHUHSHULRGLFDOO\WHVWHGIRUH[SUHVVLRQRI.LWDQG)Fİ5,E\
flow cytometry.  
4.3.2 Isolation of RNA and generation of cDNA by reverse transcription 
Total RNA was isolated using the Tri Reagent method (Sigma-Aldrich Canada, 
2DNYLOOH21&DQDGD,QDOOȝJRIWRWDOFHOOXODU51$ZDVUHYHUVH-transcribed to cDNA 
using M-MLV Reverse Transcriptase (Life Technologies) in a 20-ȝO UHDFWLRQ PL[, 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VUHFRPPHQGDWLRQ 
4.3.3 Real-time quantitative PCR (qPCR) 
Gene expression was analyzed using qPCR on a StepOnePlus system (Applied 
Biosystems, Foster City, CA, USA). For each qPCR assay, a total of 50 ng of cDNA was 
used. Primer sets (Table 4.1) for PCR amplifications were designed using the Primer 
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Express software. All reactions were performed in triplicate for 40 cycles as per the 
PDQXIDFWXUHU¶V UHFRPPHQGDWLRQ $OO GDWD ZHUH QRUPDlized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) internal controls (31) and are reported as fold over 
GAPDH expression.  
4.3.4 Flow cytometric analysis 
Cells were washed, suspended at 2 × 105 cells/ml in 0.1% bovine serum albumin 
(BSA)/phosphate-buffered saline (PBS), blocked with 3% BSA/PBS, and stained for 1 h 
with either a phycoerythrin (PE)-labeled anti-C3aR antibody (R&D Systems, 
Minneapolis, MN, USA) or an isotype control antibody at 4°C. Cells were washed twice, 
resuspended in 0.1% BSA/PBS and analyzed on a FACSArray (BD Biosciences, 
Mississauga, ON, Canada).  
4.3.5 Degranulation assay 
LAD2 cells were washed, resuspended in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (10 mM HEPES, 137 mM NaCl, 2.7 mM 
KCl, 0.38 mM Na2HPO4.7H2O, 5.6 mM glucose, 1.8 mM CaCl2.H2O, 1.3 mM 
MgSO4.7H2O, 0.4% BSA, pH 7.4) at 2.5 × 104 cells per well and stimulated for 30 min 
with serial dilutions of C3a (Calbiochem, Billerica, MA, USA) at 37°C/5% CO2. In some 
cases, the cells were pretreated with various agonists and antagonists (Table 4.2 ȕ-
hexosaminidase released into the supernatants and in total cell lysates solubilized with 
0.1% Triton X-100 was quantified by hydrolysis of p-nitrophenyl N-acetyl-ȕ-D-
glucosamide (Sigma-Aldrich, Oakville, ON, Canada) in 0.1 M sodium citrate buffer (pH 
4.5) for 90 min at 37°C/5% CO2 7KH SHUFHQWDJH RI ȕ-hexosaminidase release was 
calculated as a percent of total content.   
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Table 4.1 Sequences of oligonucleotides used for real-time qPCR 
Gene Forward primer Reverse primer Probe: FAM/TAMRA 
(GAPDH: MAX/BHQ) 
GAPDH 5'-TCG TGG AAG GAC TCA 
TGA C-3' 
5'-CCA TCA CGC CAC AGT 
TT-3' 
5'-/5MAXN/AGT CCA TGC 
CAT CAC TGC 
CAC/3IABlk_FQ/-3' 
GM-
CSF 
5'-CAG CCC TGG GAG 
CAT GTG-3' 
5'-ATT CAT CTC AGC AGC 
AGT GTC TCT A-3' 
5'-/56-FAM/AGG CCC GGC 
GTC TCC TGA ACC/36-
TAMSp/-3' 
 
IP-10 5'-CGA TTC TGA TTT GCT 
GCC TTA TC-3' 
5'-TGA TTA CTA ATG CTG 
ATG CAG GTA CA-3' 
5'-/56-FAM/TGG CAT TCA 
AGG AGT ACC TCT CTC 
TAG AAC CGT/36-TAMSp/-3' 
 
MCP-1 5'-TCT CTG CCG CCC TTC 
TGT-3' 
5'-GCC TCT GCA CTG AGA 
TCT TCC-3' 
5'-/56-FAM/CTG CTC ATA 
GCA GCC ACC TTC ATT 
CCC/36TAMSp/-3' 
 
MIP-ȕ 5'-CAG CGC TCT CAG 
CAC CAA-3' 
5'-TTC CTC GCG GTG TAA 
GAA AAG-3' 
5'-/56-FAM/CTC AGA CCC 
TCC CAC CGC CTG C/36-
TAMSp/-3' 
TGF-ȕ 5'-CTC TCC GAC CTG CAA 
CAG A-3' 
5'-AAC CTA GAT GGG CGC 
GAT CT-3' 
5'-/56-FAM/CCC TAT TCA 
AGA CCA CCC ACC TTC 
TGG T/36-TAMSp/-3' 
 
TNF 5'-TCT GGC CCA GGC 
AGT CA-3' 
5'-GCT TGA GGG TTT GCT 
ACA ACA TC-3' 
5'-/56-FAM/ CTT CTC GAA 
CCC CGA GTG ACA AGC 
C/36T-AMSp/-3' 
 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GM-CSF, granulocyte macrophage colony-
stimulating factor; IL, interleukin; IP-10, inducible protein-10; MCP-1, monocyte chemoattractant protein-1; 
MIP, monocyte inflammatory protein; TGF-ȕWUDQVIRUPLQJJURZWKIDFWRU-beta; TNF, tumor necrosis factor.  
 
 
Table 4.2 Agonists and antagonists used in this study 
Compound Specificity Concentration(s) used Supplier 
Pertussis toxin *Įi protein 0.01, 0.1, 1 µM Sigma-Aldrich 
Wortmanin PI3K 0.1, 0.5, 1 µM Sigma-Aldrich 
H-89 PKA 0.1, 1, 10 µM Sigma-Aldrich 
Ro-31-8220 PKC 0.1, 0.5, 1 µM Sigma-Aldrich 
NECA AR 0.01, 0.1, 1, 10 µg/ml Sigma-Aldrich 
CGS 21680  A2A agonist 0.01, 0.1, 1, 10 µM Tocris Bioscience 
BAY 60-6583 A2B agonist 0.01, 0.1, 1, 10 µM Tocris Bioscience 
IB-MECA A3 agonist 0.01, 0.1, 1, 10 µM Sigma-Aldrich 
SCH 58261 A2A antagonist 1, 10, 100 µM Sigma-Aldrich 
SQ 22536 Adenylyl cyclase 10 µM Tocirs Bioscience 
AR, adenosine receptors; 1(&$ƍ-(N-ethylcarboxamido) adenosine, PKA, phosphokinase A; PKC, 
phosphokinase C; PI3K, phosphoinositol 3-kinase. 
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4.3.6 Intracellular Ca2+ mobilization  
LAD2 cells were loaded for 30 min with 1 ȝM fura-2 acetoxymethyl (AM) (Life 
Technologies) in HEPES buffer, washed and incubated for 15 min in BSA-free HEPES 
at 37°C/5% CO2. A total of 4 × 106 cells were placed in a glass-bottom culture dish under 
an inverted microscope (Axiovert 200, Carl Zeiss Canada Ltd., Canada). Fura-2 was 
excited at 340 and 380 nm alternately. The Ca2+ response was recorded at 100 ms 
intervals using SlideBook for Stallion, version 4.26.04 software (Intelligent Imaging 
Innovations, USA). In all,  ȝJPO &D was added at the 70 s time point and  ȝ0
ionomycin (Sigma-Aldrich) at the 256 s time point. The Ca2+ response of 20 randomly 
selected cells was analyzed for each experiment and plotted as 340/380 ratio vs. time. 
4.3.7 ELISA 
In all, 1 × 106 cells wHUHVWLPXODWHGIRUKZLWKȝJPO&DDW&&22. 
Cell-free supernatants were isolated and analyzed for cytokine content using the 
following commercial competitive enzyme linked immunosorbent assay (ELISA) kits: 
human tumor necrosis factor (TNF)-alpha quantikine ELISA kit, human granulocyte-
macrophage colony-stimulating factor (GM-CSF) quantikine ELISA kit, human 
interleukin-3 (IL-3) quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA). The 
minimum detection limits were TNF, 5.5 pg/ml; GM-CSF, 3 pg/ml; and IL-3, 7.4 pg/ml. 
4.3.8 Cytometric bead array 
In all, 0.3 × 106 cells were stimulated for 24 h with 0.0001- ȝJPO &D DW
37°C/5% CO2. Cell-free supernatants were isolated and analyzed for chemokine content 
using the human chemokine cytometric bead array (CBA) kit (BD Biosciences). The 
minimum detection levels were inducible protein-10 (IP-10), 2.9 pg/ml; monocyte 
chemoattractant protein-1 (MCP-1), 2.7 pg/ml; monokine induced by interferon-Ȗ0,*
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2.5 pg/ml; RANTES (regulated on activation, normal T cell-expressed and secreted), 1 
pg/ml; and IL-8, 0.2 pg/ml. 
4.3.9 Adhesion assay 
Maxisorp 96-well plates (NUNC, Naperville, IL, USA) were coated for 16 h with 
 ȝJPO KXPDQ ILEURQHFWLQ 6LJPD-Aldrich) in PBS at 4°C, washed three times with 
PBS, blocked for 1 h with 3% BSA in HEPES buffer at 37°C/5% CO2 and then washed 
three times with HEPES buffer. Cells were washed with HEPES buffer, suspended at 1 × 
106 FHOOVPO DQG ODEHOHG IRU  PLQ ZLWK  ȝ0 FDOFHLQ-AM (Life Technologies) at 
37°C/5% CO2. After labeling, cells were washed and resuspended at 1 × 106 cells/ml in 
HEPES buffer. Cell suspension (5 × 104 cells) ± HEPES buffer containing 0.1 µg/ml SCF 
or 0.1 µg/ml C3a was added and incubated for 2 h at 37°C/5% CO2. In some 
experiments, cells were pretreated for 30 min with NECA. After incubation, non-adherent 
cells were washed away with warm HEPES buffer. Fluorescence emission at 530 nm 
(485 nm excitation) was measured using a fluorescence plate reader (Varioskan Flash 
Multimode Reader, Thermo Fisher Scientific, Nepean, ON, Canada).  
4.3.10 Chemotaxis assay 
Performed using the 96-well monocyte cell migration kit (Calbiochem) with slight 
modifications. Briefly, cells were incubated overnight in SCF-free media, washed with 
HEPES buffer, and suspended at 0.25 × 106 cells/ml. Agonists (0.1 µg/ml SCF or 100 
ng/ml C3a) were added to the lower chamber of the 96-well tray and cell suspension (2.5 
× 104 cells) was added to the insert (upper chamber). Cells were allowed to migrate 
towards the agonists for 6 h at 37°C/5% CO2. In some experiments, the cells were 
pretreated for 30 miQZLWKȝJPO1(&$$IWHULQFXEDWLRQWKHLQVHUWZDVZDVKHGWZLFH
with warm HEPES buffer. The cHOOV ZHUH ODEHOHG IRU  PLQ ZLWK  ȝ0 FDOFHLQ-AM at 
37°C/5% CO2. After labeling, the cells that had migrated across the insert membranes 
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were lysed using 0.01% Triton X-100. Fluorescence emission was measured at 530 nm 
(485 nm excitation).  
4.3.11 Cyclic AMP (cAMP) assay 
In all, 1 × 106 cells were stimulated for 30 min with 0.1-1000 µg/ml NECA or 0.1-10 µg/ml 
forskolin (Sigma-Aldrich) at 37°C/5% CO2 and treated with 0.1 µM HCl for 20 min at RT. 
Cell-free supernatants were analyzed for cAMP accumulation using the cyclic AMP EIA 
kit (Cayman Chemical, Ann Arbor, Michigan, USA). The minimum detection limit is 3 
pmol/ml.  
4.3.12 Statistical analysis 
Each experiment was performed at least three separate times. Statistical 
significance was determined by two-WDLOHG 6WXGHQW¶V SDLUHG t-test and P<0.05 was 
considered significant. The results are shown as mean ± S.E.M. 
 
4.4 RESULTS 
4.4.1 Human mast cells express C3a  and adenosine receptors 
To confirm the expression of C3aR by human mast cells, we performed flow 
cytometry using a C3aR-specific antibody. LAD2 cells expressed C3aR on the cell 
surface (Figure 4.1A). As shown in Figure 4.1B, the mean florescent intensity (MFI) of 
anti-C3aR antibody-stained LAD2 cells was significantly higher (MFI 1782.1 ± 220.7) 
than the cells stained with an isotype control antibody (MFI 153.6 ± 3.1). Upon agonist 
stimulation, GPCRs undergo phosphorylation, leading to receptor desensitization and 
internalization (Chapter 1.3.5). We thus tested if C3a engagement would stimulate C3aR 
on mast cell surface leading to internalize. As shown in Figure 4.1C, exposure of LAD2 
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cells to different concentrations of C3a for 30 min resulted in ~54% internalization of 
C3aR. 
We next characterized the expression of adenosine receptor subtypes by human 
mast cells. Previous studies with mast cells have shown that the stimulatory or inhibitory 
effects of adenosine on IgE-induced degranulation are mediated by adenosine receptors 
(Chapter 1.5.3.4). These receptors have not been characterized in LAD2 cells. qPCR 
analysis showed that LAD2 cells expressed A2A, A2B and A3 receptors, but not A1. The 
expression level of A2A receptor was the highest among the four subtypes (A2A > A2B > 
A3) (Figure 4.1D).  
4.4.2 Adenosine inhibits C3a-induced mast cell degranulation and mobilization 
of intracellular Ca2+  
Adenosine and adenosine receptor subtypes have been shown to differentially 
limit antigen-induced mast cell activation (Chapter 1.5.3.4). To determine whether 
adenosine modulated C3a-mediated activation of human mast cells, we utilized a non-
selective adenosine receptor agonist, 5'-N-ethylcarboxamidoadenosine (NECA). LAD2 
cells were treated with various concentrations of NECA prior to stimulation with C3a and 
GHJUDQXODWLRQ ZDV DVVHVVHG E\ WKH UHOHDVH RI ȕ-hexosaminidase enzyme (Chapter 
1.2.6.1). As shown in Figure 4.2A, NECA alone did not induce LAD2 cell degranulation. 
Exposure for 30 min to NECA resulted in inhibition of C3a-induced degranulation and the 
effect was concentration-dependent. LAD2 cells treated with 0.1-ȝJPO1(&$VKRZHG
significant reductions LQȕ-hexosaminidase release.  
To determine if the inhibition of degranulation by NECA was due to toxicity, we 
incubated LAD2 cells with 0.1, 1, and 10 ȝJPO 1(&$ DQG PHDVXUHG WKH PHWDEROLF
activity of cells using the XTT assay. There was no change in cell metabolic activity 
following 0.5, 3 or 24 h treatments (data not shown).  
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Figure 4.1 C3a and adenosine receptor expression by human mast cells. (A) The expression of 
C3aR on the LAD2 cell surface was measured using flow cytometry with phycoerythrin (PE)-
labeled mouse IgG isotype control (red histogram) and PE-anti-C3aR antibodies (green 
histogram). (B) Results of flow cytometric analysis expressed as differences in MFI between 
LAD2 cells stained with PE-isotype control or PE-anti-C3aR antibody (n=3). (C) C3a induces 
C3aR internalization. LAD2 cells were exposed to indicated concentrations of C3a for 30 min, 
incubated with PE-isotype control or PE-anti-C3aR antibody and cell surface C3aR expression 
was analyzed using flow cytometry (n=3). (D) Total RNA was isolated from LAD2 cells and A1, 
A2A, A2B, and A3 receptor mRNA expression was examined by qPCR. The data was normalized to 
GAPDH, and is reported as ratio of GAPDH expression (n=4). * P<0.05, ** P<0.051 compared 
with untreated.  
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Mobilization of intracellular Ca2+ is essential for mast cell degranulation and 
incubation of mast cells with C3a has been shown to elicit transient increases of 
intracellular Ca2+ (Chapter 1.5.2.3). As NECA inhibited C3a-induced degranulation, we 
determined its effect on intracellular Ca2+. LAD2 cells loaded with the Ca2+-sensing 
fluorescent dye fura-2 AM showed a rapid increase in intracellular Ca2+, reaching a peak 
within 70 s after C3a exposure. As expected, ionomycin used as a positive control 
caused additional Ca2+ influx. Pretreatment with 10 µg/ml NECA for 30 min significantly 
blocked C3a-induced mobilization of intracellular Ca2+ in LAD2 cells (Figure 4.2B-C). No 
inhibitory effect was seen on ionomycin-induced Ca2+ flux.  
4.4.3 Adenosine inhibits C3a-induced production of cytokines 
Mast cell-derived cytokines and chemokines propagate inflammatory reactions 
(Chapter 1.2.6.3). C3a is known to induce their production by mast cells (Chapter 
1.5.2.3). We therefore determined if adenosine would modulate the effect of C3a on 
cytokine release from LAD2 cells. While C3a caused no change in mRNA expression of 
the indicated cytokines (Figure 4.3A), mRNA expression levels of the chemokines MCP-
1/CCL2 and IP-10/CXCL10 increased significantly (Figure 4.3B). To confirm our 
observation that C3a preferentially activated chemokine production in LAD2 cells, we 
performed ELISA for TNF, GM-CSF, and IL-3 (Figure 4.3C), and CBA for IP-10, MCP-1, 
MIG, RANTES, and IL-8 (Figure 4.3D). C3a induced production of MCP-1 (43.3 pg/ml 
per 300,000 cells) and IP-10 (28.8 pg/ml per 300,000 cells) (Figure 4.3D). We next 
assessed the effect of NECA on C3a-induced MCP-1 production. LAD2 cells were 
pretreated with NECA for 30 min and activated with C3a for 24 h, and MCP-1 production 
was then analyzed by ELISA. NECA inhibited C3a-induced MCP-1 production compared 
with untreated cells (Figure 4.3E). 
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Figure 4.2 The inhibitory effect of adenosine on C3a-mediated degranulation and intracellular 
Ca2+ mobilization. (A) LAD2 cells were treated with the indicated concentrations of NECA prior to 
stimulation with 0.1 µg/ml C3a after which the percentages RI ȕ-hexosaminidase release were 
measured (n=3). (B) LAD2 cells were pretreated with for 30 min with 10 µg/ml NECA, loaded with 
fura- VWLPXODWHG ZLWK JPO &DDW WLPH SRLQW  V IROORZHG ZLWK  ȝ0 LRQRP\FLQ DW WLPH
point 256 s and mobilization of intracellular Ca2+ was measured (n=3). (C) Ca2+ response in 20 
randomly selected individual LAD2 cells reported as mean ± S.E.M. ** P<0.01, *** P<0.001 
compared with untreated. 
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Figure 4.3 Inhibitory effect of adenosine on the production of inflammatory mediators. After 3 h 
treatment with 0.1 µg/ml C3a, mRNA expression of (A) TNF, TGF-ȕ ,/-6, (B) MCP-1, MIP-ȕ
and IP-10 was measured by qPCR (n=3).  Data were normalized GAPDH mRNA levels and are 
expressed as fold increase over unstimulated controls. After 24 h of treatment the levels of (C) 
TNF, GM-CSF, IL-3, (D) IP-10, MCP-1, MIG, RANTES, and IL-8 in cell-free supernatants was 
measured by ELISA or CBA (n=3). (E) LAD2 cells were treated with 10 µg/ml NECA prior to 
stimulation with 0.1 µg/ml C3a, and the levels of MCP-1 in cell-free supernatants were measured 
by ELISA (n=3). * P<0.05, ** P<0.01, *** P<0.001 compared with untreated. 
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4.4.4 Adenosine inhibits C3a induced mast cell adhesion and chemotaxis 
Activation of mast cell degranulation in allergic inflammation requires their 
migration and accumulation at sites of infection. C3a can evoke mast cell adhesion, 
chemotaxis, and subsequent degranulation (Chapter 1.5.2.3). As NECA inhibited mast 
cell degranulation, we evaluated whether it could also block mast cell migration and 
adhesion. Comparable with SCF, C3a activated LAD2 cells to adhere to fibronectin, an 
extracellular matrix protein. Treatment with 10 µg/ml NECA blocked C3a-induced mast 
cell adhesion to fibronectin (Figure 4.4A). Next, we measured the chemotaxis of NECA-
treated LAD2 cells towards C3a. Results showed that, similar to SCF, C3a activated 
LAD2 chemotaxis. Pretreatment with 10 µg/ml NECA blocked C3a-activated cell 
chemotaxis (Figure 4.4B).  
4.4.5 Adenosine inhibits human mast cell degranulation through activation of the 
A2A receptor 
After demonstrating that adenosine blocked the effect of C3a on human mast cell 
chemotaxis, adhesion, degranulation and MCP-1 release, we questioned which 
adenosine receptor subtype(s) mediated the inhibitory effects of adenosine. As our first 
set of experiments had revealed that LAD2 cells express A2A, A2B and A3 receptors, we 
utilized agonists and antagonists (Table 4.2) for these receptors and performed 
degranulation assays. LAD2 cells were pretreated with the A2A receptor selective agonist 
CGS 21680, the A2B receptor selective agonist BAY 60-6583, or the A3 receptor selective 
agonist IB-0(&$SULRUWRDFWLYDWLRQZLWK&DDQGWKHUHOHDVHRIȕ-hexosaminidase was 
measured. Pretreatment with CGS 21680 inhibited C3a-induced mast cell degranulation 
(Figure 4.5A). BAY 60-6583 and IB-MECA failed to inhibit C3a-induced degranulation 
(Figure 4.5B-C). We next blocked A2A receptor by SCH 58261, a highly selective A2A 
receptor antagonist, and then tested the ability of NECA to inhibit C3a-induced 
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degranulation. As shown in Figure 4.5D, SCH 58261 reduced the inhibitory effect of 
NECA on C3a-induced mast cell degranulation.  
To determine if the effects mediated by CGS 21680 and SCH 5826 were due to 
toxicity, we incuEDWHG /$' FHOOV ZLWK   DQG  ȝJPO 1(&$ DQG PHDVXUHG WKH
metabolic activity of cells using the XTT assay. There was no change in cell metabolic 
activity following 0.5, 3 and 24 h treatments (data not shown). Collectively, these results 
indicate that the inhibitory effect of adenosine on C3a-mediated degranulation of human 
mast cells is mediated via A2A adenosine receptor.  
4.4.6 Inhibitory effect of adenosine is cAMP-dependent 
To understand the mechanism by which adenosine inhibits C3a-stimulated mast 
cell function, we investigated the cAMP levels in human mast cells. LAD2 cells were 
pretreated with NECA and an ELISA was performed for cAMP. As shown in Figure 
4.6A, NECA elevated the cAMP levels in LAD2 cells in a concentration-dependent 
manner. We next utilized forskolin to confirm the role of cAMP signaling in inhibiting C3a 
effect on human mast cells. Forskolin enhances intracellular cAMP accumulation in cells 
by directly activating adenylyl cyclase. LAD2 cells were treated with forskolin prior to 
stimulation with C3a and the degranulation was measured. Forskolin inhibited C3a-
induced mast cell degranulation (Figure 4.6B).  Collectively, these findings suggest that 
increase in intracellular cAMP is required for inhibition of C3a-mediated mast cell 
activation by adenosine.  
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Figure 4.4 Inhibitory effect of adenosine on mast cell adhesion and chemotaxis. (A) LAD2 cells 
were treated with 10 µg/ml NECA for 30 min, allowed to adhere to fibronectin-coated wells for 2 h 
in the presence of 0.1 µg/ml C3a and the percentages of cell adhesion were assessed. 0.1 µg/ml 
SCF was used as a positive control (n=3). (B) LAD2 cells were treated with 10 µg/ml NECA for 30 
min, allowed to migrate towards 0.1 µg/ml C3a for 6 h and the percentage of cell chemotaxis 
were assessed. 0.1 µg/ml SCF was used as a positive control (n=3). * P<0.05, ** P<0.01 
compared with untreated. 
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Figure 4.5 Effect of adenosine receptor agonists and antagonist on mast cell degranulation. 
LAD2 cells were treated for 30 min with the indicated concentrations of (A) CGS 21680, (B) BAY 
60-6583, or (C) IB-MECA prior to stimulation with 0.1 µg/ml C3a and the percentages RI ȕ-
hexosaminidase release were measured (n=3). (D) LAD2 cells were treated for 30 min with the 
indicated concentrations of SCH 58261 followed by 30 min treatment with 10 µg/ml NECA prior to 
stimulation with 0.1 µg/ml C3a and the SHUFHQWDJHRIȕ-hexosaminidase release were measured 
(n=3). * P<0.05, ** P<0.01 compared with untreated. 
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Figure 4.6 The role of cAMP in the inhibitory effects of adenosine on C3a-induced mast cell 
activation. (A) LAD2 cells were treated for 30 min with the indicated concentrations of NECA and 
the accumulation of cAMP in cell-free supernatants was measured using ELISA (n=5). (B) LAD2 
cells were treated for 30 min with the indicated concentrations of forskolin prior to stimulation with 
0.1 µg/ml C3a and the percentages RI ȕ-hexosaminidase release were measured (n=3). * 
P<0.05, ** P<0.01, *** P<0.001 compared with untreated. 
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4.4.7 $GHQRVLQHPHGLDWHVLWVHIIHFWRQKXPDQPDVWFHOOVYLD*Įs protein 
*Įs-coupled receptors mediate their effects through activation of adenylyl 
cyclase and subsequent accumulation of cAMP in cells. A2A and A2B receptors stimulate 
DGHQ\O\O F\FODVH YLD FRXSOLQJ WR *Įs protein, whereas A1 and A3 receptors inhibit 
DGHQ\O\O F\FODVH YLD FRXSOLQJ WR *Įi protein. In our study, LAD2 cells showed highest 
expression of A2A receptor, activation of which led to inhibition of C3a-induced mast cell 
degranulation. Moreover, treatment with adenosine elevated cAMP levels in LAD2 cells. 
Therefore, the findings indicated a functional role of A2A receptor in C3a-activated LAD2 
cells. To verify that adenosine modulated KXPDQ PDVW FHOOV E\ *Įs-mediated signal 
transduction, LAD2 cells were pretreated with the adenylyl cyclase inhibitor, SQ 22536 
prior to stimulation with NECA or C3a and degranulation was measured. As shown in 
Figure 4.7A, SQ 22536 had not effect on mast cell degranulation induced by C3a. 
However, it significantly attenuated the inhibitory effect of NECA on C3a-induced 
degranulation. We also confirmed signal transduction mediated by C3a in human mast 
cells. LAD2 cells were treated with pertussis toxin, an inKLELWRURI*Įi prior to stimulation 
with C3a and degranulation was assessed. Pertussis toxin significantly attenuated 
degranulation by C3a (Figure 4.7B). Collectively, the data demonstrated that adenosine 
DQG&DDFWYLD*Įs DQG*Įi proteins, respectively. 
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Figure 4.7 The effects of adenosine and C3a on mast cell activation DUH *Įs- DQG *Įi-
dependent. (A) LAD2 cells were treated for 30 min with 10 µM SCH 58261 followed by treatment 
for 30 min with 10 µg/ml NECA prior to stimulation with 0.1 µg/ml C3a and the percentages RIȕ-
hexosaminidase release were measured (n=3). (B) LAD2 cells were treated for 2 h with the 
indicated concentrations of pertussis toxin (PTx) prior to stimulation with 0.1 µg/ml C3a and the 
percentages RIȕ-hexosaminidase release were measured (n=3). * P<0.05, ** P<0.01 compared 
with untreated. 
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4.5 DISCUSSION 
Complement component C3a is a potent mediator of inflammation and the 
functions of C3a on various inflammatory cells are mediated through binding to the 
specific receptor C3aR (Chapter 1.5.2.1). Consistent with the previous reports (17), we 
showed that the human mast cell line LAD2 expressed C3aR on its cell surface. C3a 
stimulation degranulated LAD2 cells and stimulated secretion of the proinflammatory 
mediators MCP-1 and IP-10. In addition, we demonstrated that it stimulated cell 
adhesion to fibronectin, an important extracellular matrix protein that has been 
implicated in the migration of immune cells in inflammation. Indeed, we found that C3a 
facilitated the chemotaxis of human mast cells, an effect which was mediated in a G-
protein dependent manner. Contribution of mast cells and their biologically active 
PHGLDWRUVWRDOOHUJLFLQIODPPDWLRQDUHZHOOGHVFULEHG0DVWFHOODFWLYDWLRQE\)Fİ5,LVD
critical event in allergic inflammation (32, Chapter 1.2.5.1), and growing evidence has 
demonstrated that mast cell activation via cell-surface GPCRs also plays a crucial role in 
inflammation (33, Chapter 1.2.5.2). GPCRs can mediate mast cell degranulation, either 
GLUHFWO\ RU YLD WKH PRGXODWLRQ RI )Fİ5,-mediated degranulation (34). Activation of C3a 
and sphingosine-1-phosphate can induce degranulation directly; however, adenosine 
and prostaglandin E2 alone cannot induce degranulation, but they can enhance antigen-
induced mast cell degranulation via their cognate GPCR (34). Furthermore, cross-talk 
between different GPCRs has also been acknowledged to modulate mast cells 
responses (34, 35, Chapter 1.4). In this study, we elucidated a novel role for adenosine 
receptor as a negative regulator of C3a-mediated human mast cell activation. LAD2 cells 
incubated with a potent non-selective adenosine receptor agonist, NECA, displayed 
reduced ȕ-hexosaminidase release to C3a challenge. The inhibitory effect of NECA on 
degranulation correlated with decreased calcium influx in mast cells following activation 
with C3a. Mast cell adhesion to fibronectin, chemotaxis, and MCP-1 and IP-10 
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production were also reduced in NECA-treated mast cells, suggesting that adenosine 
receptor signaling may be of importance in regulation of human mast cell activation in 
inflammation.  
Our observations of the inhibitory effect of adenosine on C3a-stimulated mast 
cell degranulation in vitro are consistent with several previous reports on human lung 
fragments, dispersed human lung mast cells, human umbilical cord blood-derived mast 
cells and murine BMMC (29, 36-38). These studies have shown that adenosine can 
inhibit antigen-induced histamine release from mast cells. Our study is the first to 
characterize the inhibitory effect of adenosine on complement-mediated degranulation. 
Some studies have shown a biphasic effect of adenosine on antigen-induced human 
mast cell activation (37, 39). Low concentrations of adenosine potentiate, and high 
concentrations inhibit antigen-induced degranulation of human mast cells (37). 
Furthermore, a few studies have reported that adenosine alone can induce release of 
cytokines from the human mast cell line HMC-1 (27, 40-43). The contrasting effect of 
adenosine on mast cells and in allergic asthma have been linked to the differential 
activation of the adenosine receptors.  
Adenosine receptors are cell surface GPCR; four subtypes (A1, A2A, A2B, and A3) 
have been described (25, Chapter 1.5.3). A1 and A3 subtypes predominantly couple to 
*Įi/o and the A2A and A2B couple WR *Įs (25, Chapter 1.5.3.1). We characterized the 
expression of adenosine receptors by human mast cells and found that LAD2 human 
mast cell line expressed A2A, A2B, A3 but not A1 adenosine receptors. A2A receptor had 
the highest expression levels compared to A2B and A3 receptors. This pattern of 
adenosine receptor expression was different to that shown for BMMC, RBL-2H3, 
cutaneous mast cells and murine primary lung mast cells, where the A3 receptor is 
predominantly expressed. The abundance of A3 receptor transcripts in these cells might 
explain the direct effect of adenosine on mast cell degranulation (44-46). We observed 
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no degranulation of mast cells with NECA per se in the absence of C3a. Moreover, the 
selective A2A receptor agonist, CGS 21680 and the A3 receptor agonist, IB-MECA, alone 
had no direct activity on mast cell degranulation. 
Previous studies have shown that the A1, A2B or A3 receptors elicit 
proinflammatory effects in asthma through the activation of histamine and 
bronchoconstrictive substances release from mast cells, mucus secretion and 
bronchoconstriction (26, Chapter 1.5.3.5). A2A receptors are believed to elicit anti-
inflammatory signals by inhibiting histamine and tryptase release from mast cells in vitro 
(29, 37, 38, 47). In vivo administration of an A2A receptor agonist attenuates airway 
inflammation in ovalbumin-sensitized and ±challenged rats (48). Similarly, genetic 
ablation of the A2A receptor augments airway inflammation and hyperresponsiveness in 
a murine model of allergic airway inflammation (49), further supporting the role of the A2A 
receptor as mediating anti-inflammatory functions. We therefore attempted to determine 
which specific adenosine receptor(s) were involved in inhibition of C3a-mediated 
DFWLYDWLRQRIKXPDQPDVWFHOOV$V1(&$LQKLELWHGȕ-hexosaminidase release from C3a-
stimulated mast cells, these findings suggested that A2A or A2B receptor activation evoke 
inhibitory effects on degranulation of these cells. Indeed, the selective A2A receptor 
agonist, CGS 21680, inhibited C3a-induced degranulation of human mast cells but the 
A3 receptor agonist, IB-0(&$ KDG QR HIIHFW 1(&$ KRZHYHU IDLOHG WR LQKLELW ȕ-
hexosaminidase release from mast cells pretreated with A2A receptor antagonist, SCH 
58261, but A2B receptor and A3 receptor antagonists had no effect, further suggesting 
that the inhibition of degranulation was mediated by A2A receptor. 
Pharmacological agents with cyclic adenosine monophosphate (cAMP)-elevating 
properties have long been observed to inhibit mast cell function (50). cAMP is a 
ubiquitous intracellular second messenger that is produced from AMP after the activation 
of adenylyl cyclase. cAMP can inhibit store-operated calcium channels in mast cells 
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through a PKA-dependent pathway, which subsequently limits antigen-induced mast cell 
degranulation (51, Chapter 1.5.3.3). Different strategies can raise intracellular cAMP 
OHYHOVLQFOXGLQJDFWLYDWLRQRI*Įs-coupled receptors (52, 53),QGHHGDFWLYDWLRQRI*Įs-
coupled A2A and A2B receptors have been shown to increase cAMP levels in mast cells 
(36, 40). Thus, we addressed the question as to whether the inhibition of degranulation 
by NECA was cAMP-dependent. We found the treatment with NECA elevated 
intracellular cAMP levels in human mast cells in a concentration-dependent manner, 
suggesting that A2A-*Įs signaling may be of critical importance in the regulation of mast 
cells activation in inflammation. Forskolin also exerts its biological activities by direct 
stimulation of adenylyl cyclase, thereby increasing cellular concentrations of cAMP (54). 
Forskolin potentiation of cAMP in turn inhibits basophils and mast cells degranulation 
and histamine release (55). We therefore utilized forskolin to further confirm the role of 
constitutive cAMP in regulation of mast cell functions. Similar to NECA, forskolin showed 
inhibited C3a-mediated mast cell activation. In addition, forskolin also inhibited human 
mast cell adherence to fibronectin as well as chemotaxis.  
To further understand the molecular mechanisms underlying the activities of C3a 
and NECA, we investigated the requirements for G protein subtypes, as their roles in 
complement- (56-63) and adenosine-mediated (40) mast cell activation have been 
previously reported. Pertussis toxin blocked C3a-induced degranulation of human mast 
cells. The adenylyl cyclase inhibitor, SQ 22536, had no effect on C3a-activated 
degranulation but blocked the effect of NECA, demonstrating that C3a and NECA 
PHGLDWH WKHLU HIIHFWV WKURXJK *Įi DQG *Įs proteins, respectively. Overall, this data 
confirmed that C3a activates G protein-dependent signal transduction in human mast 
cells and adenosine inhibits complement activation of human mast cells through a GĮs 
protein pathway 
175 
 
,QVXPPDU\WKLVVWXG\GHPRQVWUDWHGWKDWDFWLYDWLRQRIWKH*Įs-coupled inhibitory 
A2A DGHQRVLQHUHFHSWRUGLPLQLVKHVWKHDFWLYDWLQJHIIHFWRI*Įi-coupled C3aR on human 
mast cells. This provides a critical balance between mast cell activation and mediator 
release in host defense and inflammation. In cases of unregulated mast cell activation 
via a GPCR, for instance the C3aR, targeting inhibitory A2A adenosine receptors might 
prove beneficial. Thus adenosine receptors offer novel therapeutic targets in allergic 
inflammation and hypersensitivity. 
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CHAPTER 5. GENERAL DISCUSSION  
 
5.1 SUMMARY 
We live in an environment filled with microorganisms that are constantly trying to 
breach our immune system to gain dominance. The innate immune system acts as a 
sensor for these pathogens and eliminates them by utilizing a range of defense 
processes, such as the immune cells. To develop an effective immune response, the 
cells of the immune system are required to communicate between each other through 
secretion of soluble mediators and direct cell-cell interactions. Among the cells of the 
innate immune system, mast cells appear to be among the most powerful in terms of 
their ability to respond to multiple stimuli and to selectively release different types and 
amounts of mediators (1). The most studied and well-described (classical) mechanism of 
mast cell activation is via stimulation of the high-affinity immunoglobulin E (IgE)-receptor, 
)Fİ5, %LQGLQJ RI DQ DQWLJHQ WR )Fİ5,-ERXQG VSHFLILF ,J( OHDGV WR )Fİ5, DJJUHJDWLRQ
which in turn induces downstream signaling events and the release of mediators (2). 
Previous studies from our laboratory and the data presented in this thesis demonstrate 
that IgE-antigen stimulation of human mast cells (Laboratory of Allergic Diseases 2 
KXPDQPDVWFHOOOLQHLQGXFHGGHJUDQXODWLRQDQGUHOHDVHRIȕ-hexosaminidase, cysteinyl 
leukotrienes (CysLTs) and prostaglandin D2 (PGD2). No significant effect was observed 
on cytokine and chemokine production (3). Whereas the signaling pathways leading to 
degranulation and production of mediators are relatively well understood, while those 
involved in IgE-antigen-mediated mast cell chemotaxis are still vague, however the 
phosphoinositol 3-kinase (PI3K)-dependent pathway appears to contribute to 
chemotactic response (4).  
With the expansion of research on mast cell pathophysiology, our perception of   
mast cells in immune functions has changed. Mast cells are no longer viewed solely as 
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mediators of allergic inflammation; their presence serves essential functions in host 
defense. In fact, their functions extend throughout all of the stages of the immune 
response, ranging from shaping the response against pathogens, regulating both innate 
and adaptive immune cell functions, to supporting regulatory cells in the maintenance of 
tissue-tolerance (1, 5). Mast cells are strategically positioned at the interface with the 
environment where they can be activated directly by interacting with pathogens through 
pattern-recognition receptors (PRRs), including Toll-like receptors (TLR), Nod-like 
receptors (NLRs), C-type lectin receptors such as Dectin-1, and the 
glycosylphosphatidylinositol (GPI)-anchored protein CD48. PRRs have the ability to 
recognize pathogens using evolutionarily conserved patterns called pathogen-
associated molecular patterns (PAMPs), resulting in opsonization, activation of 
complement and coagulation cascades, phagocytosis, activation of proinflammatory 
signaling pathways, and induction of apoptosis (5). Engagement of PRRs leads to 
selective release of mast cell mediators. For example, peptidoglycan stimulation of mast 
cells via TLR2 leads to both degranulation and cytokine production, whereas stimulation 
through TLR3 and TLR4 results in cytokine release alone (6, 7). Furthermore, Dectin-1 
ELQGLQJ RI IXQJDO ȕ-glucan induces the release of leukotriene LTC4 by mast cells (8), 
while CD48 binds to the E. coli adhesin FimH and induces the release of tumor necrosis 
factor (9). Activation of PRR also induces the production of antimicrobial peptides, such 
as defensins and cathelicidins, which may further regulate host defense against 
pathogens by serving as an alarm for sentinels, such as mast cells (10).  
Antimicrobial peptides are a unique and diverse group of gene-encoded proteins, 
which are highly conserved in their structure, function and mechanism of action (11). In 
addition to their antibacterial role, many of the antimicrobial peptides have been shown 
to interact with immune cells, resulting in activation of innate and adaptive immune 
responses (11). This conclusion is based on the chemotactic effect of antimicrobial 
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peptides for selected immune cells. The chemotactic ability of the antimicrobial peptides 
indicates that they can attract cells, including mast cells, expressing the appropriate 
receptors along a gradient to their site of origin, Furthermore, as their chemotactic 
responses can be inhibited by pertussis toxin, the antimicrobial peptides interact with 
*Įi-coupled receptors. The major antimicrobial peptides found in humans are defensins 
and cathelicidins. The chemotactic effect of cathelicidin for neutrophils, monocytes, and 
T cells occurs through interaction with N-formyl peptide receptor-like 1 (FPRL1) receptor. 
Although the chemotactic effect of cathelicidin for mast cells is also pertussis toxin-
sensitive, prior to our study the interaction of antimicrobial peptides with FPRL1 in 
human mast cells was questionable (12) 3OHXURFLGLQ LV D QRYHO Į-helical cationic 
antimicrobial peptide that displays a broad spectrum antibacterial activity along with 
diverse proinflammatory and immunomodulatory functions. As pleurocidins are 
structurally and functionally similar to cathelicidins, we chose them for our agonist model 
for investigating the biological roles of FPRL1 in human mast cells. Our studies showed 
that some pleurocidins caused human mast cells to adhere, migrate, degranulate and 
release cysteinyl leukotrienes, prostaglandins, and chemokines. Pleurocidin NRC-04 
activated human mast cells by binding and signaling via the FPRLI receptor. FPRL1 is a 
classical chemoattractant GPCR originally identified in phagocytic leukocytes; it 
mediates cell chemotaxis and activation in response to bacterial formylated chemotactic 
peptides (e.g. fMLF). Agonist binding to FPRL1 activateV D *Įi protein signal 
transduction cascade involving PI3K, phospholipase C (PLC), protein kinase C (PKC), 
mitogen-activated protein kinases (MAPKs) and the transcription factor nuclear factor 
(NF)-ț%(12). Indeed, we demonstrated that pertussis toxin, wortmannin (PI3K inhibitor), 
U-73122 (PLC inhibitor) and Ro-31-8220 (PKC inhibitor) each blocked pleurocidin-
induced mast cell mediator release. Our data described a novel proinflammatory and 
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stimulatory role for GPCR FPRL1 in mast cell-driven immune response to cationic 
antimicrobial peptides. 
Similar to the antimicrobial peptides, the complement system represents an 
evolutionarily ancient and conserved part of the innate immune system which is involved 
in a rapid and nonspecific host response. Activation of the complement system leads to 
release of multiple proteolytic fragments, including C3a and C5a (13, 14). C3a and C5a 
are collectively called anaphylatoxins because they induce the release of mediators from 
mast cells, basophils, which causes a rapid increase in vascular permeability that is a 
characteristic of anaphylaxis. In addition to their traditional roles in inflammation, 
anaphylatoxins also significantly influence the innate and adaptive immune responses by 
activation and modulation of different dendritic cell populations, B cells, and T cells. C5a 
promotes phagocytosis and the oxidative burst in neutrophils and monocytes, 
upregulates adhesion molecules like CD11b in neutrophils, and induces the release of 
granular enzymes. At subnanomolar to nanomolar concentrations, C5a elicits 
chemotaxis of cells of the myeloid lineage, including neutrophils, monocytes, 
eosinophils, and basophils. Higher nanomolar concentrations of C5a also elicit 
degranulation and an oxidative burst (15). The effects of C5a are mediated through two 
receptors, the C5a receptor (C5aR) and C5a receptor-like 2 (C5L2), which are 
distributed on immune cells of myeloid origin as well endothelial, epithelial and 
parenchymal cells. The significance and biological role of C5L2 is debated and not fully 
understood. We investigated the roles of C5aR and C5L2 in human mast cells for C5a-
induced activation. C5a caused human mast cells to adhere, migrate and produce 
cytokines and chemokines, but not WR UHOHDVH ȕ-hexosaminidase, CysLTs and PGD2. 
C5a activated human mast cells by signaling via the C5L2 receptor, but not via the 
C5aR. Furthermore, treatment with pertussis toxin and wortmannin (a PI3K inhibitor) 
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blocked C5a-induced mast cell adhesion to fibronectin. Our studies thus elucidated a 
QRYHOVWLPXODWRU\UROHIRU*Įi-coupled C5L2 in human mast cell, indicating that the C5L2 
receptor may participate in innate immune modulation of inflammation.  
Like C5a, C3a participates in homeostasis and inflammation by modulating 
activities, such as increases in vascular permeability, smooth muscle contraction, 
immune cell recruitment, and other responses (e.g., chemotaxis and phagocytosis). C3a 
and its inactivated derivative C3a desArg also possess potent antibacterial activity (16). 
The functional responses of C3a are mediated by its interaction with C3a receptor 
(C3aR). Our studies confirmed the previous reports and demonstrated that C3a 
activated mast cell degranulation and selective release of chemokines only. In addition, 
we showed that C3a also induced human mast cell chemotaxis and adhesion to 
ILEURQHFWLQ %LQGLQJ RI &D WR &D5 UHVXOWHG LQ FRXSOLQJ WR *Įi proteins, as 
demonstrated by the inhibitory effect of pertussis toxin on C3a-induced activation of 
human mast cells. Moreover, treatment with wortmannin (a PI3K inhibitor), H-89 (a PKA 
inhibitor), and Ro-31-8220 (a PKC inhibitor) blocked the effect of C3a, confirming the 
activation of stimulatory C3aR-*Įi signal transduction in human mast cells. 
6LPXOWDQHRXVDFWLYDWLRQRI*Įs-coupled adenosine receptor, A2A, inhibited C3a-mediated 
activation of human mast cell chemotaxis, adhesion, and mediator release. Interestingly, 
adenosine by itself displayed no effect on mast cell activation. This confirmed our central 
hypothesis that human mast cells express inhibitory GPCRs which display cross-talk 
with other GPCR, an important phenomenon in mast cell modulation of innate 
inflammation. 
The data presented in this thesis also confirmed that while the antimicrobial 
peptides and the complement proteins differentially activated the release of 
proinflammatory mediators from human mast cells, chemotaxis and adhesion were the 
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most common responses induced. More importantly, the effects on chemotaxis and 
adhesion were conserved through the G protein-dependent signaling mechanism. Also, 
PI3K appeared to be the common molecule utilized downstream of the G protein 
signaling cascade by the three agonist-GPCR interactions. PI3K is a family of lipid 
kinases that play crucial roles in multiple biological processes, such as mast cell 
degranulation and cytokine production. It is also critical for mast cell chemotaxis, 
adhesion and homeostasis. This has been evidenced by the ability of wortmannin and 
LY294002 to effectively inhibit antigen-, stem cell factor-, and PAMP-mediated mast cell 
migration and adhesion to fibronectin-coated plates (4). Consistent with this, in our 
studies wortmannin blocked adhesion of human mast cells to fibronectin in response to 
pleurocidin, C5a, and C3a. Due to their central roles in the generation and activation of 
mast cells, PI3K-regulated pathways are attractive targets for the regulation of mast cells 
responses in health and disease. PI3K has also been proposed to regulate amplification 
pathways for ongoing signaling events initiated by the GPCR pathways (4). 
As mentioned before, precisely how GPCRs influence mast cell function depends 
GLUHFWO\XSRQWKHFODVVRI*SURWHLQHQJDJHGDQGWKHLQGLYLGXDOVXEXQLWV*ĮDQGȕȖWKDW
regulate effector proteins. 7UDQVPLVVLRQRIVLJQDOLQJYLD*Įi alone is sufficient for most 
GPCRs to initiate activation of both PLC and PI3K, and to promote degranulation of 
mast cells (17))35/DQG&D5*3&5VOLQNWR*Įi in human mast cells as evidenced 
by their sensitivity to pertussis toxin and the ability of these receptors to degranulate 
human mast cells in our studies. Exceptions to this paradigm also exist. For example, 
S1P1 UHFHSWRU OLQNV WR *Įi and induces mast cell chemotaxis but not degranulation. 
Whereas, S1P2 receSWRU ZKLFK DOWKRXJK OLQNHG WR *Įi, likely mediates its effects via 
*Į12/13 RU*Įq and degranulates mast cells (18). In accord, we showed that, although it 
did not degranulate human mast cells, C5L2 induced mast cell adhesion which was 
sensitive to pertussis toxin, suggesting that C5L2-induced adhesion may be mediated 
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YLD *Įi. All of the three GPCRs, i.e. FPRL1, C3aR and C5L2, transduced signals 
through PI3K as demonstrated by the inhibition studies, further supporting with our 
hypothesis that chemotaxis and adhesion are G protein-dependent mechanisms in 
KXPDQPDVWFHOOV OLNHO\YLD*Įi. The ability of specific GPCRs, such as prostaglandin 
receptoU (3 DQG ȕ DGUHQHUJLF UHFHSWRU to down-regulate mast cell activation is 
dependent on the fact that these receptors stimulate adenylyl cyclase-dependent cyclic 
$03F$03SURGXFWLRQYLD*Įs. cAMP has been demonstrated to negatively regulate 
mast cell function. The A2A DGHQRVLQH UHFHSWRU OLQNV ZLWK *Įs and dampHQV )Fİ5,-
mediated mast cell activation (18). Our studies revealed that A2A receptor inhibited C3a-
LQGXFHGPHGLDWRUUHOHDVHIURPKXPDQPDVWFHOOVOLNHO\YLD*Įs, thus activating adenylyl 
cyclase. The A2A receptor, however, was incapable of inducing degranulation on its own. 
In conclusion, both stimulatory and inhibitory G protein-dependent signal transduction 
pathway play roles in mast cell activation. While the stimulatory pathways are crucial for 
mast cell function in innate immunity and inflammation, the inhibitory pathways keep a 
check on unregulated mast cell activation in allergic reactions and hypersensitivity. 
 
5.2 PERSPECTIVE 
The variety of routes by which pathogen can activate mast cells during primary 
and secondary infection ensure that these cells have an effective sentinel role. Direct 
interaction with pathogens via TLR does not lead to degranulation (7, 19), although 
cytokine, chemokine and lipid mediator production have been reported. In our 
experiments, FPRL1 and C3a receptor activation led to degranulation of mast cells and 
the production of newly-generated mediators. Activation of C5L2 resulted in cytokine and 
chemokine production without degranulation. Based on our observations, we could 
postulate that during an infection these receptors respond to pathogens differentially in 
terms of time required to act and outcomes mediated at the site of infection. Following 
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the TLR, the C3aR is probably the first receptor system to respond to the complement 
fragment C3a generated early on during the complement activation cascade activated by 
PAMPs. This leads to rapid release of proinflammatory mediators required to combat 
infection as well as secretion of chemoattractants for recruitment of phagocytic 
leukocytes. Tissue resident mast cells located nearby recognize these chemoattractants 
and migrate towards the site of infection. It is when C5L2 system responds to infection 
facilitating mast cell migration without degranulation, thereby conserving cytokines and 
chemokines to be released later at the site of infection. Once mast cells have 
accumulated in high numbers, antimicrobial peptides released from the epithelial layer 
breached by pathogens bind the FPRL1 receptors and drive a robust mast cell response 
against infection.  
Although all these systems have been investigated primarily as separate entities, 
an emerging body of evidence indicates extensive cross-talk between the N-formyl 
peptide, complement and TLR signaling pathways. Molecular interplay between these 
receptors can results in synergistic or even antagonistic interactions critical in reinforcing 
innate immunity or regulating excessive inflammation, respectively (20). Future studies 
should focus on defining such interactions in vitro as well as in vivo mast cell models. 
Future studies are also expected to elucidate additional regulatory links between 
stimulatory and inhibitory GPCRs and their cross-talk with PRRs, which is essential for 
understanding their precise roles in health and disease. The potential of mixing 
adenosine receptor agonists and antagonists with stimulatory GPCRs, such as C5aR 
and FPRL1, may lead to improved therapeutic interventions to enhance protective 
immunity or attenuate immunopathology.  
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